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Utilizing adoptive transfer of autologous T cells engineered to express a transgenic tumor-
reactive T cell receptor (TCR) is a promising immunotherapeutic approach to treat cancer 
(Restifo, Dudley and Rosenberg, 2012). However, severe side-effects observed in clinical trials 
due to on-target/off-tumor or off-target reactivity emphasize the need for extensive safety 
testing of transgenic TCRs before clinical application (Cameron et al., 2013; Morgan et al., 
2013). In addition to excluding toxicities in patients, the tumor antigen-specific TCR has to be 
proven fully functional in a transgenic setting to ensure efficient anti-tumor responses of 
patient-derived peripheral blood lymphocytes (PBL) displaying the transgenic TCR. A large 
number of cells expressing the transgenic TCR are required for this elaborate efficacy and 
safety evaluation. While bulk PBL can be isolated in sufficient numbers and carry all effector 
functions essential for a physiological read-out, the presence of endogenous TCRs with 
unknown specificities could severely affect or alter the function of the transgenic TCR by 
dominant negative effects of the endogenous TCRs or TCR mispairing. Therefore, appropriate 
recipient cells are needed that can serve as a stable and reproducible test system for the 
thorough characterization of transgenic TCRs without the constraints of endogenous TCR 
expression. However, the generation of TCR-negative recipient cells is complicated by the fact 
that once the endogenous TCR of a T cell is absent, physiological T cell activation is impeded 
and the possibility to subsequently expand the T cell to sufficient numbers is lost. To 
circumvent this classical T cell activation via the TCR complex, chimeric antigen receptors 
(CARs) were tested for their potential to induce proliferation in isolated T cell clones for long-
term in vitro expansion. While CARs are generally introduced into bulk PBL to redirect T cells 
to eliminate tumor cells, prolonged persistence of CAR-expressing T cells in patients months 
after treatment indicates that re-activation of these T cells could be attributed to the introduced 
CAR (Porter et al., 2011). Using two well-characterized CAR constructs recognizing the CEA 
antigen, optimal in vitro expansion conditions for isolated T cell clones could be determined. 
In T cell clones showing TCR-independent, high proliferative capacity, the endogenous TCR 
was targeted for knockout using the TALEN technology. Initial poor survival of the resulting 
TCR-negative recipient cells could be overcome by the introduction of a CAR recognizing the 
CD19 antigen on B cells, which also provide co-stimulatory molecules for T cell activation. 
Additionally, a CD3 fusion protein, termed CD3-Chimera, was generated that should mimic 
physiological activation of T cells in the absence of TCR expression via binding of mitotic 
antibodies. Using these chimeric constructs, a new high-throughput strategy could be 
developed that allowed the generation and immediate identification of TCR-deficient T cell 
clones that could be expanded via engagement of CD19-CAR or CD3-Chimera, respectively. 
These well-defined universal recipient cells retained their effector functions and served as a 
stable and reproducible in vitro test system for the characterization and direct comparison of 
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different transgenic TCRs. Besides constituting an in vitro tool for the safety and efficacy testing 
of transgenic TCRs, the generated universal recipient cells represent the first step towards a 





1.1 T cell biology 
The human immune system comprises powerful weapons to defend our body against various 
viral and microbial invaders. While the innate immune system efficiently detects and eradicates 
pathogens carrying conserved components that can be recognized by invariant pattern 
recognition receptors, the adaptive immune system evolved to recognize specific antigens 
derived from any invader it encounters and to establish immunological memory that will protect 
from re-infection (Ahmed and Gray, 1996). Key players in this adaptive immunity are B cells 
and T cells, that both generate receptors of unique specificity by somatic recombination of 
germline variable (V), diversity (D) and joining (J) gene segments during lymphocyte 
development (Bassing, Swat and Alt, 2002). The B cell receptor (BCR) is composed of 
immunoglobulin light (IgL) and heavy (IgH) chains created by VJ- or VDJ-recombination, 
respectively, and will be secreted as antibody once the B cell is activated by specific binding 
of the BCR to cognate antigen (Dal Porto et al., 2004). Two types of T cell receptors (TCRs) 
have been identified that are either generated by combination of  and  chains (TCR) or  
and  chains (TCR). While both types of TCRs use the CD3 complex for signaling, they differ 
in the way they recognize antigen (Love and Hayes, 2010). The much more prevalent  T 
cells bind to peptide presented by major histocompatibility complex (MHC) molecules on 
antigen presenting cells (APCs). In contrast,  T cells, which make up about 5% of peripheral 
blood T cells, are thought to bind directly to antigens, like proteins, phosphorylated ligands or 
lipids, independent of the classical MHC molecules (Allison and Garboczi, 2002). In the 
following, the focus lies on  T cells, which will be simply referred to as T cells, and their role 
in adaptive immunity.  
The TCR  and  chains are encoded by different loci on chromosome 14 and 7, respectively. 
The TRA locus contains V and J gene segments as well as a constant region segment (C), 
while the TRBC locus comprises V, D and J gene segments and 2 constant region gene 
segments (C1 and C2). To enable expression of the TCR on the cell surface, irreversible V(D)J 
recombination of the germline DNA has to occur to join the respective gene segments into one 
open-reading frame. V(D)J recombination is mediated by a complex comprising lymphocyte-
specific proteins encoded by recombination activating genes 1 and 2 (RAG1 and RAG2), which 
bind recombination signal sequences (RSS) flanking the gene segments to introduce single-
strand nicks at the 3’ end of the gene segments resulting in closed hairpin structures (Bassing, 
Swat and Alt, 2002; Jung and Alt, 2004; Abbey and O’Neill, 2008). Subsequently, double strand 
breaks (DSB) are repaired by error-prone non-homologous end-joining (NHEJ), which in 
concert with terminal deoxynucleotidyl transferase (TdT) results in modification of the cut 
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region creating highly variable junctions (Schatz and Ji, 2011). Random selection of joined 
gene segments in combination with these imprecise junctions generates unique and highly 
variable sequences coding for the variable regions of the TCR chains. The rearranged V(D)J 
segments are joined to the respective constant regions by mRNA splicing to generate mature 
TCR  and  chain transcripts. Pairing of unique TCR  and  chains in the endoplasmic 
reticulum (ER) results in formation of the TCR molecule. Pairing of different TCR  and  
chains to generate a functional TCR together with genetic recombination events creates a 
unique antigen specificity and contributes to the high diversity of TCR repertoire (reviewed in 
Bassing, Swat and Alt, 2002; Jung and Alt, 2004; Abbey and O’Neill, 2008; Schatz and Ji, 
2011).  
To ensure that only one functional TCR will be expressed in each diploid T cell, a process 
known as allelic exclusion regulates the silencing of the second allele during lymphocyte 
development (Malissen et al., 1992). TCR  chain rearrangements initially start on both alleles 
and occur prior to recombination events in the TRA locus (Raulet et al., 1985). Once a 
functional pre-TCR complex comprising an invariant pre-TCR  chain and a productive TCR  
chain can be expressed, feedback inhibition mechanisms stop rearrangements of the TRB 
locus on the second allele and prevent transcription (Fehling and Boehmer, 1997; Carpenter 
and Bosselut, 2010). After -selection, the T cells express one productive TCR  chain and 
initiate CD4 and CD8 expression as well as rearrangements of the TRA locus (Borgulya et al., 
1992; Carpenter and Bosselut, 2010). VJ recombination is thought to occur simultaneously on 
both alleles encoding the TCR  chains, while successful interaction of a functional TCR with 
self-peptide-MHC complexes in the thymus results in positive selection of the T cell and stops 
recombinase activity (Borgulya et al., 1992; Malissen et al., 1992; Petrie et al., 1993). In 
general, this results in expression of one functional TCR  chain that pairs with the 
corresponding TCR  chain. However, in up to 20% of circulating T cells two TCR  chains 
can be detected on mRNA level (Malissen et al., 1992). While usually one of these TCR  
chains comprises unproductive rearrangements resulting in the expression of only one 
functional TCR on the surface, in rare cases two productive TCR  chains can give rise to two 
TCRs with different specificities (Malissen et al., 1988; Padovan et al., 1993). Overall, more 
than 90% of the T cells will not pass positive selection in the thymus due to the expression of 
“non-functional” TCRs, which are not able to interact properly with self-peptide-MHC 
complexes on antigen-presenting cells, termed cortical thymic epithelial cells (cTECs) (Klein 
et al., 2014). In the subsequent negative selection, auto-reactive cells strongly recognizing 
self-peptide presented by self-MHC molecules will undergo apoptosis and are eliminated from 
the T cell repertoire (Starr, Jameson and Hogquist, 2003). T cells expressing functional TCRs 
while not recognizing self-peptide, will undergo a lineage choice between CD4-expressing T 
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cells (CD4+ T cells) or CD8-expressing T cells (CD8+ T cells), that includes the termination of 
either CD8 or CD4 expression, respectively. These co-receptors interact with MHC molecules 
on APCs and enhance signaling via the TCR complex by recruiting Lck kinase associated with 
their cytoplasmic tail to the immunological synapse (Veillette et al., 1989). While CD4+ T cells 
recognize antigen presented by MHC class II molecules, CD8+ T cells interact with peptide on 
MHC class I molecules. However, it is thought that lineage choice depends on signaling 
strength mediated by presence of Lck kinase, where strong signals promote CD4-lineage 
choice and weak signals promote CD8-lineage choice (Singer, Adoro and Park, 2008).  
MHC class I molecules, corresponding to human leukocyte antigens (HLA) A, B and C, are 
expressed by most cells of the human body and present peptides derived from intracellular 
proteins (Germain, 1994). This allows the efficient detection of virus-infected cells as well as 
cancerous cells displaying mutated or aberrantly expressed self-peptides (Boon et al., 1994; 
Coulie et al., 2014). In contrast, MHC class II molecules are usually found on specialized APCs 
and predominantly present extracellularly-derived peptides that have been internalized by 
phagocytosis or endocytosis (Germain, 1994). Naïve T cells that underwent thymic selection 
have to be activated in order to survive and mediate an immune response, which requires 3 
signals: (I) interaction of the TCR complex with specific antigen presented by MHC molecules 
on APCs, (II) interaction of co-stimulatory molecules on APCs and naïve T cells, like CD28-
CD80/CD86 ligation, and (III) cytokine secretion by APCs to control T cell differentiation into 
different T cell subsets (Curtsinger et al., 1999). Guided by cytokine secretion, CD4+ T cells 
differentiate into functionally distinct T helper subsets, Th1, Th2 and Th17, and regulatory T 
cells (Treg) that exhibit different effector functions (Zhu and Paul, 2010). Th1 cells secret the 
signature cytokines IFN- and IL-2 and support activation of macrophages, B cells and CD8+ 
T cells to defend against viral pathogens, while Th2 cells are characterized by the secretion of 
IL-4 and IL-5, which is required for antibody isotype switch to IgE in B cells and recruitment of 
eosinophils and mast cells to fight parasite infection. Th17 cells play critical roles in protection 
against extracellular bacteria and fungi by mediating neutrophil responses. Treg in turn, help 
to suppress immune responses to prevent autoimmunity (Zhu and Paul, 2010). While CD4+ T 
cells predominantly help to mediate the adaptive immune response, CD8+ T cells are 
characterized as cytotoxic lymphocytes, which efficiently kill virus-infected or cancerous cells 
by inducing apoptosis via release of perforin, granzymes and granulysin or engagement of Fas 
death receptors (Harty, Tvinnereim and White, 2000). Upon antigen encounter, naïve T cells 
progressively differentiate into central-memory (Tcm), effector memory (Tem) and finally, 
effector (Teff) T cells, accompanied by changes in metabolism, cell surface molecules and 
acquisition of effector functions, eventually resulting in senescence (Restifo and Gattinoni, 
2013). Multipotent, self-renewing memory stem cells (Tscm) that exhibit increased proliferative 
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capacity and superior anti-tumor responses were identified as an efficacious T cell subset for 
the use in adoptive T cell therapy (Gattinoni et al., 2011).  
The first signal required for activation of a T cell is the specific recognition of peptide-MHC 
complexes on APCs via the TCR. The TCR  and  chains form a heterodimer that binds the 
target via the extracellular variable domain assuming a barrel-shaped structure of two anti-
parallel -strands that contact antigen via hypervariable complementary-determining regions 
(CDRs) (Garcia et al., 1996). However, the constant region of the TCR comprises hydrophobic 
transmembrane domains that anchor the TCR in the cell membrane but lack any signaling 
function. Therefore, to enable signal transduction upon antigen recognition, the TCR has to 
associate with invariant accessory proteins, which are termed the CD3 complex. The CD3 
complex comprises six subunits, which form three signaling dimers, CD3 CD3 and CD3 
that assemble with the TCR  and  chains in the ER (Exley, Terhorst and Wileman, 1991). 
Correct assembly of the TCR complex is thought to occur via polar interactions in the 
transmembrane regions of the respective dimers resulting in association of the TCR  chain 
with the CD3 the CD3 dimer, while the CD3 dimer interacts with the TCR  chain (Call 
et al., 2002). Additional interactions of the extracellular domains comprising conserved 
CxxCxE motif in CD3 stalk regions and loops in the TCR  and  constant immunoglobulin 
domains contacting CD3 ectodomains are thought to contribute to the correct assembly of the 
TCR complex (Call and Wucherpfennig, 2007; Natarajan et al., 2016). Conformational changes 
in the TCR complex upon antigen contact resulting in rearrangements of the respective 
subunits are thought to trigger signal transduction possibly amplified by TCR dimerization or 
clustering (Call and Wucherpfennig, 2007; Birnbaum et al., 2014; Pryshchep et al., 2014; 
Natarajan et al., 2016) However, recent studies showed that exclusively monomeric TCR-CD3 
complexes drive the recognition of peptide-MHC complexes via the immunological synapse 
without the requirement of ligand-induced multimerization of TCRs (Brameshuber et al., 2018).  
While the exact mechanism by which TCR-peptide-MHC interaction is transmitted across the 
membrane is still a topic of active research, downstream signal transduction has been well 
elucidated. Signal transduction is initiated by phosphorylation of tyrosine-based activation 
motifs (ITAMs) present in the cytoplasmic domain of the CD3 subunits by Scr family kinase 
Lck associated with the co-receptors CD4 and CD8. This results in the recruitment and 
activation of tyrosine kinase ZAP-70, which binds to the phosphorylated ITAMs via SH2 
domains. ZAP-70 in turn phosphorylates the scaffold proteins LAT and SLP-76, which, 
together with another adaptor protein (Gads), form a membrane-proximal complex with 
phospholipase C- (PLC-). PLC- activation is mediated by Itk tyrosine kinase and represents 
the key event in downstream signaling mediated through the generation of the second 
messengers diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3). Downstream signaling 
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events result in the activation of the transcription factors NFB, NFAT and AP-1, which 
coordinate transcription of specific genes resulting in T cell activation, proliferation and 
differentiation. (Smith-Garvin, Koretzky and Jordan, 2009; Kannan et al., 2012; Malissen and 
Bongrand, 2015) 
 
1.2 TCR-based cancer immunotherapy 
While T cells have the ability to recognize various viral and microbial invaders mediated by the 
high variability of their TCRs recognizing specific antigens, recognition of self-antigens is 
usually prevented by thymic selection of T cells to avoid autoimmunity (Klein et al., 2014). 
However, in the last century the theory that cancerous cells displaying altered or aberrantly 
expressed self-antigens could be detected and efficiently eradicated by the immune system 
was proposed by Burnet in 1957 (Burnet, 1957). Over the past decades, extensive research 
utilizing immunocompromised mouse models led to the acceptance of the principle of cancer 
immune surveillance and immunoediting, which consists of three phases: (I) elimination of 
developing tumors by the immune system, (II) equilibrium state, in which the tumor growth is 
restrained, and (III) escape of tumor variants that are no longer recognizabled by the immune 
system (Dunn et al., 2004; Schreiber, Old and Smyth, 2011). The effector functions required 
for tumor eradication include IFN- secretion and cytotoxicity, both characteristics of antigen-
specific T cell responses (Dunn et al., 2004). This led to a new focus in cancer therapy, that 
included the administration of tumor-specific T cells to patients with the aim of targeting 
cancerous cells utilizing the immune system, termed adoptive T cell transfer (ACT) therapy 
(Dudley and Rosenberg, 2003). First proof of concept in humans was provided by Rosenberg 
et al., who observed cancer regression in patients suffering from metastatic melanoma after 
re-infusion of ex vivo expanded autologous tumor-infiltrating lymphocytes (TILs) (Rosenberg, 
Spiess and Lafreniere, 1986; Dudley et al., 2005; Rosenberg et al., 2011). While the presence 
of TILs in human tumors  simultaneously demonstrated the involvement of the immune system 
in protection from cancerous cells, this approach is dependent on the pre-existence of tumor-
reactive cells in the patient and might therefore not be applicable to all patients nor indications 
other than melanoma (Morgan et al., 2006; Restifo, Dudley and Rosenberg, 2012; Miller and 
Sadelain, 2015). Utilizing autologous T cells engineered to express tumor-specific TCRs can 
circumvent this limitation and has been shown to induce anti-tumor responses in melanoma 
patients (Morgan et al., 2006; Johnson et al., 2009). Currently, various clinical trials utilizing 
ACT of genetically engineered T cells have been registered to target tumors other than 
melanoma, including synovial cell sarcoma, neuroblastoma, colorectal cancer and leukemia 
(Duong et al., 2015; Ping, Liu and Zhang, 2017). Production procedures for this kind of therapy 
usually comprise the isolation of patient-derived autologous T cells, which are subsequently 
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transduced with the tumor-specific TCR utilizing retroviral vectors, and re-infusion of the 
expanded cells into the patient (Restifo, Dudley and Rosenberg, 2012). A key prerequisite of 
TCR immunotherapy is the identification of tumor-specific TCRs that efficiently recognize 
cancerous cells without showing off-target recognition. Different methods have been 
developed for the isolation of these TCRs, which can be derived from TILs of cancer patients, 
humanized mice or in vitro priming methods, that utilize autologous or allogenic peptide-
specific stimulation of T cells from healthy donors  (Ho et al., 2006; Wilde et al., 2009; 
Dössinger et al., 2013; Blankenstein et al., 2015; Obenaus et al., 2015). After identification of 
T cell clones exhibiting the desired effector functions and specificity, the sequence of the 
endogenous TCR has to be isolated by polymerase chain reaction (PCR)-based methods, like 
rapid amplification of cDNA-ends (RACE)-PCR, and subsequently evaluated for safety and 
efficacy in a transgenic setting (Wilde, Sommermeyer, et al., 2012; Dössinger et al., 2013; 
Simon et al., 2014; Rosati et al., 2017). However, the basis for obtaining tumor-specific TCRs 
that can be used in a clinical setting is the selection of appropriate target antigens. Two classes 
of non-viral antigens can be distinguished: tumor-associated antigens (TAAs) and tumor-
specific antigens (TSAs). TAAs are aberrantly- or over-expressed self-antigens also present 
on healthy tissues, which include cancer-testis antigens, like the MAGE family, tissue 
differentiation antigens, like Melan-A, and overexpressed self-proteins, like Her-2/Neu. In 
contrast, TSA are neoantigens that arise as a consequence of somatic mutations in tumors, 
which would make them ideal targets for immunotherapy. However, while neoantigens are 
mostly patient-specific, TAA are usually shared between patients making them more suitable 
for the development of widely applicable therapies (Heemskerk, Kvistborg and Schumacher, 
2013; Blankenstein et al., 2015). Moreover, toxicities due to on-target recognition of TAAs in 
tissues other than tumor is a major concern and has already been proven fatal in the case of 
the MAGE-A3 antigen (Morgan et al., 2013). One strategy to improve the safety of adoptive T 
cell therapy is the inclusion of so-called suicide genes, like the genes encoding herpes simplex 
virus-1 thymidine kinase (HSV-TK) or inducible caspase 9 (iCasp9), which can be activated by 
prodrugs or small molecules, respectively, and result in the rapid elimination of the infused T 
cells (Bonini and Mondino, 2015). Another way to reduce the risk of off-target toxicity is to 
prevent mispairing of endogenous and exogenous transgenic TCR chains, which can result in 
unpredictable new TCR specificities possibly causing autoimmunity (Bendle et al., 2010; Yang, 
2015). Strategies to achieve preferential pairing of the transgenic TCR chains include minimal 
amino acid exchanges or addition of cysteines into the TCR constant regions, as well as 
generation of hybrid molecules comprising the extracellular part of the TCR chains fused to 
the intracellular CD3 domain (Kuball et al., 2007; Sebestyen et al., 2008; Sommermeyer and 
Uckert, 2010). However, in order to completely abolish the risk of TCR mispairing and ensure 
high surface expression of the tumor-specific TCR, the endogenous TCR chains have to be 
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suppressed. This can be achieved by TCR knockout mediated by gene editing tools, like 
TALEN or CRISPR/Cas9 (Knipping et al., 2017).  
 
1.3 Chimeric antigen receptors (CARs) and cancer immunotherapy 
The first in vitro experiments of chimeric T cell receptors, which comprised an extracellular 
antibody-derived immunoglobulin domain and could redirect T cells to target tumor cells with 
an antibody-type specificity, were published in 1989 by Gross et al. (Gross, Waks and Eshhar, 
1989). Since then, extensive research on these chimeric antigen receptors (CARs) has 
resulted in clinical application of CAR T cells for various indications with a present focus on B 
cell malignancies (Gill, Maus and Porter, 2016). CARs are modularly assembled proteins that 
link the extracellular ligand recognition domain, comprised typically of an antibody-derived 
single chain variable fragment (scFv), to an intracellular signaling domain containing the CD3 
chain to mimic signal transduction via the TCR complex and induce T cell activation (Srivastava 
and Riddell, 2015). The scFv is coupled to the intracellular signaling moiety via a hinge domain 
and a transmembrane domain. However, these first generation CARs failed to provide 
necessary T cell stimulation to achieve tumor cell lysis and persistence, probably due to the 
lack of co-stimulation required for proper T cell activation (Gong et al., 1999; Sadelain, 
Brentjens and Rivière, 2009). The development of second generation CARs targeting CD19 
that comprised additional intracellular co-stimulatory domains, including CD28, 4-1BB, and 
OX40, dramatically improved efficacy in clinical trials even obtaining complete remissions in 
some patients (Ramos, Savoldo and Dotti, 2014; Maus and June, 2016). Third generation 
CARs containing a combination of two co-stimulatory domains, like CD28/4-1BB or 
CD28/OX40, targeting CD20 and CD19, respectively, show promising results in mouse models 
and are currently evaluated in clinical settings (Till et al., 2012; Tang et al., 2016). However, 
severe fatal toxicities and cytokine storm syndrome were reported for a patient treated with a 
third generation ERBB2-specific CAR (Morgan et al., 2010). This demonstrates the importance 
of thorough target evaluation equivalent to TCR-based adoptive T cell transfer. While TCRs 
recognize intracellularly processed protein in an MHC-dependent manner, CARs utilize the 
specificity of monoclonal antibodies to bind directly to target structures present on the tumor 
cell surface (Harris and Kranz, 2016). Both TCRs and antibodies are generated by 
hypervariable V(D)J recombination enabling the recognition of a vast variety of antigens, 
however, determining the required affinity suitable for T cell activation and tumor cell 
eradication is still challenging due to factors like antigen density and receptor expression levels 
affecting activity (Turatti et al., 2007; Harris and Kranz, 2016). Spatial constraints between 
CAR T cells and target epitopes on APCs, influencing formation of the immunological synapse, 
might additionally impact tumor cell recognition (Srivastava and Riddell, 2015). The 
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dependency on the nature and length of the extracellular spacer domain for in vivo anti-tumor 
activity demonstrated the influence of this spatial interaction, which in turn can vary based on 
structure and density of the target molecule (Hudecek et al., 2015). While it could be assumed 
that the higher the affinity of the receptor the better the activation of the T cell, recent studies 
demonstrated an affinity threshold for both TCRs and CARs that did not further increase 
activation, but rather contributed to decreased sensitivity (Zhong et al., 2013; Chmielewski et 
al., 2004; Caruso et al., 2015). Especially when targeting overexpressed TAAs in 
immunotherapy, discrimination between tumor and healthy tissue is imperative to avoid on-
target off-tumor toxicity. Another factor affecting CAR T cell efficacy in eradicating tumors is 
proliferation and persistence of the adoptively transferred T cells. While this can be negatively 
influenced by a suppressive tumor microenvironment, proliferative capacity is largely 
dependent on the co-stimulatory signaling domains incorporated in the CAR construct (Lim 
and June, 2017). Most of the CARs tested in recent clinical trials utilize CD28 or 4-1BB for co-
stimulation to enhance efficacy in vivo. While CD28-containing CARs seem to exhibit a higher 
initial anti-tumor activity, CARs comprising the 4-1BB signaling domain show better 
persistence and overall tumor control (Milone et al., 2009; Lim and June, 2017). This was 
impressively demonstrated by sustained remission in CLL patients months after infusion of 
4-1BB-containing CD19-CAR T cells, which simultaneously showed that immunological 
memory can be established using adoptively transferred receptor-engineered T cells (Kalos et 
al., 2011; Porter et al., 2011).  
 
1.4 TCR knockout – TALEN & CRISPR/Cas9 in immunotherapy 
Transcription activator-like effectors (TALEs) is a class of specific DNA binding proteins 
derived from plant pathogenic bacteria Xanthomonas spp., which contribute to disease by 
mimicking eukaryotic transcription factors (Kay et al., 2007; Boch and Bonas, 2010). The DNA 
binding domain of TALEs is characterized by a central repeat domain of variable length, each 
repeat typically consisting of 24 amino acids (Herbers, Conrads-Strauch and Bonas, 1992). 
While the number of repeats can vary between 1.5 and 33.5, 17.5 repeats followed by a half 
repeat are most frequently observed (Boch and Bonas, 2010). Binding specificity is mediated 
by an adjacent pair of hypervariable amino acids, termed repeat-variable di-residues, (RVDs), 
at positions 12 and 13 in each repeat, which independently bind one base of the DNA. The 4 
most frequent RVDs (NG, HD, NI, NN) preferentially associate with one of the four bases of 
the DNA (T, C, A, G) resulting in a remarkably simple code that governs sequence specificity 
(Boch et al., 2009; Moscou and Bogdanove, 2009). Each RVD consists of two -helices 
connected by a short RVD loop that contacts the major groove of the DNA. While residue 12 
stabilizes the RVD loop, the 13th residue mediates the base-specific contact and serves as 
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the structural basis of the sequence-specific interaction (Deng et al., 2012). In contrast to other 
DNA binding proteins, like zinc fingers, which can be challenging to design due to difficult target 
prediction, the straightforward sequence relationship of TALEs allows the easy identification 
of TALE binding sites. Additionally, the modular repeat structure in combination with the simple 
DNA binding code enables the easy assembly of TALE repeat arrays that can function as 
highly specific DNA binding domains (Boch, 2011; Bogdanove and Voytas, 2011). Combining 
the customized DNA binding domain of TALEs with catalytic domains of nucleases or 
transcription activation or repressor domains to generate TALE nucleases (TALENs) or TALE 
transcription factors (TALE-TFs), respectively, opened the possibility to create sequence-
specific gene editing tools that could be used for gene knockout or for modulation of gene 
expression (Bogdanove and Voytas, 2011). While the modular repeat structure facilitates 
TALE design, assembly can be challenging due to the highly repetitive nature of these RVD-
containing repeats (Cermak et al., 2011). Several groups developed different protocols for the 
generation of TALEN and TALE-TF that are predominately based on Golden Gate cloning 
strategy enabling the simultaneous assembly of multiple DNA fragments in an ordered fashion 
(Cermak et al., 2011; Li et al., 2011; Morbitzer et al., 2011; Zhang et al., 2011; Sanjana et al., 
2012). Golden Gate cloning is based on type IIS restriction enzymes characterized by their 
property of cleaving outside the recognition site to create unique 4 bp overhangs. When utilized 
for molecular cloning, correct ligation of DNA fragments is guided by pairing of the unique 
overhangs, which simultaneously eliminates restriction enzyme recognition site upon correct 
assembly (Engler et al., 2009). Based on the described protocols TALENs and TALE-TF can 
be customized to target any gene in different organisms, which has been already demonstrated 
in vitro and in vivo (Christian et al., 2010; Cermak et al., 2011; Zhang et al., 2011; Huang et 
al., 2011; Li et al., 2011; Miller et al., 2011; Mussolino et al., 2011; Sander et al., 2011; Tesson 
et al., 2011; Wood et al., 2011; Haute et al., 2013).  
To improve target specificity and reduce the risk of off-target cleavage, TALENs are designed 
as pairs that bind different target sites, which are separated by a 10 – 30 base pair spacer 
(Bogdanove and Voytas, 2011). Since the commonly used FokI endonuclease functions as a 
dimer, each TALEN can be fused to a monomeric catalytic domain (Bitinaite et al., 1998). Only 
upon specific binding of both TALENs to the respective target site in inverse orientation, 
dimerization of the monomeric FokI domains in the spacer region can occur and nuclease 
activity will generate a non-specific DNA double strand break (DSB) (Pingoud and Wende, 
2011). For the identification of suitable TALEN target sites in any gene of interest, which are 
usually preceded by a T or C, prediction tools have been developed that scan the input 
sequence according to custom set parameters, like number of repeats and spacer length, and 
allow identification of potential off-target sites (Doyle et al., 2012)  
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In addition to TALENs, another gene editing system has recently been developed that is based 
on clustered regularly interspaced short palindromic repeats (CRISPR) RNAs that guide 
CRISPR-associated (Cas) proteins to mediate DNA cleavage (Cong et al., 2013; Mali et al., 
2013). The CRISPR/Cas system functions as a nucleic acid-based adaptive immune system 
in prokaryotes for protection against invading viral and plasmid DNA (Wiedenheft, Sternberg 
and Doudna, 2012; Barrangou and Marraffini, 2014). CRISPR loci comprise short palindromic 
DNA repeats (CRISPR repeats) separated by unique spacer sequences (CRISPR spacers) 
homologous to exogenous genetic elements. It has been shown in S. thermophilus that new 
short virus-derived sequences will be preferentially integrated at the leader end of the CRISPR 
locus upon phage-challenge, thereby demonstrating how protective immunity is acquired in 
prokaryotes (Barrangou et al., 2007). Proto-spacer adjacent motifs (PAMs) have been 
identified in exogenous donor DNA, termed proto-spacer, that mediate both immunization by 
identifying spacer sequences for incorporation and target selection for foreign DNA cleavage 
(Mojica et al., 2009; Gasiunas et al., 2012; Jiang et al., 2013; Paez-Espino et al., 2013). The 
mechanism of spacer integration involves the conserved Cas1 and Cas2 proteins that form an 
integrase complex, which catalyzes a nucleophilic attack of prespacer 3’OH ends on the 
leader-proximal repeat thereby mediating integration of the spacer sequence into the CRISPR 
loci (Jackson et al., 2017; Xiao et al., 2017). The CRISPR/Cas system functions in three steps: 
(I) Acquisition of new spacers into the CRISPR locus, (II) CRISPR RNA (crRNA) biogenesis to 
generate small interfering RNAs, and (III) targeting of foreign homologous sequences with Cas 
nucleases guided by crRNAs (Barrangou and Marraffini, 2014). Three types of CRISPR/Cas 
systems can be distinguished that differ in the mechanism of crRNA processing and the protein 
machinery involved in target recognition and cleavage. In contrast to type I and III CRISPR/Cas 
systems utilizing large multimeric nucleoprotein complexes, type II CRISPR/Cas system 
requires only Cas9 nuclease to mediate DNA cleavage via intrinsic RuvC and NHN domains. 
Due to its simplified nature, this system predominately serves as the basis for the use of 
CRRISPR/Cas as a gene editing tool (Barrangou and Marraffini, 2014). Cas9 endonuclease is 
guided to the PAM-containing target sequence by crRNA, which is processed and loaded onto 
Cas 9 with the help of RNaseIII and trans-encoded CRISPR RNA (tracRNA), comprising a 
complementary region of 24 nucleotides to the repeat region of the crRNA precursor transcript 
(Deltcheva et al., 2011). By generating a chimeric fusion RNA of tracRNA and crRNA, termed 
single-guide RNA (sgRNA) that retains secondary structures required for Cas9 cleavage 
activity, the CRISPR/Cas9 system was further simplified for the use as an RNA-directed gene 
editing tool (Jinek et al., 2012). Therefore, in order to target a specific gene for disruption by 
Cas9 nuclease, only the crRNA moiety that mediates specific DNA binding has to be adapted 
to show homology to the DNA target region. Several structural studies in the recent years 
revealed that the CRISP/Cas9-mediated DNA cleavage mechanism requires sgRNA 
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accommodation in Cas9 to induce conformational changes that convert the ribonucleoprotein 
complex into an active form. The Cas9 protein comprises six domains responsible for sgRNA 
binding (RecI), initiation of binding to target DNA (PAM interacting domain) and cleavage of 
single-stranded DNA (RuvC and HNH). Upon recognition of the PAM-containing target 
sequence, the DNA duplex is unwound to allow specific pairing of target DNA and homologous 
crRNA, which triggers DNA cleavage by RuvC and HNH nuclease domains, each targeting 
separate DNA strands. An arginine-rich bridge helix is critical for sgRNA and ssDNA 
interaction, which form a heteroduplex via Watson-Crick base pairs that is accommodated in 
a central channel in the Cas9 protein between two lobes (Jinek et al., 2014; Nishimasu et al., 
2014; Jiang and Doudna, 2017; Nishimasu and Nureki, 2017). Cleavage activity of both 
nuclease domains is regulated by HNH conformational changes into the active form, which is 
prevented by mismatches between target DNA and sgRNA, thereby serving as a 
conformational checkpoint to prevent off-target cleavage (Dagdas et al., 2017).  
While TALENs mediate target recognition via amino acid residues interacting with the DNA, 
the CRISPR/Cas9 system utilizes Watson-Crick base pairing of an RNA-DNA-heteroduplex to 
identify homologous target regions. However, both systems utilize non-specific nuclease 
domains that are guided by the DNA binding moiety to create a sequence-specific DNA double 
strand break (DSB) in the host genome. The introduced DSB activates endogenous DNA 
repair mechanisms, which attempt to restore the integrity of the genome. Two highly conserved 
mechanisms are predominately used in eukaryotes for repair of DSB: (I) non- homologous end 
joining (NHEJ), which mostly results in small deletions or insertions at the break site that can 
disrupt gene function and lead to gene knockout, and (II) homologous recombination (HR), 
which restores the break site without introducing mutations by utilizing the sister chromatid or 
homologous chromosome as a repair template (Jackson, 2002). HR can be exploited for 
directed genome editing to introduce a gene of interest or correct a mutated gene by providing 
repair templates comprising homologous sequences to the DNA target site (Pingoud and 
Wende, 2011; Sander and Joung, 2014).  
The simple design and production process of both TALEN and CRISPR/Cas system 
revolutionized gene editing in the scientific community and opened the possibility for 
therapeutic applications (Gaj, Gersbach and Barbas, 2013; Hsu, Lander and Zhang, 2014; 
Sander and Joung, 2014; Mojica and Montoliu, 2016). Several clinical trials have been 
registered at clinicaltrials.gov (Table 2.16) in the recent years that comprise ex vivo and in vivo 
gene therapy (Shim et al., 2017; Dunbar et al., 2018). As of today, in vivo approaches mainly 
focus on the delivery of wildtype-genes to replace a mutated or missing gene in patients 
predominantly utilizing randomly integrating viral vectors or adeno-associated virus (AAV) 
vectors. However, first genome editing trials in patients using zinc finger nucleases (ZFNs) to 
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replace defective genes in the albumin locus for the treatment of mucopolisaccharidosis (MPS) 
I and II were launched in 2017 (Dunbar et al., 2018). Despite rapid technological advances in 
TALEN- and CRISPR/Cas-mediated gene editing in vitro, application and safety hurdles that 
include potential off-target mutations and immunogenicity will first have to be overcome before 
these therapies will be approved for clinical testing in patients (Shim et al., 2017). In contrast, 
TALEN and CRISPR/Cas system are currently already applied in ex vivo modification of 
autologous cells before re-infusion into the patient. This includes the disruption of the CCR5 
gene in T cells and hematopoietic stem and progenitor cells (HSPC) of patients infected with 
HIV using CRISPR, however ZFN are more often used in this indication based on extensive 
pre-clinical studies (Gu, 2015). TALENs targeting the TCR  chain of T cells are predominately 
used in the production of universal CD19-CAR T cells for treatment of B cell malignancies to 
prevent off-target recognition mediated by the endogenous TCR. Treatment of two infants 
suffering from acute lymphoblastic leukemia (ALL) with genetically engineered cells resulted 
in sustained molecular remission and currently more patients are being recruited (Qasim et al., 
2017). Clinical studies utilizing the CRISPR/Cas9 system involve primarily the knockout of 
inhibitory PD-1 (programmed cell death protein 1) to prevent T cell dysfunction and exhaustion 
mediated by interaction with PD-1 ligands (Xu-Monette et al., 2017; Dunbar et al., 2018). 
Recently, the first phase I CRISPR gene editing trial was initiated in the United States that 
uses autologous T cells redirected with a NY-ESO-1-specific TCR and genetically engineered 
to eliminate endogenous TCR as well as PD-1 expression for the treatment of melanoma, 
synovial sarcoma, and multiple myeloma (Baylis and McLeod, 2017). The knockout of the 
endogenous TCR in this setting prevents mispairing with transgenic TCR chains and the 
possible generation of unintended neo-reactivities (Heemskerk, 2010). Another approach is 
currently investigated in pre-clinical studies, which comprises the directed knockin of a CD19-
CAR into the TRAC locus utilizing the CRISP/Cas9 system to generate a sequence-specific 
DSB and an AAV vector coding for the CAR to mediate integration into the target loci (Eyquem 
et al., 2017). This enables the expression of the CD19-CAR under natural regulatory elements 
and simultaneously prevents possible off-target recognition through the endogenous TCR.  
 
1.5 Aim of this thesis 
Various high-throughput platforms have been developed for the isolation of tumor antigen-
specific TCRs for the use in adoptive immunotherapy for cancer (Montagna et al., 2001; Ho et 
al., 2006; Wilde, Geiger, et al., 2012). For clinical application, tumor antigen-specific TCRs are 
introduced into patient lymphocytes followed by adoptive transfer of the ex vivo engineered T 
cells. To facilitate efficient anti-tumor reactivity of the transferred lymphocytes, the introduced 
TCR has to be fully functional in the transgenic setting. That means the TCR has to confer the 
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antigen specificity and effector functions of the original T cell clone to the recipient T cell 
population.  Additionally, extensive evaluation of potential toxicities has to be performed prior 
to the clinical use of the respective TCR to ensure safe administration of the genetically 
modified T cells to patients. Common TCR-induced toxicities can be divided into on-target and 
off-target toxicities. On-target toxicities occur by antigen expression in tissues other than the 
targeted tumor, while common off-target toxicities are caused by cross-recognition of 
alternative epitopes by the transgenic receptor or newly formed specificities of mispaired 
heterodimers of endogenous and transgenic TCR  and  chains, i.e. TCR mispairing (Bendle 
et al., 2010; Yang, 2015). Both toxicity scenarios have to be excluded by elaborate safety 
testing of the TCR against healthy tissue samples and peptide libraries before the initiation of 
clinical trials. However, a large number of cells expressing the transgenic TCR are required for 
thorough efficacy and safety evaluation. Hence, appropriate TCR recipient cells are needed 
that allow efficient testing of isolated candidate TCRs. To date, bulk peripheral blood 
lymphocytes (PBL), which can be isolated from donor blood in sufficient numbers, are 
commonly used as TCR recipient cells. Even though these cells carry all signaling and effector 
functions required for a physiological read-out of transgenic TCR function and reactivity, they 
also comprise a diverse mixture of different lymphocyte subsets with heterogenous reactivity 
profiles that introduce unknown variables into experiments. In addition, the resulting recipient 
cells express the introduced antigen-specific TCRs as well as the endogenous TCRs of 
unknown specificity, which could severely affect or alter the function of the transgenic TCR by 
dominant effects of the endogenous TCR or TCR mispairing.  
To prevent interference of endogenously expressed TCRs with experimental procedures and 
read-outs, the endogenous TCR chains would have to be eliminated in recipient cells. The 
generation of a suitable TCR-negative universal recipient cell that efficiently proliferates in vitro 
and retains all necessary effector functions for efficacy and safety testing would allow the 
creation of a stable test system, in which transgenic TCRs could be introduced without the 







Figure 1.1: Recipient cells for the characterization of transgenic TCRs. A tumor antigen-specific TCR is 
isolated from the original T cell clone exhibiting the desired reactivity patterns. To test whether effector functions 
and specificity can be conferred to recipient cells, the transgenic TCR is introduced either in PBL or universal 
recipient cells, respectively. PBL express the introduced tumor antigen-specific TCR as well as endogenous TCRs 
of unknown specificity. In contrast, universal recipient cells lacking an endogenous TCR will only express the 
transgenic TCR specific for the desired tumor antigen, thereby abolishing the risk of TCR mispairing and dominant 
effects of endogenously expressed TCRs.   
 
However, the generation of TCR-negative recipient cells is complicated by the fact that 
physiological activation and proliferation of T cells is mediated through the specific interaction 
of the TCR with peptide-bound MHC molecules on antigen presenting cells (Figure 1.2). Once 
the endogenous TCR of a T cell is absent, the possibility to activate and expand the cell to 
sufficient numbers is lost. Therefore, in order to generate a stable test system for the 
characterization of multiple transgenic TCRs, continuous T cell growth has to be achieved 
independent of TCR signaling prior to TCR knockout. Ideally, the desired test system would 
utilize an alternative route for expansion – other than the TCR itself – without introducing 
adverse modifications into the inherent T cell signal transduction cascade.  
A promising alternative to classical activation of T cells via the endogenous TCR is the 
stimulation of T cells through the engagement of an introduced CAR. Although the exact 
signaling events following specific antigen binding via the scFv of CARs are still a topic of 
active investigation, various studies have demonstrated the feasibility of TCR-independent 
activation of T cells via these chimeric receptors (Maher et al., 2002; Finney, Akbar and 
Alastair, 2004; Sommermeyer et al., 2015). Observed long persistence of these CAR T cells 
in patients, months after treatment, could be attributed to re-activation of these cells in vivo 
mediated through the introduced CAR (Porter et al., 2011). However, it is unknown whether 
long-term continuous T cell expansion can be achieved via CAR engagement in T cells lacking 
endogenous TCR expression.  
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The ability of a selected CAR to promote T cell expansion can be influenced by various factors, 
including the combination of the incorporated signaling domains as well as the respective 
target antigen. Since CAR constructs are generally designed to mediate tumor cell killing, 
rather than to enhance proliferative capacity of recipient T cells, the CAR domain structure 
best suited for physiological T cell expansion is not yet fully resolved.  
The aim of this thesis was the generation of universal recipient cells for testing and 
characterization of transgenic TCRs that can be expanded independently of the endogenous 
TCR (Figure 1.2). TCR-independent activation of T cells was achieved through an introduced 
CAR that can mediate T cell proliferation upon specific binding of antigen. CAR constructs 
comprising different combinations of signaling domains were evaluated for their ability to 
promote T cell growth. Once the modified T cells expanded sufficiently via CAR engagement, 
the endogenous TCR was knocked out utilizing state-of-the-art gene editing tools, like TALEN 
and CRISPR/Cas9, to generate recipient cells that lack the endogenous TCR. The resulting 
TCR-negative universal recipient cells that proliferated upon CAR-specific activation 
subsequently served as recipients for transgenic TCRs to validate their suitability as a stable 
and reproducible test system for direct comparison of individual TCRs.  
 
 
Figure 1.2: Strategy for generation of universal recipient cells for testing of transgenic TCRs. Physiological 
antigen-specific activation of T cells is mediated through the interaction of the TCR and peptide-bound MHC 
molecules on antigen presenting cells (APCs). CD4 or CD8 co-receptors support this interaction and distinguish 
CD4+ and CD8+ T cells, respectively. Once the TCR is absent, the ability to expand T cells is lost. By introducing a 
CAR into T cells, TCR-independent stimulation can be achieved. The knockout of the endogenous TCR creates 




2.1 Equipment and consumables 
Table 2.1: Equipment and consumables 
Product Name Manufacturer 
Accu-jet® pro Brand, Wertheim, Germany 
BD™ High Throughput Sampler (HTS) BD Bioscience, Heidelberg, Germany 
BD Plastipak™ Wund- und Blasenspritze, 100 ml BD Bioscience, Heidelberg, Germany 
C-Chip, Neubauer improved NanoEnTek, Seoul, Korea 
Cell culture flasks (25, 75 and 150 cm2) Cellstar ®  Greiner Bio-One, Munich, Germany 
Cell culture plates (6, 12, 24, 48, 96 well) Corning, New York,USA 
Cell culture plates (6, 12, 24, 48, 96 well) TPP, Trasadingen, Switzerland 
Cell Sorter FACSAriaTM Fusion BD Bioscience, Heidelberg, Germany 
Centrifuge 1-16K  Sigma, Osterode am Harz, Germany 
ChemiDoc™ XRS+ Gel Documentation System  Bio-Rad Loboratories, Munich, Germany 
Counting chamber according to Neubauer Neo-Lab, München, Germany 
Cryopreservation vials (1 and 2 mL) Nunc, Wiesbaden, Grmany 
Cryopreservation vials (1.8 mL) Corning, New York, USA 
DNA LoBind Tubes (0.5 and 1.5 mL) Eppendorf, Hamburg, Germany 
DynaMag™-2/5 Magnet Thermo Fisher Scientific, Waltham, MA, USA 
ECOSHIELD™ ECO NITRILE PF 250 Shield Scientific, Bennekom, Netherlands 
Electrophoresis chambers Bio-Rad Laboratories, Munich, Germany 
Electroporation cuvettes (0.4/0.1cm) Bio-Rad Laboratories, Munich, Germany 
Electroporator Gene Pulse XcellTM Bio-Rad Laboratories, Munich, Germany 
Elix® Advantage 15 Water Purification System Merck, Darmstadt, Germany 
Falcon® tubes (15 and 50 mL) Corning, New York, USA 
Falcon® round bottom test tubes sterile (5 mL) Corning, New York, USA 
FinnpetteTM F2 Pipette 8/12-channel  Thermo Fisher Scientific, Waltham, MA, USA 
Flow cytometer, LSR Fortessa BD Bioscience, Heidelberg, Germany 
Freezer -150 °C Panasonic, Kadoma, Osaka, Japan 
Freezer -20 °C  Liebherr, Bulle, Sitzerland 
Freezer -80 °C Panasonic, Kadoma, Osaka, Japan 
Freezing container, Nalgene ® Mr. Frosty Nalgene, Hereford, UK 
Glass beads  Carl Roth, Karlsruhe, Germany 
GRIPTIPS (sterile) 300 µL, 1250 µL Integra Biosciences AG, Zizers, Switzerland 
HeracellTM 150i CO2 incubator Thermo Fisher Scientific, Waltham, MA, USA 
Heraeus™ Multifuge™ X3R Universalzentrifuge Thermo Fisher Scientific, Waltham, MA, USA 
Herasafe HSP 12, laminar flow Heraeus, Hanau, Germany 
Materials  
17 
Product Name Manufacturer 
ImmunoSpot® S6 ULTIMATE CTL, Cleveland, OH, USA 
IncuCyte® ZOOM System  Essen Bioscience, Ann Arbor, Michigan, USA 
Laboratory balance Satorius, Goettingen, Germany 
Magnet DynaMagTM Thermo Fisher Scientific, Waltham, MA, USA 
Mastercycler® nexus  Eppendorf, Hamburg, Germany 
MC6® chemical hood Waldner, Wangen, Germany 
Microcentrifuge tubes (0.5, 1.5 and 2 mL) Eppendorf, Hamburg, Germany 
Microwave Bosch, Stuttgart, Germany 
Mikroskop Primovert Zeiss, Göttingen, Germany 
Multiskan™ FC Mikrotiterplatten-Photometer Thermo Fisher Scientific, Waltham, MA, USA 
NanoDropTM 2000c Thermo Fisher Scientific, Waltham, MA, USA 
Nunc Immuno Washer 8/12-channel Nunc, Wiesbaden, Grmany 
Nunc-Immuno™ 96 Well Plate Thermo Fisher Scientific, Waltham, MA, USA 
Parafilm Pechiney, Menasha, USA 
Pasteur pipettes Peske OHG, Munich, Germany 
Petri dishes 10 cm Thermo Fisher Scientific, Waltham, MA, USA 
Pipette tips (2, 20, 200, 1000 µL) Mettler Toledo, Giessen, Germany 
Pipette tips filtered (2, 20, 100, 200, 1000 µL) Starlab, Hamburg, Germany 
Pipettes Eppendorf, Hamburg, Germany 
PMC-60 Tomy Capsulefuge Tomy, Tokyo, Japan 
Power supply PowerPacTM Bio-Rad Laboratories, Munich, Germany 
Radiation facility Xstrahl RS225 Xstrahl Limited, Camberly, Surrey, UK 
Refrigerator 4 °C  Liebherr, Bulle, Sitzerland 
RNase-free Microfuge Tubes (1.5 mL); Ambion Thermo Fisher Scientific, Waltham, MA, USA 
Round bottom tubes 5 ml Corning, New York, USA 
Round bottom tubes with cell strainer cap 5 ml  Corning, New York, USA 
Scotsman AF103 Ice Flaker Hubbard Systems, Ipswich, UK 
SONY SH800S Cell Sorter SONY Biotechnology, San Jose, CA, USA 
Sterile plastic pipettes (5, 10, 25 mL) Corning, New York, USA 
Surflo® winged infusion sets Terumo, Eschborn, Germany 
Thermomixer comfort Eppendorf, Hamburg, Germany 
Tritec® Cooling Incubator with orbital shaker Tritec, Hannover, Germany 
UV transilluminator (366 nm) Bachofer, Reutlngen, Germany 
VIAFLO II 12-channel, 1250 µl Integra Biosciences AG, Zizers, Switzerland 
Vortex-Genie 2 Scientific Industries, Inc., Bohemia, NY, USA 
VOYAGER II 6-channel, 1250 µl Integra Biosciences AG, Zizers, Switzerland 
VWB 12 waterbath VWR International, Darmstadt, Germany 
WTW inolab 720 pH meter WTW, Weilheim, Germany 
Materials  
18 
2.2 Chemicals and reagents 
Table 2.2: Chemicals and reagents 
Product Name Manufacturer 
Agarose, Ultra Pure Thermo Fisher Scientific, Waltham, MA, USA 
Ampicillin Merck, Darmstadt, Germany 
Aqua ad iniectabilia Braun, Kronberg im Taunus, Germany 
Bacillol AF Bode science center, Hamburg, Germany 
Biocoll Biochrom, Berlin, Germany 
BSA (bovine serum albumin) Sigma-Aldrich, St. Louis, MO, USA 
DEPC (diethylpyrocarbonate) Sigma-Aldrich, St. Louis, MO, USA 
Dismozon® plus Bode science center, Hamburg, Germany 
DMSO (dimethyl sulfoxide) Merck, Darmstadt, Germany 
EDTA Sigma-Aldrich, St. Louis, MO, USA 
EDTA (0.5 M) Thermo Fisher Scientific, Waltham, MA, USA 
Ethanol absolute Carl Roth, Karlsruhe, Germany 
Ethidium bromide 0,025 % Carl Roth, Karlsruhe, Germany 
FACSTM Flow and Rinse BD Bioscience, Heidelberg, Germany 
FcR Blocking Reagent, human  Milteny Biotec, Bergisch Gladbach, Germany 
Glycerol Sigma-Aldrich, St. Louis, MO, USA 
Heparin-Natrium   Braun, Kronberg im Taunus, Germany 
IncuCyte® NucLight Red Lentivirus Reagent Essen Bioscience, Ann Arbor, Michigan, USA 
Ionomycin Sigma-Aldrich, St. Louis, MO, USA 
Isopropanol Carl Roth, Karlsruhe, Germany 
Luria Broth Base powder Thermo Fisher Scientific, Waltham, MA, USA 
Nuclease-free water Thermo Fisher Scientific, Waltham, MA, USA 
Paraformaldehyde 4% in PBS Thermo Fisher Scientific, Waltham, MA, USA 
PBS Dubelco w/o Ca2+ Merck, Darmstadt, Germany 
Phenol-chloroform-isoamylalcohol  Carl Roth, Karlsruhe, Germany 
Phosphoric acid 85% Carl Roth, Karlsruhe, Germany 
PMA (phorbol 12-myristate 13-acetate) Sigma-Aldrich, St. Louis, MO, USA 
Remel™ Phytohaemagglutinin (PHA) Thermo Fisher Scientific, Waltham, MA, USA 
Retronectin® Takara Bio, Montain View, CA, USA 
RNaseZap™  Thermo Fisher Scientific, Waltham, MA, USA 
Select agar  Thermo Fisher Scientific, Waltham, MA, USA 
Skim milk powder Sigma-Aldrich, St. Louis, MO, USA 
SOC medium  Thermo Fisher Scientific, Waltham, MA, USA 
Sodium acetate (3M) Thermo Fisher Scientific, Waltham, MA, USA 
Sodium carbonate (Na2CO3) Sigma-Aldrich, St. Louis, MO, USA 
Materials  
19 
Product Name Manufacturer 
Sodium hydrogen carbonate (NaHCO3) Sigma-Aldrich, St. Louis, MO, USA 
TAE 50X buffer (Tris Acetate EDTA) Thermo Fisher Scientific, Waltham, MA, USA 
TRI-Reagent® Sigma-Aldrich, St. Louis, MO, USA 
Tween® 20 Sigma-Aldrich, St. Louis, MO, USA 
UltraComp eBeads® Thermo Fisher Scientific, Waltham, MA, USA 
 
2.3 Solutions and buffer systems 
Table 2.3: Solutions and buffer systems 
Buffer Components 
Blocking Buffer  2% (v/v) BSA in PBS 
Cell Fixation Solution 1% (v/v) PFA in PBS 
DEPC-treated water 0.1% (v/v) DEPC in Elix® H2O 
ELISA Blocking Buffer 1% (w/v) skim milk powder in PBS 
ELISA Coating Buffer 8.4 g/L NaHCO3, 3.56 g/L Na2CO3 in Elix® H2O (pH 9.5) 
ELISA Washing Buffer  0.05% (v/v) Tween® 20 in PBS 
FACS Buffer 1% (v/v) FBS in PBS 
Isolation Buffer 0.1% (v/v) BSA, 2 mM EDTA in PBS (pH 7.4) 
TAE Buffer (RNA) 1X 1x TAE (50X Thermo Fisher Scientific) in DEPC-treated water 
TEA Buffer (DNA) 1X 1x (50X Thermo Fisher Scientific) TAE in Elix® H2O 
 
2.4 Kits 
Table 2.4: Kits 
Product Name Manufacturer 
OptEIA™ Human IFN-γ ELISA Set BD Bioscience, Heidelberg, Germany 
Dynabeads® Human T-Activator CD3/CD28 Thermo Fisher Scientific, Waltham, MA, USA 
Dynabeads® FlowCompTM Human CD3 Thermo Fisher Scientific, Waltham, MA, USA 
Golden Gate TALEN and TAL Effector Kit 2.0 Addgene, Cambridge, USA 
RNeasy® Mini Kit Qiagen, Hilden, Germany 
JetStarTM Plasmid Purification Kit (mini, maxi) Genomed, Löhne, Germany  
QIAquick Gel Extraction Kit (250) Qiagen, Hilden, Germany 
mMessage mMachinTM T7 Transcription Kit Thermo Fisher Scientific, Waltham, MA, USA 
Poly(A) Tailing Kit Thermo Fisher Scientific, Waltham, MA, USA 
CTL-LDC™ Live/Dead Cell Counting Kit CTL, Cleveland, OH, USA 
TMB Substrate Reagent Set BD Bioscience, Heidelberg, Germany 
SMARTer® RACE 5’/3’ Kit Takara Bio, Montain View, CA, USA 
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First Strand cDNA Synthesis Kit for RT-PCR  Roche Diagnostics, Mannheim, Germany 
PCR Master Mix Promega, Madison, WI, USA 
CellTrace™ Violet Cell Proliferation Kit Thermo Fisher Scientific, Waltham, MA, USA 
Dynabeads™ CD3 Thermo Fisher Scientific, Waltham, MA, USA 
GeneArtTM CRISPR Nuclease mRNA and 
CRISPR T7 Strings 
Thermo Fisher Scientific, Waltham, MA, USA 
TransIT®-LT1 Transfection Reagent Mirus Bio, Madison, WI, USA 
 
2.5 Enzymes 
Table 2.5: Enzymes 
Enzymes  Buffers Manufacturer 
Restriction Endonucleases 
10x NEB Buffer1-4, 
CutSmart Buffer, BSA 
New England Biolabs, Frankfurt, 
Germany 
T4 DNA Ligase 10x T4 DNA Ligase Buffer 




Table 2.6: Description vector backbones 
Vector backbone Description 
pMA 
Vector for molecular cloning and amplification in bacteria purchased from 
Geneart® (Thermo Fisher Scientific); AmpR 
pGEM 
Vector for synthesis of ivt-RNA containing T7 promoter and polyA120-tail; 
AmpR (S. Milošević) 
pES-12.6 
Retroviral self-inactivating (SIN) vector for transduction (BioNTech IMFS); 
EF1A internal promoter, CMV enhancer, 5’ LTR of MoMuLV, psi/psi+ 
packaging signal of MoMuLV, MCS, WPRE element of Woodchuck 
Hepatitis Virus 8, self-inactivating (SIN) 3’ LTR of MoMuLV, AmpR 
pMP71 
Retroviral vector for transduction; (Engels et al., 2003) 
Myeloproliferative sarcoma virus (MPSV)-LTR promoter-enhancer 
sequences and improved UTR derived from the murine embryonic stem cell 









Table 2.7: Plasmids 
Plasmid Description Source 
pGEM_eGFP_A120 Vector for generation of eGFP ivt-RNA S. Milošević* 
pES.12-6-MIT Retroviral SIN vector backbone without insert C. Ellinger* 
pMP71-MIT Retroviral vector backbone without insert C. Ellinger* 
pMA_CD3-Chimera 
_FCS_P2A_RS_eGFP 
Cloning vector encoding CD3-Chimera coding 
sequence coupled to eGFP via P2A element; 
Furin cleavage site (FCS) and additional 




Vector for ivt-RNA synthesis encoding CD3-
Chimera coding sequence coupled to eGFP 
via P2A element 
this work  
pES.12-6_CD3-Chimera 
_P2A_GFP_EF1a_MIT 
Retroviral SIN-vector encoding CD3-Chimera 
coding sequence coupled to eGFP via P2A 
element 
this work  
pMP71_CD3-Chimera 
_P2A_GFP_MIT 
Retroviral vector encoding CD3-Chimera 
coding sequence coupled to eGFP via P2A 
element 
this work  
pMA_CD19-CAR_P2A_GFP 
Cloning vector encoding CD19-CAR coding 
sequence coupled to eGFP via P2A element 
this work#  
pGEM_CD19-CAR 
_P2A_GFP_wm-A120 
Vector for ivt-RNA synthesis encoding CD19-
CAR coding sequence coupled to eGFP via 
P2A element 
this work  
pES.12-6_CD19-CAR 
_P2A_GFP_EF1a_MIT 
Retroviral SIN-vector encoding CD19-CAR 
coding sequence coupled to eGFP via P2A 
element 
this work  
pMP71_CD19CAR_P2A_GF
P_MIT 
Retroviral vector encoding CD19-CAR coding 
sequence coupled to eGFP via P2A element 
this work  
pBullet_CAR#607 
Retroviral vector encoding CAR#607,  
termed “CEA-CAR_CD8” in this work 
H. Abken$ 
pBullet_CAR#908 
Retroviral vector encoding CAR#908,  




Vector for ivt-RNA synthesis encoding TALEN 




Vector for ivt-RNA synthesis encoding TALEN 




Vector for ivt-RNA synthesis encoding TALEN 




Vector for ivt-RNA synthesis encoding TALEN 
coding sequence targeting the TRBC locus 
N. Sailer§ 
TRAC Crispr String 
String DNA fragment for ivt-RNA synthesis of 
CRISPR gRNA for targeting of TRAC locus 
this work# 
TRBC Crispr String 
String DNA fragment for ivt-RNA synthesis of 
CRISPR gRNA for targeting of TRBC locus 
this work# 
pcDNA3.1(+) (gag/pol) 
Expression vector encoding retroviral 
structural proteins (gag) and reverse 
transcriptase (pol); for generation of viral 
particles in mammalian cells (HEK293FT) 
S. Milošević* 
K83-hCMV-GALV 
Expression vector encoding gibbon ape 
leukemia virus (GALV) envelope protein 
(Env); for generation of viral particles in 
mammalian cells (HEK293FT) 
S. Milošević* 
pMP71-T58-b-P2A-a muco 
Retroviral vector encoding coding sequence 
of TCR T58  and  chain coupled via P2A 
element; murine constant region 
S. Wilde*  
(Wilde et al., 2009) 
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pMP71-D115-b-P2A-a muco 
Retroviral vector encoding coding sequence 
of TCR D115  and  chain coupled via P2A 
element; murine constant region 
S. Wilde*  
(Wilde et al., 2009) 
pES.12-6_mmcys 
_NY-ESO_ab 
Retroviral SIN vector encoding coding 
sequence of NY-ESO TCR  and  chain 
coupled via P2A element; minimal murinized 
constant region with additional cysteine bridge 
G. Longinotti* 
 
*Medigene Immunotherapies GmbH, Martinsried, Germany  
#Synthesized by Thermo Fisher Scientific, Waltham, MA, USA 
$Hinrich Abken, Center for Molecular Medicine Cologne, University of Cologne, and Department I of Internal Medicine, 
  University Hospital Cologne, Cologne, Germany 
§Generated in a previous work: Master thesis “Targeting the Human T Cell Receptor with TAL Effector Nucleases in  
  Herpesvirus saimiri Transformed T Cells”, 2013 (Sailer, 2013).  
 
2.7 Primer and oligonucleotides  
Table 2.8: Primer 
Primer Sequence Manufacturer 
3'AST CTTGCCTCTGCCGTGAATGT Sigma-Aldrich* 
3'BST GAGGTAAAGCCACAGTTGCT Sigma-Aldrich* 
CD3-CAR_P1_for AGAATATCGGCTCCGATGAGG Sigma-Aldrich* 
CD3-CAR_P2_for ATGAAGGGCGAGCGGAGAAG Sigma-Aldrich* 
CD3-CAR_P3_for GGCCACAAGCTGGAGTACAAC Sigma-Aldrich* 
pGEM_for  ACAGGAAACAGCTATGACCATG Sigma-Aldrich* 
pGEM_rev CGTGATTCACTCGTTCTCACC Sigma-Aldrich* 
pGEM_wm_rev GAATTACGTGATTCACTCGTTCT Sigma-Aldrich* 
pES.12-6_for CGCAACGGGTTTGCCGCCA Sigma-Aldrich* 
pMP71_for GCTCCGCCACTGTCCGAG Sigma-Aldrich* 
pMP71_rev AATGGCGGTAAGATGCTC Sigma-Aldrich* 
TCRab_P2A GCAGCGGCGCCACCAACTT Sigma-Aldrich* 
pMA_for (M13 uni (-21));  TGTAAAACGACGGCCAGT  Eurofins Genomics# 









TRAC_RACE_PCR CGGCCACTTTCAGGAGGAGGATTCGGAAC Sigma-Aldrich* 
TRBC_RACE_PCR CCGTAGAACTGGACTTGACAGCGGAAGTGG Sigma-Aldrich* 
 
* Sigma-Aldrich, St. Louis, MO, USA 




2.8 Molecular weight markers and loading dyes 
Table 2.9: Molecular weight markers and loading dyes 
Name Manufacturer 
100 bp DNA Ladder Thermo Fisher Scientific, Waltham, MA, USA 
1 kb DNA Ladder Thermo Fisher Scientific, Waltham, MA, USA 
2X RNA Loading Dye Thermo Fisher Scientific, Waltham, MA, USA 
DNA Gel Loading Dye (6X) Thermo Fisher Scientific, Waltham, MA, USA 
RiboRulerTM High Range RNA Ladder Thermo Fisher Scientific, Waltham, MA, USA 
RNA Loading Dye, (2X) Thermo Fisher Scientific, Waltham, MA, USA 
 
2.9 Antibodies 
Table 2.10: Antibodies 
Antibody Clone Isotype Species Conjugation Manufacturer 
CCR7 3D12 IgG2a rat PE Thermo Fisher Scientific 
CD16 3G8 IgG1 mouse Alexa700 Thermo Fisher Scientific 
CD19 HIB19 IgG1 mouse Hz450 BD Biosciences 
CD19 HIB19 IgG1 mouse PE-Cy7 Thermo Fisher Scientific 
CD19 SJ25C1 IgG1 mouse PE-Cy7 BD Biosciences 
CD3 UCHT1 IgG1 mouse BUV395 BD Biosciences 
CD3 UCHT1 IgG1 mouse FITC BD Biosciences 
CD3 UCHT1 IgG1 mouse PB BD Biosciences 
CD3 SK7 IgG1 mouse PE-Cy7 BD Biosciences 
CD3 SK7 IgG1 mouse PerCP BD Biosciences 
CD3delta MEM-57 IgG2a mouse FITC antikörper-online 
CD3gamma MEM-57 IgG2a mouse PE antikörper-online 
CD4 RPA-T4 IgG1 mouse APC BD Biosciences 
CD4 RPA-T4 IgG1 mouse APC-Cy7 BD Biosciences 
CD4 SK3 IgG1 mouse FITC BD Biosciences 
CD4 RPA-T4 IgG1 mouse PB BD Biosciences 
CD4 RPA-T4 IgG1 mouse PE BD Biosciences 
CD4 VIT4 IgG2a mouse PerCP Miltenyi Biotec 
CD45RA HI100 IgG2b mouse APC BD Biosciences 
CD45RA T6D11 IgG2b mouse FITC Miltenyi Biotec 
CD45RA HI100 IgG2b mouse PerCP-Cy5.5 Thermo Fisher Scientific 
CD45RO UCHL1 IgG2a mouse PE BD Biosciences* 
CD56 B159 IgG1 mouse Alexa700 BD Biosciences* 
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CD56 B159 IgG1 mouse V450 BD Biosciences* 
CD62L 145/15 IgG1 mouse APC Miltenyi Biotec# 
CD62L DREG-56 IgG1 mouse APC-Cy7 Thermo Fisher Scientific§ 
CD62L SK11 IgG2a mouse FITC BD Biosciences* 
CD62L DREG-56 IgG1 mouse PE BD Biosciences* 
CD8 RPA-T8 IgG1 mouse Alexa700 BD Biosciences* 
CD8 HIT8a IgG1 mouse FITC BD Biosciences* 
CD8 RPA-T8 IgG1 mouse Horizon V500 BD Biosciences* 
CD8 RPA-T8 IgG1 mouse PB BD Biosciences* 
CD8 RPA-T8 IgG1 mouse PE BD Biosciences* 
CD8 RPA-T8 IgG1 mouse V450 BD Biosciences* 




IgG1 mouse APC 
BD Biosciences* 
CD95 DX2 IgG1 mouse APC BD Biosciences* 






goat  R-PE Southern Biotech*** 
HLA-A2 BB7.2 IgG2b mouse FITC BD Biosciences* 
mTCR H57-597 IgG2a hamster APC BD Biosciences* 
mTCR H57-597 IgG2a hamster PE BD Biosciences* 
panTCR a/ IP26A IgG1 mouse PE Beckman Coulter$ 
panTCR a/ IP26A IgG1 mouse PC5 Beckman Coulter$ 
panTCR / B1.1 IgG1 mouse FITC Thermo Fisher Scientific§ 
panTCR / IMMU510 IgG1 mouse PE Beckman Coulter$ 
TCR-V1 BL37.2 IgG1 Rat PE Beckman Coulter$ 
TCR-V23 AF23 IgG1 mouse PE Beckman Coulter$ 
TCR-V8 56C5.2 IgG2a mouse PE Beckman Coulter$ 
FcR Blocking 
reagent 
- - - - Miltenyi Biotec 
 
*BD Biosciences, Heidelberg, Germany 
#Milentyi Biotec, Bergisch Gladbach, Germany 
§Thermo Fisher Scientific, Waltham, MA, USA 
**R&S Systems, Minneapolis, MN, USA 
***Southern Biotech, Birmingham, AL, USA 





Table 2.11: Tetramer and peptides 
Compound Peptide HLA Conjugation Manufacturer 
Tetramer YMDGTMSQV HLA-A2 PE immunAware* 
Peptide YMDGTMSQV - - Peps4LS GmbH# 
Peptide SLLMWITQC - - ProteoGenix§ 
 
*immunAware, Copenhagen, Denmark 
#Peps4LS GmbH, Heidelberg, Germany 
§ProteoGenix, Schiltigheim, France 
 
2.10 Bacteria culture 
2.10.1 Bacterial strains 
Table 2.12: Bacterial strains 
Bacterial Strain Genotype Source 
XL1-Blue Competent 
Cells (E. coli) 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 lac [F´ proAB lacIqZΔM15 Tn10 (Tetr)] 
Aligent Technologies, 




F´ proA+ B+ lacIq ∆ lacZ M15/ fhuA2 ∆(lac-
proAB) glnV gal R(zgb210::Tn10)TetS 
endA1 thi-1 ∆(hsdS-mcrB)5 















2.11 Cell culture 
2.11.1 Cells 
Table 2.13: Cells 
Cells Description Source/Reference 
HEK293FT 
Human embryonic kidney 293 cells, transformed 
with SV40 Large T antigen  
Thermo Fisher Scientific* 
Jurkat-76-IVB10 
TCR  and  chain deficient T cell lymphoma cell 
line  
M. Heemskerk# and M. 
Bürdek** 
K562 Chronic myelogenous leukemia (CML) cell line 
ATCC® CCL-243™, ATCC§  
(Lozzio and Lozzio, 1975) 
K562_A2 
K562 CML cell line transduced with vector coding 
for HLA-A*02:01 
G. Longinotti** 
K562_A2_CD86 K562_A2 transduced with vector coding for CD86  G. Longinotti** 
Mel624.38 Melanoma cell line  
M. Panelli*** 
(Rivoltini et al., 1995) 
MelA375 Melanoma cell line  
ATCC® CRL-1619™, 
ATCC§ 
647-V Urothelial bladder carcinoma cell line ACC 414, DSMZ$ 
LS174T Dukes' type B colorectal adenocarcinoma cell line ATCC® CL-188™, ATCC§ 
Clone 234 CD4+ T cell clone, HLA-A24-restricted isolated by D.J. Schendel** 
LCL_BW 
Lymphoblastoid cell line, B cells transformed with 
EBV 
isolated by D.J. Schendel** 
mLCL_ME 








Peripheral blood mononuclear cells (PBMC). 
Derived from human peripheral blood of healthy 
donors by density gradient centrifugation (Biocoll) 
this work 
PBL 
Peripheral bool lymphocytes (PBL).  
Derived from human peripheral blood of healthy 
donors by density gradient centrifugation (Biocoll) 
and subsequent plate adherence 
this work 
 
* Thermo Fisher Scientific, Waltham, MA, USA  
# Hematology, Leiden University Medical Center 
§ ATCC, Manassas, VA, USA 
** Medigene Immunotherapies GmbH, Planegg, Germany 
*** National Cancer Institute, Bethesda, MD, USA 





2.11.2 Media, solutions and supplements 
Table 2.14: Media, solutions and supplements for cultivation of cells 
Product Name Manufacturer 
Dulbecco’s Modified Eagle Medium (DMEM) Thermo Fisher Scientific, Waltham, MA, USA 
Dulbecco’s phosphate buffer saline (PBS) Thermo Fisher Scientific, Waltham, MA, USA 
Endotoxin-Free Dulbecco’s PBS (1X) Sigmal-Adrich, St. Louis, MO, USA 
Fetal bovine serum (FBS) Thermo Fisher Scientific, Waltham, MA, USA 
HEPES (1M) Thermo Fisher Scientific, Waltham, MA, USA 
Human Serum MDG (HS_MDG) Medigene Imuunotherapies, Planegg, Germany 
Ibidi Freezing medium Ibidi, Planegg, Germany 
L-Glutamin 200 mM Thermo Fisher Scientific, Waltham, MA, USA 
MEM Non-essential amino acids (NEAA) 
100X 
Thermo Fisher Scientific, Waltham, MA, USA 
Penicillin-Streptomycin (10,000 U/mL) Thermo Fisher Scientific, Waltham, MA, USA 
Pool Human Serum (PHS) ZKT Tübingen, Tübingen, Germany 
Proleukin ® S (IL-2) Novartis, Basel, Switzerland 
Puromycin Invivogen, San Diego, CA, USA 
RPMI Medium 1640  Thermo Fisher Scientific, Waltham, MA, USA 
Sodium pyruvate (100 mM) Thermo Fisher Scientific, Waltham, MA, USA 
Trypan blue stain 0.4% Thermo Fisher Scientific, Waltham, MA, USA 
Trypsin-EDTA (0.05%), phenol red Thermo Fisher Scientific, Waltham, MA, USA 
 
 
Table 2.15: Composition of cell culture media 
Medium Composition 
Freezing medium 10% (v/v) FBS (inactive) in DMSO 
DMEM_IV 
2mM L-Glutamine, 1 mM Sodium Pyruvate, 1% (v/v) MEM NEAA 
and 10% (v/v) inactive FBS in DMEM medium 
RPMI_IV 
2mM L-Glutamine, 1 mM Sodium Pyruvate, 1% (v/v) MEM NEAA 
and 10% (v/v) inactive FBS in RPMI 1640 medium 
T cell medium (TCM) 
2mM L-Glutamine, 1 mM Sodium Pyruvate, 1% (v/v) MEM NEAA, 
10 mM HEPES, 1% (v/v) Penicillin-Streptomycin and 10% (v/v) 
inactive PHS or HS_MDG in RPMI 1640 medium 
Clone234 medium 
2mM L-Glutamine, 1 mM Sodium Pyruvate, 1% (v/v) MEM NEAA, 
10% (v/v) inactive FBS and 6% (v/v) inactive HS_MDG in RPMI 
1640 medium 




2.12 Software and Databases 
Table 2.16: Software and databases 
Software or Database Manufacturer or Website 
Adobe Illustrator® CC Adobe Systems, San Jose, USA 
Adobe Reader XI  Adobe Systems, San Jose, USA 
BD FACSDivaTM Software BD Biosciences, Franklin Lakes, NJ, USA 
Chromas Lite Technelysium, South Brisbane, Australia 
ClinicalTrials.gov 
ClinicalTrials.gov [Internet] Bethesda (MD): National Library 
of Medicine (US) at the National Institutes of Health (NIH); 
[2002] – [cited 2018 Sep 12]. Available from:  
https://clinicaltrials.gov/ 
Clone Select Imager Molecular Devices, Sunnyvale, CA, USA 
Clone Manager Basic 9 Scientific & Educational Software, Denver, USA 
Clustal Omega EMBL-EBI, Hixton, UK (Sievers et al., 2011) 
FlowJo v10 Tree Star, Ashland, OR, USA 
GeneartTM CRISPR Search and 
Design Tool 
GeneartTM CRISPR Search and Design Tool [Internet] 
Thermo Fisher Scientific, Waltham, MA, USA; [cited 2018 




GraphPad Prism 6 GraphPad Software, La Jolla, CA, USA 
Image LabTM Software Bio-Rad Laboratories, Munich, Germany 
IMGT®  (THE INTERNATIONAL  
IMMUNOGENETICS INFORMATION 
SYSTEM®) 
Laboratoire d'ImmunoGénétique Moléculaire 
Institut de Génétique Humaine, IGH, UMR9002 CNRS-UM, 
Montpellier Cedex 5, France 
http://www.imgt.org/  (Lefranc et al., 2015) 
IncuCyte® ZOOM Software 2016B Essen Bioscience, Ann Arbor, Michigan, USA 
Mendeley Reference Manager Mendeley, London, UK 
Microsoft Office 2010/2016 Microsoft Corporation, Redmond, WA, USA 
National Center of Biotechnology 
Information (NCBI) Databases 
National Center for Biotechnology Information 
(NCBI)[Internet]. Bethesda (MD): National Library of 
Medicine (US), National Center for Biotechnology 
Information; [1988] – [cited 2018 Apr 12]. Available from: 
https://www.ncbi.nlm.nih.gov/    (Agarwala et al., 2016) 
NEB Tm Calculator 
NEB Tm Calculator [Internet] New England Biolabs, 
Frankfurt, Germany; [cited 2018 Sep 12]. Available from: 
http://tmcalculator.neb.com/#!/main 
NEBcloner®  
NEBcloner® [Internet] New England Biolabs, Frankfurt, 







3.1 Molecular biology methods 
3.1.1 Cryopreservation of bacteria 
For cryopreservation of bacteria 500 µL of an overnight culture were thoroughly mixed with 
500 µL of sterile 99% glycerol. The mixture was immediately frozen and stored at - 80 °C. 
These glycerol stocks can be used to inoculate a new bacteria culture for plasmid preparations. 
 
3.1.2 Transformation of bacteria 
Transformation describes the uptake of exogenous genetic material into bacteria. To enable 
this uptake, it is required to permeabilize the bacterial cell wall and plasma membrane. One 
method to achieve this is electroporation. By applying an exogenous electrical field, transient 
pores are generated in the membrane that allow hydrophilic molecules to enter the bacterial 
cell (Tieleman, 2004).  
To efficiently transform electrocompetent E. coli (XL1-Blue) with exogenous plasmid DNA an 
aliquot of bacteria suspension was first thawed on ice. After addition of 1 - 5 µL of purified 
ligation (3.1.8) or plasmid DNA, the suspension was transferred into a pre-cooled 
electroporation cuvette (0.1 cm, Gene Pulser, Bio-Rad). Using the electroporator Gene Pulser 
XcellTM (Bio-Rad), an electric pulse of 1.8 kV was applied. For recovery, bacteria were 
immediately transferred into 1 mL SOC medium (Thermo Fisher Scientific) and incubated 
under 220 rpm agitation for 45 min at 37 °C. Afterwards, 20 µL - 200 µL of the bacterial 
suspension were plated onto LB agar plates (Select Agar™, Thermo Fisher Scientific) that 
contained the appropriate antibiotic for selection and incubated at 37 °C overnight. 
 
3.1.3 Cultivation of bacteria 
The transformed bacteria (3.1.2) were cultivated overnight at 37 °C on LB agar plates that 
contained the appropriate antibiotic for selection. If not used directly for plasmid preparation, 
bacteria were stored at 4 °C for up to 1 week.  
For small-scale plasmid isolation 4 mL LB medium containing the appropriate antibiotic for 
selection were inoculated with a single bacteria colony from the LB agar plates. The 4-mL- 
culture was incubated overnight at 37 °C in an orbital shaker (220 rpm). This pre-culture could 
subsequently be used for the inoculation of a large-scale bacteria culture. 
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For the isolation of larger amounts of plasmid DNA 400 mL LB medium containing the 
appropriate antibiotic for selection were inoculated with 1 - 2 mL of the 4-mL-pre-culture or 
10 µL of a glycerol stock (3.1.1). The 400-mL-culture was also incubated overnight at 37 °C in 
an orbital shaker (220 rpm). 
 
3.1.4 Plasmid DNA isolation from bacteria 
For small-scale plasmid isolation 4 mL overnight cultures (3.1.3) were centrifuged at 825 x g 
at 4 °C for 10 min. The plasmid DNA was isolated from the bacteria pellet using the JetStarTM 
Plasmid Purification Kit (Genomed) according to the manufacturer’s instructions. The pelleted 
plasmid DNA was resuspended in the appropriate amount of ddH2O (typically 60 µL).  
For large-scale plasmid isolation 400 mL bacteria cultures (3.1.3) were pelleted at 5000 x g for 
15 min at 4 °C. Isolation of the plasmid DNA was performed using the JetStarTM Plasmid 
Purification Kit (Genomed) according to the manufacturer’s instructions. The dried DNA pellet 
was resuspended in 200 - 800 µL sterile ddH2O. 
 
3.1.5 Agarose gel electrophoresis 
Linearized plasmid DNA, ivt-RNA or DNA fragments were separated according to their sizes 
by agarose gel electrophoresis. To prepare a 1% agarose gel, 1% (w/v) agarose was dissolved 
in 1 x TEA buffer (Table 2.3) by boiling using a microwave. After letting the solution cool down 
to approximately 60 °C, it was poured into a gel rack and 0.2 µg/mL ethidium bromide were 
added. Prior to loading the DNA samples onto the solid 1% gel, they were mixed with DNA Gel 
Loading Dye 6X (Thermo Fisher Scientific). To determine the respective DNA fragment sizes 
8 µL of GeneRuler 1 kb or 100 bp DNA Ladder (Thermo Fisher Scientific) were loaded 
separately onto the agarose gel. The DNA was separated by electrophoresis at a voltage of 
100 - 120 V for 45 - 120 min. Ethidium bromide – intercalated into the DNA – was visualized 
under UV light using the ChemiDoc™ XRS+ Gel Documentation System (Bio-Rad) or an UV 
transilluminator (Bachhofer). Documentation and analysis of the agarose gel was performed 
using the Image LabTM Software (Bio-Rad).  
For the visualization of ivt-RNA, DEPC-treated water was used for the generation of the 
agarose gel as well as the running buffer. The ivt-RNA samples were denatured by incubation 
at 70 °C for 10 min in the presence of 2X RNA Gel Loading Dye (Thermo Fisher Scientific). 
RiboRuler High Range RNA Ladder (Thermo Fisher Scientific) was treated the same way and 
used for length determination of ivt-RNA.   
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3.1.6 DNA extraction from agarose gels 
DNA fragments that were separated by agarose gel electrophoresis (3.1.5), were purified 
utilizing the QIAquick Gel Extraction Kit (Qiagen). After visualizing the DNA fragments under 
UV light, they were cut out of the agarose gel. DNA fragments were then extracted by 
proceeding according to the manufacturer’s instructions. Generally, DNA was eluted from the 
spin column by adding 25 - 30 µL ddH2O.     
 
3.1.7 Restriction digest of plasmid DNA 
Restriction digest of plasmid DNA can either be performed for preparative or analytical 
purposes. The preparative digest is part of the cloning procedure for a given plasmid in which 
two DNA molecules are cut with the same combination of restriction enzymes. This allows the 
ligation (3.1.8) of two chosen DNA fragments to generate a new plasmid.  
An analytical restriction digest can be performed to check the quality of newly generated DNA 
plasmids. The corresponding DNA fragment pattern can be analyzed by agarose gel 
electrophoresis (3.1.5). 
For the restriction digest, 1 - 4 units (U) of restriction enzyme were used according to the 
manufacturer’s instructions. Plasmid DNA or PCR product was incubated for 1 - 2 h with the 
restriction enzyme at the recommended temperature using appropriate buffer conditions.  
Whenever preparative restriction digest was performed, the digest was followed by purification 
of the extracted DNA fragments as described in 3.1.6. The purification allows the removal of 
excess nucleotides, proteins or buffer agents that could interfere with downstream 
applications.  
 
3.1.8 Ligation of DNA fragments 
The purpose of a ligation reaction is to generate a new vector plasmid from two DNA fragments 
that have been digested with the same restriction enzymes (3.1.7). With the help of DNA 
ligases, the complementary ends of the DNA molecules can be joined to generate a 
recombinant DNA molecule. For this T4 DNA ligase (NEB) and the appropriate buffer was used 
according to the manufacturer’s instructions. The ligation reaction was performed in a total 
volume of 20 µl with DNA fragments in a vector to insert ratio of 1:3. After incubation over night 
at 16 °C, the ligation reaction was directly used for the transformation of bacteria (3.1.2) in 
order to allow the selection of newly generated plasmids with the correct nucleotide sequence.   
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3.1.9 Isolation of messenger RNA (mRNA) 
In order to determine the coding sequence of a specific gene or to verify its expression, mRNA 
was isolated from T cell clones using TRI-Reagent® (Sigma-Aldrich). For this, up to 1 x 106 
cells were resuspended in 200 µL TRI-Reagent® and mRNA was isolated according to the 
manufacturer’s instructions. The mRNA pellet was resuspended in 20 µl nuclease-free H2O 
and the concentration was determined (3.1.17).  
 
3.1.10 Complementary DNA (cDNA) synthesis 
Reverse transcription of 0.5 - 1 µg isolated mRNA (3.1.9) was performed using the First Strand 
cDNA Synthesis Kit for RT-PCR (Roche Diagnostics) according to the manufacturer’s 
instructions. The generated cDNA was directly used for PCR (3.1.11) without further 
purification. 
 
3.1.11 Polymerase chain reaction (PCR) 
PCR allows the selective amplification of a particular DNA sequence for sequencing (3.1.13) 
or molecular cloning. Using a heat-stable DNA polymerase, the DNA template is exponentially 
amplified during thermal cycling. One reaction cycle is characterized by heat-induced de-
hybridization of the DNA double strand (melting), annealing of specific primers to single-
stranded DNA and DNA synthesis by a DNA Polymerase (Mullis et al., 1986).  
For the amplification of a specific DNA sequence the 2X PCR Master Mix (Promega) was used, 
that includes Taq DNA Polymerase, dNTPs, MgCl2 and the appropriate reaction buffer. 
Depending on the target sequence, specific primers were used (Table 2.8) that show 
complementarity with the target gene’s 3’ and 5’ end, respectively. Based on the primer 
composition, a unique melting temperature for each reaction was calculated with the help of 
the online-tool “NEB Tm Calculator” (Table 2.16). Table 3.1 shows the typical composition of 
a PCR.       
Table 3.1: PCR composition 
Components Concentration 
2X PCR Master Mix 50% (v/v) total volume 
3’ Primer (10 µM) 0.1 – 1 µM 
5’ Primer (10 µM) 0.1 – 1 µM 
DNA template <250 ng 




3.1.12 Rapid amplification of cDNA ends (RACE)-PCR 
The determination of TCR sequences by classical PCR amplification is impeded by the large 
number of possible 5’ variable TCR  and  variable gene segments, which have to be covered 
using unique specific primers. RACE-PCR allows the amplification of the full-length sequence 
of an RNA transcript independent of a known 5’ template sequence (Chenchik et al., 1996). 
For the TCR complex, the known sequence is represented by the constant regions of the TCR 
 and  chain. Starting from the constant region, every TCR sequence – irrespective of the 
variable regions – can be amplified using 5’ RACE-PCR. For this, the SMARTer® RACE 5’/3’ 
Kit was used according to the manufacturer’s instructions. 1 - 10 µg isolated mRNA (3.1.9) 
was used as a template to generate RACE-ready cDNA. 5’ RACE-PCR was subsequently 
performed utilizing 2.5 - 5 µL RACE-ready cDNA and the gene specific primers for TCR  
(TRAC_RACE_PCR) and  (TRBC_RACE_PCR) chain, respectively (see Table 2.8). RACE-
PCR reactions were analyzed using agarose gel electrophoresis (3.1.5). After extraction from 
the agarose gel (3.1.6) the isolated PCR products were sent for DNA sequencing (3.1.13) to 
allow the determination of the full-length DNA sequence of the respective TCR chains.  
 
3.1.13 DNA sequencing 
To verify the correct DNA sequence of isolated plasmid DNA (3.1.4) or PCR products (3.1.11, 
3.1.12), DNA samples were sent for sequencing by Eurofins MWG (Ebersberg, Germany) 
according to the provider’s instructions. The sequencing results were reviewed using the 
software Clone Manager 9 (Scientific & Educational Software),  Chromas Lite (Technelysium) 
and the online tools Clustal Omega (EMBL-EBI) or IMGT® databases (Lefranc et al., 2015).  
 
3.1.14 Molecular cloning of vector constructs 
For molecular cloning of CD19-CAR and CD3-Chimera the respective constructs were ordered 
from GeneArt Gene Synthesis (Thermo Fisher Scientific) in the backbone vector pMA 
comprising ampicillin resistance (Table 2.7). The vector plasmids were transformed into 
electrocompetent E. coli (XL1-Blue) by utilizing a 1/1000 dilution as described in 3.1.2. Large-
scale plasmid DNA was isolated with JetStarTM Plasmid Purification Kit (Genomed) as 
described in 3.1.4. 20 µg of plasmid was digested with the restriction enzymes NotI-HF and 
EcoRI-HF (New England Biolabs) (3.1.7). To allow isolation of the desired insert fragment 
coding for the respective construct, agarose gel electrophoresis was performed with the 
digested DNA (3.1.5). The insert was excised from the gel and subsequently purified using the 
QIAquick Gel Extraction Kit (Qiagen) as described in 3.1.6. To allow ligation of the insert with 
the desired backbone vector, the vectors pGEM_eGFP_A120, pES.12-6-MIT and pMP71-MIT 
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(Table 2.7) were cut with the same restriction enzymes and processed as described for the 
CD19-CAR and CD3-Chimera constructs, except for isolation of the backbone fragment 
instead of the insert. The isolated insert coding for CD19-CAR or CD3-Chimera, respectively, 
were ligated with the respective backbone vector fragments comprising complementary ends 
(3.1.8). The ligation reaction was transformed into bacteria (3.1.2) to allow identification of 
colonies carrying ampicillin resistance. Selected colonies were picked for inoculation of small-
scale cultures (3.1.3). After isolation of plasmid DNA (3.1.4), the vectors were sent for 
sequencing (3.1.13) utilizing the respective primers CD3-CAR_P1_for, CD3-CAR_P2_for, 
CD3-CAR_P3_for, pGEM_for, pGEM_wm_rev, pES.12-6_for, TCRab_P2A, pMP71_for and 
pMP71_rev (Table 2.8). Bacteria cultures comprising the plasmid with the correct DNA 
sequences were used to inoculate large-scale cultures (3.1.3) to allow the isolation of large 
amounts of plasmid DNA (3.1.4). The correctness of the isolated DNA sequence was again 
verified by DNA sequencing (3.1.13) with the same primers described above. The generated 
vectors could now be used for transduction of T cells with the CD19-CAR or CD3-Chimera 
construct (3.2.9).  
Tyrosinase-specific TCRs T58 and D115 in pMP71 backbone vectors were provided by S. 
Wilde (Wilde et al., 2009). NY-ESO-1-specific TCR in pES-12.6 backbone vector was provided 
by G. Longinotti (Longinotti, 2018).  
The CD3-Chimera construct comprised CD8 leader sequence (NCBI database M12828.1) 
followed by a CD3 subunit without the stalk region (NCBI database BC039035.1) and CD3 
subunit without the stalk region (NBCI database X03884.1) separated by (Gly4Ser)3 linker. The 
extracellular domain is coupled to the CD28 transmembrane domain (NCBI database 
J02988.1) and the intracellular CD3 signaling domain (NCBI database J04132.1) via a CD8 
hinge region (NCBI database M12828.1). The construct was codon-optimized before synthesis 
by GeneArt (Thermo Fisher Scientific).  
The CD19-CAR construct was designed as described by Hudecek et al. (Hudecek et al., 2015).  
The CAR constructs CEA-CAR_CD4 (CAR#908) and CEA-CAR_CD8 (CAR#607) were kindly 
provided by H. Abken (Hombach et al., 2001).  
TALEN pairs targeting the TCR  and  chains, respectively, were developed in a previous 
work (Sailer, 2013). TALEN pairs were designed and generated according to Cermak et al. 
(Cermak et al., 2011) utilizing Golden Gate cloning method. TALEN were designed as pairs to 
target either the TRAC locus (TALEN_TCR_left, TALEN_TCR_right) or the TRBC locus 




Table 3.2: TALEN RVD sequences and corresponding target sequences in TRAC and TRBC loci 









*target DNA sequence indicated by the 4 bases cytosine (C), guanine (G), adenine (A) and thymine (T); corresponding TALEN 
RVDs indicated by the amino acids asparagine (N), isoleucine (I), glycine (G) histidine (H) and aspartic acid (D).   
The GeneartTM CRISPR Search and Design Tool (Thermo Fisher Scientific) was used for 
design and generation of CRISPR gRNA.  CRISPR gRNAs was designed to target either the 
TRAC locus (TRAC_CRISPR) or TRBC locus (TRBC_CRISPR), respectively (Table 3.3).  
Table 3.3: CRISPR gRNA target sequence in TRAC and TRBC loci 




3.1.15 Next generation sequencing (NGS) 
To determine mutations in the TRAC and TRBC genes introduced by TALEN-induced double 
strand breaks, mRNA of selected clones was isolated utilizing the Dynabeads® mRNA 
DIRECTTM Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. Isolation 
of mRNA was performed in FrameStar® Break-A-Way PCR Plates (4titude) using the 
DynaMag 96 Slide Magnet (Life Technologies). Supernatant containing mRNA was transferred 
to Eppendorf® twin-tec PCR plates 96 (Eppendorf) after incubation at 70°C for 2 min in 
Thermocycler Nexus (Eppendorf). Reverse transcription was performed using the 
SMARTScribeTM reverse transcriptase (Clontech) according to the manufacturer’s instructions. 
Specific 3’ primers binding either the TCR  or  constant region, respectively, were combined 
with 5’ Switch oligos comprising a unique barcode to synthesize cDNA coding for the 
respective TCR chains. Subsequent PCR steps utilizing KAPA HiFi Hot Start Ready Mix (KAPA 
Biosystems), according to the manufacturer’s instructions, allowed amplification of the target 
sequence and addition of specific sequences to the PCR product required for NGS. In PCR I 
Illumina universal oligos (IUO) was added to the 5’ and 3’ ends, whereas 2 new primers, 
PCR1_3pAC_IUP and PCR1_3pBC_IUP, were used to attach IUO to the 3’ end of TCR  or 
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 chain sequences, respectively. PCR products were purified utilizing CleanPCR kit (CleanNA) 
and used as templates for PCR II that included addition of Nextera oligos to the ends of the 
PCR product using Nextera® Index Kit v2 (Illumina). The prepared DNA library was 
concentrated by phenol-chloroform-isoamylalcohol (Roth) extraction and QIAquick spin 
columns (Qiagen) and subsequently purified using the BluePippin pulsed-field electrophoresis 
device (sage science) according to the manufacturer’s instructions. Purification of the PCR 
products was verified utilizing High Sensitivity NGS Fragment Analysis Kit (Advanced 
Analytica) and Fragment Analyzer (Advanced Analytica) according to the manufacturer’s 
instructions. NGS was performed on MiSeq System (Illumina) with MiSeq V3 Kit (Illumina) 
according to the manufacturer’s instructions. Irrelevant DNA Library, PhiX control v3 (Illumina), 
is mixed with the sample DNA library to enable reliable cluster formation by MiSeq System.  
Bioinformatic analysis of NGS data was performed by A. Moesch (Medigene Immunotherapies 
GmbH). For this, raw FASTQ reads were searched for both flanking TALEN target sites and 
the target sequence in between was aligned to the wildtype sequence [NCBI Database 
X02883.1, M12887.1, M14157.1]. Reads containing the same mismatches, deletions, 
insertions or the wildtype sequences were grouped, and average read quality was calculated. 
To unambiguously identify whether a T cell clone contained wildtype or mutated sequences, a 
high number of reads was required comprising an average read quality of at least 30.  
 
3.1.16 Generation of in vitro transcribed RNA (ivt-RNA) 
For the in vitro transcription of plasmid DNA into capped ivt-RNA the mMessage mMachineTM 
T7 Transcription Kit (Thermo Fisher Scientific) was used according to the manufacturer’s 
instructions. The required plasmid DNA was linearized using the appropriate restriction 
enzyme (3.1.7) and subsequently purified via precipitation with 0.25 M EDTA, 0.3 M sodium 
acetate in the presence of 70% ethanol at – 20 °C for 30 min. After centrifugation with 
15500 x g at 4 °C for 15 min, the DNA pellet was resuspended in the appropriate amount of 
ddH2O to a final concentration of 0.5 µg/µL. 2 – 5 µg of the purified, linearized plasmid DNA 
was used as template for the in vitro transcription reaction. The reaction mixture was incubated 
for 3 h at 37 °C using the Mastercyler® nexus (Eppendorf). After adding 1 µL of TURBO DNase 
supplied with the kit, the mixture was incubated for another 30 min at 37 °C. For the purification 
of the generated ivt-RNA the RNeasy Mini Kit (Qiagen) was used according to the 
manufacturer’s instructions. After eluting the RNA in 50 µL nuclease-free H2O, the 
concentration was determined (3.1.17) and the ivt-RNA was stored at - 20 °C until it was used 
for electroporation (3.2.8). If the template vector did not contain a poly(A) tail in the sequence, 
the ivt-RNA was polyadenylated prior to purification. For this the Poly(A) Tailing Kit (Thermo 
Fisher Scientific) was used according to the manufacturer’s instructions. Samples were taken 
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before and after polyadenylation and loaded onto a denaturing agarose gel (3.1.5) in order to 
verify a successful addition of a poly(A) tail and to check for the correct length of the generated 
ivt-RNA. For generation of ivt-RNA for CRISPR/Cas9 approach, TRAC and TRBC string 
fragments (Table 2.7) were used as templates for in vitro transcription utilizing either 
mMessage mMachinTM T7 Transcription Kit as described above or TranscriptAid T7 High Yield 
Transcription Kit (Thermo Fisher Scientific).  
 
3.1.17 Determination of nucleic acid concentration 
The concentration of nucleic acids can be determined using spectrometric quantification by 
exposing DNA and RNA to UV light of a wavelength of 260 nm. The extinction is measured by 
a spectrophotometer. This method is based on the Beer-Lambert law, where the amount of 
light absorbed by the substance relates to the concentration of the absorbing molecule.  
The concentration of plasmid DNA and ivt-RNA was determined using the NanoDropTM 2000c 
spectralphotometer (Thermo Fisher Scientific) according to the manufacturer’s instructions. 
 
3.2 Cell biology methods 
3.2.1 Culture and passaging of human cells 
To avoid contaminations, all cell culture work was performed under sterile conditions with 
sterile media, solutions and materials. All cells were incubated in HeracellTM 150i CO2 
incubators (Heraeus) at 37.5 °C with 6% CO2 and 95% humidity. If not indicated otherwise, all 
centrifugations were performed at 350 g for 5 min in Centrifuge 1-16K (Sigma).  
 
3.2.1.1 PBL, PBMC and T cell clones  
Isolated PBL or PBMC (Table 2.13) were cultured in T cell medium (Table 2.15) in the presence 
of 100 U/ml IL-2. Depending on cell density, the cells were either split in the appropriate ratio 
or half of the culture medium was exchanged with fresh T cell medium every other day. The 
same culture conditions were used for isolated T cell clones derived from PBL or PBMC. 
Depending on cell numbers, T cell clones were cultured in 96-well, 48-well, 24-well, or 6-well 
plates. For cell numbers above 5 x 106, the cells were generally cultured in 25 or 75 cm2 cell 
culture flasks. Clone 234 (Table 2.13) was cultured in Clone234 medium (Table 2.15) in the 
presence of 50 – 100 U/IL-2. Depending on cell expansion rate, the cells were either split in 
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the appropriate ratio or half of the culture medium was exchanged with fresh Clone234 medium 
every other day. Clone234 cells were cultured exclusively in 24-well plates.  
3.2.1.2 Lymphoblastoid cell lines (LCL) 
LCL and mLCL (Table 2.13) were cultured in RPMI_IV medium (Table 2.15) in 75 cm2 cell 
culture flasks. Depending on cell density, the cells were split in the appropriate ratio or half of 
the culture medium was exchanged with fresh RPMI IV medium every 3 – 4 days. 
 
3.2.1.3 Tumor cells  
The tumor cell lines Jurkat-76-IVB10, K562, K562_A2, K562_A2_CD86, Mel624.38 and 
MelA375 (Table 2.13) were cultured in RPMI_IV medium (Table 2.15) in either 75 or 150 cm2 
cell culture flasks depending on cell numbers. HEK293FT cells and LS174T cells (Table 2.13) 
were cultured in DMEM_IV medium (Table 2.15), while 647-V cells (Table 2.13) were cultured 
in 647-V medium (Table 2.15) in either 75 or 150 cm2 cell culture flasks. Suspension cells, like 
Jurkat-76-IVB10 and the K562 derivatives, were split in the appropriate ratio every 3 – 4 days. 
Adherent tumor cells, including HEK293FT, LS174T, 647-V, Mel624.38 and MelA375, were 
grown to 80 – 100% confluence and then passaged as follows. For detachment of adherent 
cells, the cells were washed with 10 mL PBS and subsequently incubated with 3 – 5 mL Trysin-
EDTA (Table 2.14) at 37.5 °C until all cells were released from the flask surface. By adding 
7 mL pre-warmed culture medium Trypsin was inactivated. After centrifugation, the cells were 
resuspended in 30 mL of fresh culture medium and seeded into new cell culture flasks.  
3.2.2 Thawing and freezing of human cells 
The cryopreserved cells were thawed in a 37 °C water bath until only a small pellet of ice 
remained in the cryopreservation vial. The cells were immediately transferred into 10 mL of 
RPMI_IV medium (Table 2.14) to dilute the DMSO that is present in the freezing medium. After 
the cells were centrifuged at 350 g for 5 min, the supernatant was discarded and the cell pellet 
was resuspended in 2 – 10 mL of appropriate medium. The cell count was determined using 
a counting chamber according to Neubauer (3.2.3) and the cells were seeded in the 
appropriate cell culture flask at the desired cell density.  
For cryopreservation the desired number of cells was first pelleted at 350 g for 5 min and then 
resuspended in 1 mL Freezing medium (Table 2.15) or Ibidi Freezing medium (Table 2.14). 
The cryopreservation vial was immediately transferred into a Mr. Frosty Freezing Container 
(Nalgene) and stored at – 80 °C for at least 24 h. The cells were stored afterwards in -150 °C 




3.2.3 Determination of cell count 
For the determination of cell count, a counting chamber according to Neubauer (C-Chip, 
NanoEnTek) was used. 10 µL sample was taken after the cell suspension had been mixed 
thoroughly. Depending on cell density, the sample was diluted in an appropriate amount of 
trypan blue (Table 2.14) to establish a representative and countable cell concentration. The 
mixture was applied to the edge of the coverslip so that it would be drawn into the void between 
the two glass surfaces by capillarity. The living cells in the 4 large squares of the counting 
chamber were counted using a light microscope (Zeiss). The discrimination between live and 
dead cells was aided by the use of the azo compound that traverses only the porous cell 
membrane of dead cells and stains them dark blue. From the number of cells counted in the 






𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑎𝑟𝑔𝑒 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
 𝑥 𝑑𝑢𝑙𝑖𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑥 104 
 
3.2.4 Isolation and stimulation of PBMC and PBL 
PBMC and PBL were isolated from donor blood by density gradient separation using Biocoll 
(Biochrom) according to the manufacturer’s instructions. To prevent coagulation 100 µL 
Heparin-Natrium (Braun) was added per 50 mL of donor blood. Donor blood was subsequently 
diluted with PBS (Biochrom) at a ratio of 1:1 or 1:2, respectively. Approximately 35 mL of 
diluted blood per 50 mL Falcon tube was carefully layered over 15 mL Biocoll solution and 
subsequently centrifuged at 840 g for 20 min without brakes. The PBMC layer was carefully 
removed and transferred to a new 50 mL tube. Up to 3 PBMC layers from different tubes were 
pooled and PBS was added to a total volume of 50 mL. The PBMC layers were washed by 
centrifugation at 470 g for 10 min. After pooling the cell pellets of 2 tubes, the cells were 
washed again with PBS as described above. All cell pellets from one donor were pooled and 
resuspended in 20 mL PBS and the cell count was determined (3.2.3). After centrifuging the 
cells at 470 g for 10 min, the PBMC were resuspended in the appropriate amount of T cell 
medium (Table 2.15) and seeded for activation utilizing Dynabeads® Human T-Activator 
CD3/CD28 (Thermo Fisher Scientific) according to the manufacturer’s instructions. 
Alternatively, for isolation of PBL from PBMC, plate adherence was used for removal of 
monocytes from the isolated PBMC. For plate adherence, 75 x 106 PBMC were resuspended 
in 10 mL DC medium and plated in 80 cm2 NunclonTM Surface flasks. After incubating the 
cells for 60 min at 37.5 °C and 6% CO2 at 95% humidity and occasional tilting, the supernatant 
containing PBL was collected. Isolated PBL were activated as described for PBMC above.  
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3.2.5 Stimulation of T cell clones 
Isolated T cell clones were activated to induce proliferation using one of the stimulation 
methods described below.  
Stimulation of Clone 234:  
Clone 234 was activated by co-culturing 1 x 106 T cells per 24-well with 0.3 x 106 irradiated 
LCL_BW in the presence of 100 U/mL IL-2 in a total of 2 mL Clone234 medium.  
Stimulation of T cell clones with PHA:  
For activation utilizing the mitogen PHA, 1 x 106 T cells were co-cultured with 0.1 x 106 
irradiated LCL_Pia1 and 1 x 106 feeder cells in 2 mL T cell medium in 24-well plates. 
Stimulation-mix was completed with 250 ng/mL PHA and 100 U/mL IL-2. For activation of 
single cell clones in 96-well plates, 30 x 103 irradiated feeder cells and 2 x 103 LCL were used 
in combination with 250 ng/mL PHA and 100 U/mL IL-2. 
 
 
Stimulation of T cell clones with OKT-3 antibody:  
Isolated T cell clones were stimulated with 32 ng/mL OKT-3 crosslinking antibody and varying 
amounts of co-stimulatory cells dependent on number of T cells to be activated. Generally, the 
conditions depicted in Table 3.4 were used, however cell numbers could vary based on 
experimental layout.  
 
Table 3.4: Conditions for T cell stimulation via OKT-3 antibody. 
Components  96-well 24-well 6-well – 25 cm2 flask 
T cells  Up to 0.2 x 106 0.05 – 0.5 x 106 0.05 – 2 x 106 
Feeder cells Up to 0.2 x 106 2 x 106 5 – 10 x 106 
LCL Up to 0.02 x 106 1 x 106  1 - 2 x 106 
Medium 200 µL 2 mL 6 – 10 mL 
IL-2 100 U/mL 100 U/mL 100 U/mL 
 
Co-stimulatory cells were always irradiated using Radiation facility Xstrahl RS225 (Xstrahl 
limited). LCL were irradiated at 100 Gy, while feeder cells were irradiated at 50 Gy. IL-2 was 
generally added 5 – 24 hours after co-culturing the cells 
 
CAR-specific stimulation of T cell clones: 
T cell clones transduced with CEA-CARs were stimulated utilizing irradiated LS174T cells 
(250 Gy). Generally, effector to target ratios of 1:4 – 1:6 were used. In 24-well plates 
0.5 – 1 x 106 T cells were activated with CAR target cells in the presence of 100 U/mL IL-2.  
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T cell clones transduced with CD19-CAR were activated with CD19-positive LCL_Eva1 
utilizing the conditions described in Table 3.4 without addition of OKT-3 antibody. CD3-
Chimera-transduced T cells were activated utilizing OKT-3 antibody and stimulation mix as 
described in Table 3.4. 
 
3.2.6 Magnetic cell separation 
Magnetic cell separation was used to isolate CD3-negative T cells after introduction of TALEN 
pairs. For this purpose, Dynabeads® CD3 (Thermo Fisher Scientfic) were used according to 
the manufacturer’s instructions. For the separation of up to 2.5 x 106 cells, 50 – 75 µL beads 
were washed twice with 1 mL isolation buffer (Table 2.3) and then resuspended in the initial 
volume in isolation buffer. Following the procedure, bead-captured CD3-positive cells were 
depleted from the cell suspension. The supernatant that was now enriched with CD3-negative 
cells was transferred into a new 1.5 mL tube and the procedure was repeated twice. The 
repeated depletion of the bead-bound CD3-positive cells was critical to obtain a high purity of 
the CD3-negative cell population. After the cell count was determined (3.2.3), the isolated CD3-
negative cells were centrifuged and seeded in 24-well plates in the appropriate culture 
medium. 
 
3.2.7 Transfection of HEK293FT cells 
HEK293FT cells were transfected with plasmids coding for retroviral packaging vectors Gag-
Pol and GALV (Table 2.7) and respective CAR or TCR constructs included in retroviral 
backbone vectors pES-12.6, pMP71 or pBullet (Table 2.7) for generation of viral particles that 
were used for transduction of T cells. For this, 1.5 – 2 x 106 HEK293FT cells were seeded per 
10 cm petri dish in 10 mL DMEM_IV medium (Table 2.15) on day prior to transfection. Cells 
that reached a confluency of 50 – 60% after 24 h were transfected utilizing TransIT®-LT1 
Transfection Reagent (Mirus Bio) according to the manufacturer’s instructions. Per approach, 
30 µL TransIT®-LT1 Transfection Reagent was diluted in 470 µL DMEM medium without any 
supplements. After incubation at room temperature for 5 min, a total of 12.5 µg DNA was 
added and gently mixed by pipetting. The mixture was incubated for 15 min at room 
temperature and subsequently added drop-wise to the seeded HEK293FT cells. Transfection-
mix contained 3.1 µg GALV plasmid, 4.7 µg Gag-Pol plasmid and 4.7 µg retroviral vector 
containing the respective construct. HEK293FT cells were cultured for 3 – 4 days at 37 °C with 
5% CO2 and 95% humidity before viral particles were harvested from the cell culture 
supernatant. Virus-containing supernatant was centrifuged at 300 g for 10 min to remove any 
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cell debris and either used directly for transduction or stored at -80 °C and thawed when 
required for transduction.  
3.2.8 Transfection of T cells (with TALEN & Cas9/gRNA) 
T cells were transfected with ivt-RNA coding for TALENs by electroporation to allow transient 
expression of the constructs for targeting of the respective TCR chains. For this, TALEN ivt-
RNA was generated as described in 3.1.16, which included polyadenylation. Five days prior to 
electroporation, the cells were activated (3.2.4, 3.2.5) to achieve maximal T cell proliferation. 
To prepare T cells for the electroporation, they were washed twice with 10 mL serum-free 
RPMI medium and stored on ice. For one electroporation approach 2.5 – 3 x 106 cells were 
resuspended in 200 – 250 µL RPMI medium and then transferred into a pre-cooled 
electroporation cuvette (0.4 cm, BioRad). To slow down metabolism and make cells more 
resistant to overheating, they were incubated on ice for 5 min. TALEN ivt-RNA was thawed on 
ice and added to the cell suspension in the appropriate amount (Table 3.5). After mixing the 
solution thoroughly, the cuvette was placed in the Electroporator Gene Pulse XcellTM (Bio-Rad) 
and pulsed at 400 V for 5 ms utilizing the time constant protocol. After pulsing, the cells were 
immediately transferred into 4 mL pre-warmed growth medium in a 6 well culture vessel and 
incubated at 37.5 °C with 6.5% CO2 and 95% humidity until further application. For 
CRISPR/Cas9 approach ivt-RNA coding for CRISPR gRNA was generated from TRAC or 
TRBC Crispr strings (Table 2.8) as described in 3.1.16. RNA coding for Cas9 protein was 
purchased from Thermo Fisher Scientific and used together with produced gRNA for 
CRISPR/Cas9 approach (Table 3.5). Preparation of cells and electroporation was performed 
as described above. 
Table 3.5: Transfection-mix for TALEN or CRISPR/Cas9 approach. 
Approach Target Ivt-RNA Amount [µg] 
TALEN TCR  chain 
ptruncTAL3_13.3_TCRa_L 
ptruncTAL3_14.1_TCRa_R 
15 µg each 
TALEN TCR  chain 
ptruncTAL3_15.2_TCRb_L 
ptruncTAL3_16.2_TCRb_R 
15 µg each 





10 – 15 µg each 
CRISPR/Cas9 TCR  chain 
CRISPR Cas9 mRNA 
TRAC String ivt-RNA 
7.5 µg 
5.0 µg 
CRISPR/Cas9 TCR  chain 
CRISPR Cas9 mRNA 




3.2.9 Transduction of T cells and PBL 
Transduction of T cells with retroviral vectors results the incorporation of DNA sequences 
coding for the respective CAR or TCR construct into the host genome and allowed stable 
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expression. To achieve maximal transduction rates, T cells were activated 4 – 5 days prior to 
transduction as described in 3.2.4 or 3.2.5. Not-treated 24-well plates (Corning) were coated 
with 1 mL Retronectin® (Takara Bio) at a concentration of 10 µg/mL and incubated over night 
at 4 °C. After removal of Retronectin® solution, the plates were blocked with PBS containing 
2% bovine serum albumin (BSA) for 30 min at room temperature. 1 – 2 mL supernatant 
containing viral particles, which was generated as described in 3.2.7, was subsequently added 
to the blocked 24-well plates. The plates were centrifuged at 1000 g for 1.5 hours at 32 °C to 
allow binding of viral particles to Retronectin®. After supernatant was removed 0.5 – 1 x 106 T 
cells were added per well in 1 mL appropriate culture medium and incubated at 37.5 °C with 
6.5% CO2 and 95% humidity. If required, the procedure was repeated the following day to 
increase transduction rates.   
 
3.2.10 Automated workflow platform for T cell clone imaging and picking 
After single cell sorting (3.3.3) expanded T cell clones were identified in 96-well plates using 
the software Clone Select Imager (Molecular Devices) in combination with the automated 
workflow platform EVO200 (Tecan). Designated T cell clones were then picked using the Hit 
Selector Software (Tecan) to guide the liquid handling arm LiHa (Tecan), which transferred 
selected T cell clones into new 96-well plates for further analysis and expansion. 
 
3.3 Flow Cytometry 
All flow cytometric analyses were performed using the BD LSRFortessaTM cell analyzer (BD 
Bioscience), depending on sample count in combination with High Throughput Sampler (HTS, 
BD Bioscience). Flourescence-activated cell sorting (FACS) was performed utilizing either BD 
FACSAriaTM Fusion (BD Bioscience) or SONY SH800S Cell Sorter (SONY Biotechnolgy) 
according to the manufacturer’s instructions. Acquired flow cytometric data were analyzed with 
the software FlowJo v10 (Tree Star).  
 
3.3.1 Staining of cell surface markers 
For staining of cell surface markers in tubes up to 1 x 106 cells were harvested, centrifuged 
and washed with 500 µL FACS buffer (Table 2.3). The cell pellet was resuspended in 50 µL 
FACS buffer and the desired antibody conjugated with a fluorescent dye was added. The 
optimal amount of a specific antibody for the staining was tested in preceding experiments and 
was in the range of 2 – 6 µL per 50 µL. The cell suspension was mixed thoroughly and 
incubated at 4 °C for 30 – 45 min in the dark. To remove unbound antibody, the cells were 
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washed with 500 µL FACS buffer and then fixed in 100 – 150 µL cell fixation solution (Table 
2.3) or resuspended in FACS buffer. The fixed cells were stored at 4 °C in the dark until they 
were analyzed in a flow cytometer. For plate staining and subsequent analysis using HTS, the 
cells were washed with 200 µL FACS buffer. Staining with F(ab')2 anti-human IgG (-IgG 
antibody, Southern Biotech) was always performed prior to staining with other antibodies 
included in the staining panel to exclude unspecific binding. For this, harvested cells were 
washed 3-times with PBS before and after incubation at 4 °C for 30 min. Subsequent staining 
of other cell surface markers was performed as described above. Tetramer staining was 
performed according to the manufacturer’s instructions, which included incubation of washed 
cells for 20 min at room temperature with 10 µL tetramer per approach before subsequent 
staining of other surface markers, as described above. When cell samples still containing LCL 
were analyzed by flow cytometry, FcR Blocking Reagent (Miltenyi Biotec) was used prior to 
cell staining as recommended by the manufacturer.  
 
3.3.2  Labeling of T cells with dyes  
To track cell divisions and therefore proliferation of T cells, the cells were labeled with 
CellTraceTM Violet Cell Proliferation Kit (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. For cell preparation in 96-well plates, a final concentration of 5 µM 
CellTraceTM Violet in 100 µL was used for labeling of the cells. The cells were washed twice 
with 200 µL of appropriate culture medium before adding them to the stimulation-mix to 
induced proliferation. Alternatively, the cells were labeled 4 days after activation as described 
above. Subsequent staining of cell surface markers was performed as described in 3.3.1.  
 
3.3.3 Sorting of T cells  
For FACS, T cells were stained for cell surface markers as described in 3.3.1. Antibody amount 
as well as staining and washing volumes were increased proportionally to cell numbers used 
for staining. After the last washing step, cells were resuspended in 0.5 – 2 mL PBS or FACS 
buffer and strained using round bottom tubes with cell strainer cap (Corning) to generate a 
uniform single-cell suspension. Cells were stored at 4 °C until FACS. Bulk sorted cells were 
collected in 15 mL Falcon® tubes (Corning) and subsequently centrifuged and resuspended 
in appropriate cell culture medium for further cultivation (3.2.1.1) or activation (3.2.4 ,3.2.5). 
For single cell cloning, individual T cell clones were sorted into 96-well plates comprising the 
respective stimulation-mix (3.2.4, 3.2.5). IL-2 and PHA or OKT-3, respectively, were added 
after FACS to complete the stimulation-mix. 
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3.4 Immunological methods  
3.4.1 ELISA  
Enzyme-linked immunosorbent assay (ELISA) was performed using the OptEIA™ Human 
IFN- ELISA Set (BD Bioscience) according to the manufacturer’s instructions. Co-culture was 
set up 16 – 24 h prior to ELISA as descried individually for each experiment.  If not indicated 
otherwise, 5 x 104 T cells were used per 96-well in a total volume of 200 µL appropriate culture 
medium without addition of IL-2. Target cells were added in the respective effector to target 
ratios as specified for each approach. For ELISA, 50 µL co-culture supernatant per well was 
transferred to pre-coated and blocked Nunc-Immuno™ 96 Well Plates (Thermo Fisher 
Scientific). Coating was performed overnight at 4 °C utilizing 50 µL ELISA Coating Buffer 
(Table 2.3) and 0.2 µL Capture Antibody. Before and after blocking the plates with 300 µL 
ELISA Blocking Buffer (Table 2.3) per well for 30 min at room temperature, the plates were 
washed 3 times with ELISA Washing Buffer (Table 2.3). IFN- standard doublets were included 
to allow calculation of standard curves for each plate. After incubating co-culture supernatants 
for 1 h at room temperature the plates were washed 4 times before addition of detection-mix, 
which included 0.25 µL Detection Antibody and Enzyme Reagent in 50 µL ELISA Blocking 
Buffer per well. Upon incubation for 30 min in the dark, the plates were washed 4 times and 
50 µL substrate reagent derived from TMB Substrate Reagent Set (BD Bioscience) was added. 
After 3 – 5 min 100 µL 1 M H3PO4 was added per well to stop the enzymatic reaction. The 
plates were imaged using Multiskan™ FC Mikrotiterplatten-Photometer (Thermo Fisher 
Scientific) to detect absorbance at 450 nm and 570 nm to allow wavelength correction.  
 
3.4.2 IncuCyte® Immune Cell Killing Assay  
To observe real-time killing mediated by T cells targeting the respective tumor cells the 
IncuCyte® ZOOM System (Essen Bioscience) was used in combination with IncuCyte® ZOOM 
Software 2016B (Essen Bioscience) according to the manufacturer’s instructions. For this, 
tumor cells were labeled with IncuCyte® NucLight Red Lentivirus Reagent (Essen Bioscience) 
according to the manufacturer’s instructions to allow cell count based on fluorescence detected 
in cell nuclei. If not indicated otherwise, 4 x 104 T cells were co-cultured with NucLight Red-
labeled tumor cells at described effector to target ratios in 200 µL appropriate culture medium 
without addition of IL-2. Images of quadruplicates per approach were taken every 2 h and the 
data were analyzed utilizing masks created to specifically detect the cell count of the respective 





The proposed strategy for the generation of universal recipient T cells comprised the knockout 
of the endogenous TCR to enable testing of transgenic TCRs in these recipient cells without 
the risk of TCR mispairing. To generate a stable test system for the characterization of multiple 
transgenic TCRs, expansion of these universal recipient T cells has to be consequently 
achieved independent of the endogenous TCR. TCR-independent activation and proliferation 
of T cells should be mediated through an introduced chimeric antigen receptor (CAR) as soon 
as the endogenous TCR is absent after the directed knockout. Therefore, first experiments 
were performed to investigate whether selected CAR constructs can generally support TCR-
independent expansion of T cells to an extent comparable to physiological T cell proliferation. 
Once T cell expansion via CAR engagement could be demonstrated in a selected T cell clone, 
the endogenous TCR was targeted for knockout using gene editing tools, including 
transcription activator-like effector nucleases (TALENs). Subsequently, the strategy for 
generating universal recipient cells was further improved to allow the selection of various T cell 
clones that show superior proliferative capacity upon CAR engagement. Based on poor 
survival of the generated TCR-negative T cells, new chimeric constructs were generated that 
should improve TCR-independent proliferation of universal recipient cells. Using these 
chimeric constructs, a new high-throughput strategy for the generation of universal recipient 
cells could be developed that enabled the isolation of several promising candidate T cell 
clones, which exhibited high proliferative capacity in the absence of the endogenous TCR via 
engagement of the introduced chimeric construct. The generated universal recipient cells were 
subsequently characterized for suitability as a reproducible test system for transgenic TCRs. 
 
4.1 T cell stimulation via chimeric antigen receptors (CARs) 
To investigate whether CARs can support TCR-independent expansion of T cells in a manner 
comparable to physiological T cell activation via the TCR, an established and well-
characterized CD4+ T cell clone, termed Clone 234 (HLA-A*24:01-restricted), was used as a 
first test system. Clone 234 recognizes antigen presented by the HLA-A*24:01-positive 
lymphoblastiod cell line BW (LCL_BW). Co-culture of Clone 234 with LCL_BW results in high 
expansion of the T cells accompanied by specific IFN- release. It has been shown previously 
that bulk populations of primary human T cells can be expanded in vitro through CAR 
engagement, yielding cell numbers comparable to physiological TCR stimulation (Maher et al., 
2002; Finney, Akbar and Alastair, 2004). However, this has never been investigated for 
isolated T cell clones that show a lower proliferative capacity compared to mixed lymphocyte 
populations. Even though these populations expand more rapidly, they consist of different T 
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cell subsets comprising various effector functions and unknown TCR specificities. In contrast, 
the use of a defined T cell clone, like Clone 234, of known target specificity and proliferative 
capacity allows a direct comparison of the effects of TCR and CAR engagement on T cell 
expansion. 
To enable monitoring of proliferation induced by CAR engagement, it was important to use 
CAR constructs that have been shown to promote expansion of T cells. For this reason, two 
well validated CAR constructs, CEA-CAR_CD8 and CEA-CAR_CD4, that both recognize the 
human carcinoembryonic antigen (CEA),  were used for these experiments (Hombach et al., 
2001; courtesy Hinrich Abken). While the CEA-CAR_CD8 comprises a CD28 transmembrane 
and a co-stimulatory signaling domain, the CEA-CAR_CD4 contains a CD4 transmembrane 
domain followed by a 4-1BB (CD137) signaling domain (Figure 4.1). Due to the respective 
arrangements of signaling domains, CEA-CAR_CD8 is predicted to induce proliferation 
preferably in CD8+ T cells, while CEA-CAR_CD4 should be favorable when introduced into 
CD4+ T cells.  
 
 
4.1.1 Enrichment and expansion of CAR-expressing T cells 
To enable the comparison between TCR- and CAR-specific activation of T cells, the two CEA-
CAR constructs (CEA-CAR_CD8; CEA-CAR_CD4) were transduced into the defined CD4+ T 
cell clone, Clone 234. On day 10 post transduction, the T cells were stained for CAR 
expression using a F(ab’)2 goat anti-human IgG antibody (-IgG antibody) directed against the 
CH2CH3 hinge domain of the CARs and sorted by FACS. Cell preparations with initial 
transduction rates of 12.7% and 22% for CEA-CAR_CD8 and CEA-CAR_CD4, respectively, 
could be enriched to nearly 100% purity (Figure 4.2a).  
Figure 4.1: Schematic representation of CEA-
CAR constructs provided by Hinrich Abken. 
The single chain variable fragment (scFv) is 
derived from the variable light and heavy chains 
(VL, VH) of a monoclonal antibody recognizing CEA 
protein. Specificity of this antibody is conferred to T 
cells via the expression of the CAR on the cell 
surface. CEA-CAR_CD8 comprises the CD28 
transmembrane and intracellular signaling 
domains, while CEA-CAR_CD4 contains a CD4-
derived transmembrane domain followed by a 
4-1BB (CD137) signaling domain. Both constructs 
carry the same -CEA scFv coupled to the 
respective transmembrane domains via an IgG 
CH2CH3 hinge domain as well as a terminal CD3 
signaling domain. For transduction of T cells both 
constructs are embedded in the retroviral 




Figure 4.2: Flow cytometric analysis and sorting of CAR-transduced Clone 234. a) FACS of Clone 234 
transduced with the CAR constructs CEA-CAR_CD8 and CEA-CAR_CD4. FACS staining was performed 10 days 
after transduction using an -IgG antibody. Untransduced cells of Clone 234 were used as negative control.  b) 
Representative flow cytometric analysis of CAR expression in enriched CEA-CAR_CD8 and CEA-CAR_CD4-
positive cells 12 days after TCR- or CAR-specific stimulation. For activation, 1 x 106 CAR-positive cells were 
stimulated with 0.3 x 106 irradiated TCR (LCL_BW) or CAR (LS174T) target cells. Enriched (blue) and untransduced 
control cells (gray) were stained with -IgG antibody and analyzed by flow cytometry. Median fluorescence intensity 
(FI) values of enriched and untransduced cells were used for calculation of median FI for each approach to 
demonstrate CAR expression levels.  
To exclude an influence of antigen-specific activation on CAR expression levels in transgenic 
T cells, CAR-enriched cells were activated either by TCR- or CAR-specific stimulation and 
analyzed for CAR expression after the expansion period. For this, CEA-CAR_CD8- and CEA-
CAR_CD4-positive cells were activated utilizing irradiated target cells that express the 
respective TCR or CAR target molecule (TCR: LCL_BW, HLA-A24*01-positive; CAR: LS174T, 
CEA-positive). Twelve days after activation, the expanded cells were analyzed for CAR 
expression in comparison with untransduced cells (Figure 4.2b). More than 93% CAR-positive 
cells could be detected for all approaches indicating that CAR expression was stable for both 
CAR constructs independent of TCR or CAR engagement. Distinct populations, reflected by 
large median FI values between CAR-transduced and untransduced control cells, suggested 
no downregulation of CAR expression. CEA-CAR_CD4 showed 2-fold higher median FI 
values compared to CEA-CAR_CD8, which indicated a higher surface expression of CEA-
CAR_CD4 in the CD4+ T cell clone. This stable CAR surface expression was observed over 
more than 42 days, while CAR-transduced T cells were repeatedly activated every 14 days via 
CAR or TCR engagement, respectively. Even though CAR expression was comparable, 
independent of TCR- or CAR-specific activation, proliferation rates of cells stimulated via CAR 
engagement were diminished three-fold or more compared to cells activated via the TCR 
(Figure 4.3). Untransduced Clone 234 was stimulated via the TCR in presence of LCL_BW 
target cell line and used as a control to monitor the proliferation rate. These untransduced 
control cells did not expand when co-cultured with CAR target cells (data not shown). The low 
expansion rate of cells stimulated via CAR engagement indicated that optimization of the 
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activation conditions was required in order to achieve expansion comparable to physiological 
TCR-specific stimulation. It is important to note that CAR-transduced cells stimulated via the 
endogenous TCR seemed to proliferate even better than untransduced control cells.  
  
 
4.1.2 Proliferation of CAR-transduced Clone 234  
Low expansion rates of T cells activated via CAR rather than the endogenous TCR 
demonstrated differences in activation thresholds when identical conditions were used for 
stimulation. The differential activation of the cells might be attributed to differences in antigen 
recognition mediated through the respective receptors and subsequent signal transduction. 
While the TCR recognizes its target antigen in the context of MHC molecules, CARs interact 
with their target antigen directly via the antibody-derived scFv domain. Even though the 
mechanism by which binding of the scFv to cognate antigen propagates signals across the 
plasma membrane through this artificially assembled receptor is still poorly understood, T cell 
activation can be influenced by various factors, including CAR affinity, antigen density and 
CAR surface expression (Turatti et al., 2007). Therefore, enhancing antigen density by 
increasing the number of CAR target cells was used as a first attempt to positively influence T 
cell activation and proliferation mediated by CAR engagement.  
To evaluate the effect on proliferative capacity when the amount of antigen was increased, 
enriched CAR-transduced Clone 234 was co-cultured with graded numbers of irradiated CEA-
expressing target cells (Figure 4.4). Activation status of the cells was determined after 24 hours 
by IFN- ELISA (Figure 4.4a). The impact of increased antigen availability on proliferation of 
the cells was evaluated by CellTrace staining four days after initial co-culture and subsequent 
flow cytometric analysis on day seven (Figure 4.4b). To ensure exclusive evaluation of 
proliferation of CAR-positive effector cells, the cell preparations were additionally stained with 
-CD3 and -IgG antibody prior to flow cytometric analysis. While the same co-culture was 
used for both experiments, IL-2 was added to support T cell survival only after analysis of the 
co-culture supernatant in ELISA. As controls, untransduced Clone 234, which only express the 
Figure 4.3: Fold expansion of CAR-transduced 
T cells over 42 days. In vitro expansion of 1 x 106 
CAR-transduced T cells either via CAR or TCR 
engagement, respectively. 1x 103 irradiated 
LS174T cells (CAR) or LCL_BW (TCR) were used 
for CAR- or TCR-specific activation, respectively. 
Black arrows indicate timepoints of re-stimulation. 
Untransduced Clone 234 was stimulated via TCR 
by addition of their natural target cells (LCL_BW). 
Total number of cells was determined after each 
14-day expansion period. 
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endogenous TCR, as well as irrelevant LCL target cells, that express neither the TCR nor the 
CAR antigen, were used.  
 
Figure 4.4: Target cell titration for CAR-transduced Clone 234. a) IFN- release of CAR-transduced T cells with 
increasing amounts of target cells. IFN- ELISA 24 h after co-culture of 2.5 x 104 CAR-positive effector cells with 
irradiated target cells at a ratio of 1:1. Increasing numbers of CAR target cells (LS174T) are indicated as 2x – 7x. 
TCR target cells (LCL_BW) were used as positive control for TCR activation and irrelevant target cells (mLCL_ME) 
as negative control for both TCR and CAR engagement. b) Proliferation of CAR-transduced T cells with increasing 
numbers of target cells. Expansion of CAR-transduced Clone 234 was assessed by CellTrace staining 4 days after 
co-culture and subsequent flow cytometric analysis 7 days after activation. Cells were additionally stained with -
CD3 and -IgG antibody to enable the selection of CAR-transduced T cells for analysis. Decreasing median FI of 
CellTrace Violet indicates higher numbers of cell divisions and therefore proliferation. Positive control represented 
by untransduced Clone 234 activated with TCR target cells. 
 
TCR-specific activation of CAR-expressing T cells utilizing TCR target cells served as a 
positive control for maximal T cell activation, as determined by IFN- release and proliferative 
capacity. CEA-CAR-transduced Clone 234 and untransduced Clone 234 released comparable 
amounts of IFN- when incubated with TCR target cells, even though IFN- release of CEA-
CAR_CD4-transduced cells was slightly lower (Figure 4.4a). Co-culture with the same amount 
of CAR target cells led to an at least four-fold lower IFN- release for CEA-CAR_CD4-
transduced cells compared to TCR target cells. Increasing the number of CEA-expressing 
target cells led to proportionally increased IFN- release. Beyond the effector to target (E:T) 
ratio of 1:4, the quantity of IFN- was comparable to maximal activation via the TCR and did 
not increase further when more CEA target cells were present. This showed that for maximal 
activation of T cells via CEA-CAR constructs four-fold as much antigen was required compared 
to physiological activation via the TCR. Untransduced control cells did not release IFN- when 
incubated with CAR target cells, which indicated that activation of CEA-CAR_CD4-transduced 
cells in the presence of CEA antigen was triggered following specific antigen recognition 
mediated through the expressed CAR. This was further supported by the fact that CEA-
CAR_CD4-transduced cells did not release IFN- when co-cultured with CEA-negative 
irrelevant target cells. For CEA-CAR_CD8-transduced cells, IFN- levels did not exceed 
background-levels when co-cultured with CEA target cells, indicating that activation via the 
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CEA-CAR_CD8 construct could not induce IFN- release in CD4+ T cells. However, when the 
same cells were analyzed for proliferation after co-culture with increasing amounts of CEA 
target cells, a decrease in median CellTrace Violet FI could be observed, which indicated 
multiple cycles of cell division (Figure 4.4b). Hence, even though CEA-CAR_CD8 engagement 
did not result in IFN- release, antigen recognition mediated by the CAR was able to induce 
proliferation of the T cells. A median CellTrace Violet FI of nearly 30 000 was detected when 
E:T ratios were higher than 1:5, compared to more than 150 000 when T cells were incubated 
with irrelevant target cells that did not induce proliferation. As also indicated by IFN- release, 
activation of the CEA-CAR-transduced cells via TCR engagement resulted in even higher 
proliferation rates reflected by median FI values of nearly 19 000. For CEA-CAR_CD4-
transduced cells, expansion increased gradually with increasing numbers of CAR target cells, 
which reflected the observed increase in IFN- secretion. The high median FI values for E:T 
ratios of 1:1 to 1:3, that exceeded the median FI value of the negative control, hindered a 
quantitative interpretation of the results. In summary, these experiments showed that 
increasing the numbers of CAR target cells improves CAR-induced proliferation of T cells. At 
E:T ratios of 1:5, proliferation rates could be induced that were comparable to physiological 
activation via the endogenous TCR. Based on these results, E:T ratios of 1:5 or higher were 
used for CAR-specific activation of T cells in subsequent experiments.  
 
4.2 Knockout of the endogenous TCR in CAR-transduced T cells 
Increasing the number of CAR target cells in co-culture with CAR-transduced T cells resulted 
in comparable proliferation rates for CAR- or TCR-specific activation, respectively. Since 
sufficient numbers of T cells could be expanded via CAR engagement, the next step for 
generating a universal recipient cell comprised the knockout of the endogenous TCR in these 
T cells. For the directed knockout of the human TCR in CAR-expressing T cells, TALENs as 
well as CRISPR gRNAs were designed to target the TCR  (TRA) and TCR  (TRB) locus, 
respectively.  
 
4.2.1 TALEN and CRISPR/Cas9 design 
TALENs as well as the CRISPR/Cas9 system have proven effective for the knockout of the 
human TCR  and  chains in primary human T cells (Osborn et al., 2016; Knipping et al., 
2017). However, whether these gene editing tools could be also utilized for targeted TCR 
knockout in isolated T cell clones exhibiting lower proliferation rates compared to bulk T cell 
populations, has not been investigated yet. To evaluate the knockout of the human TCR in T 
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cell clones, TALEN pairs and CRISPR/Cas9 guide RNAs were designed to target the human 
TCR  and  chains, respectively (Figure 4.5). In order to allow the knockout of any TCR, 
independent of antigen specificity, the gene segments coding for the constant regions of the 
respective TCR chains (TRAC and TRBC) were chosen as target sites. Since the human TCR 
 chain can comprise either constant region 1 or 2, a homologous region that is present in both 
TRBC gene segments, TRBC1 and TRBC2, was chosen to allow targeting of both variants. To 
knockout the TCR  and  chains, sequences in exon 1 of both the TRAC and TRBC2 gene 
(homologous to TRBC1) segments were selected as target sites, since gene disruption early 
in the coding region would most likely result in a non-functional protein.  
 
Figure 4.5: Target sites for TCR knockout. TALEN pair (red) and CRISPR gRNA (light blue) recognition sites 
overlap within exon 1 of TRAC or TRBC2 gene (dark blue), respectively. Black lower-case letters represent DNA 
sequences of the TALEN target sites. a) TALEN and CRISPR gRNA binding sites in TRAC gene to target the TCR 
 constant region. b) TALEN and CRISPR gRNA binding sites in the TRBC2 gene to knockout the TCR  chain.  
TALENs were designed and generated in a previous work (Sailer, 2013) according to Cermak 
et al. utilizing the Golden Gate cloning method (Cermak et al., 2011). The assembled TALEN 
constructs encoded in ptruncTAL3 vectors (Table 2.7) were transcribed to ivt-RNA before 
transfection into T cell clones. CRISPR gRNAs were designed using the GeneartTM CRISPR 
Search and Design Tool (Thermo Fisher Scientific) and ordered as GeneArt Strings DNA 
fragments from Thermo Fisher Scientific (Table 2.7). DNA fragments encoding for CRISPR 
gRNA were in vitro transcribed and transfected into T cells together with mRNA coding for the 
Cas9 protein (Thermo Fisher Scientific).  
 
4.2.2 Knockout of the human TCR using TALEN and CRISPR/Cas9 
Before performing the TCR knockout in CAR-transduced T cells, the TALEN and 
CRISPR/Cas9 approach was evaluated for efficiency in untransduced Clone 234. Ivt-RNA 
coding for the designed TALEN pairs as well as CRISPR gRNA in combination with mRNA 
coding for Cas9 were introduced into T cells using electroporation. The resulting knockout 
efficiency was evaluated 7 days after transfection by flow cytometric analysis (Figure 4.6a). All 
components of the TCR complex, comprising the TCR  and  chains as well as the CD3 
complex, are required for correct assembly in the ER and cell surface expression (Davis and 
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Bjorkman, 1988; Exley, Terhorst and Wileman, 1991). Therefore, the successful knockout of 
the TCR by targeting either one of the TCR chains could be monitored by the downregulation 
of CD3 expression on the cell surface. Additionally, using CD3 as a marker allowed a fast and 
simple isolation of TCR knockout cells from a mixed population by using magnetic beads 
coated with -CD3 antibody (Sailer, 2013). Utilizing -CD3-coated magnetic beads, CD3-
positive T cells that do not comprise a TCR knockout are retained in the magnet, while CD3-
negative T cells containing the desired TCR knockout can be collected from the supernatant 
medium, a process termed negative isolation.  
Targeting the TCR  or  chain using the generated TALEN pairs resulted in a knockout 
efficiency of up to 20% in Clone 234, as indicated by the presence of a CD3-negative cell 
population (Figure 4.6a). In contrast, knockout of both TCR chains utilizing the CRISPR/Cas9 
system was not successful, since no CD3-negative cell population could be detected. Based 
on these results, the TALEN technology was used for all further knockout experiments.  
 
Figure 4.6: Knockout of the human TCR in Clone 234 and CAR-transduced cells. a) Flow cytometric analysis 
using -CD3 antibody for detection of successful TCR knockout 7 days after transfection of Clone 234 (blue) with 
ivt-RNA coding for TALEN pairs (TALEN) or CRISPR gRNA and Cas9 mRNA (CRISPR). TCR  and  chains were 
targeted separately. Unstained cells served as negative control (gray) and untransfected Clone 234 as positive 
control (black). b) Flow cytometric analysis of CEA-CAR_CD4- and CEA-CAR_CD8-transduced Clone 234 7 days 
after TALEN transfection. For detection of TCR  or  chain knockout, the cells were stained with -CD3 antibody. 
After enrichment of CD3-negative cells using -CD3-coated magnetic beads, separation efficiency was determined 
by antibody staining with -CD3 and -IgG antibody. Untransfected cells served as control (not shown) c) Fold 
expansion of isolated CD3-negative populations of CEA-CAR_CD4- and CEA-CAR_CD8-transduced cells after 
activation via CAR. 1 x 106 TCR knockout cells were incubated with irradiated CAR target cells (LS174T) at a ratio 




Clone 234 transduced with CEA-CAR_CD4 or CEA-CAR_CD8 could be expanded solely via 
CAR engagement reaching a proliferation rate comparable to physiological activation. To 
perform the knockout of the endogenous TCR in these CAR-transduced cells, CEA-CAR_CD4- 
and CEA-CAR_CD8-expressing Clone234 cells were transfected with TALEN pairs targeting 
either the TCR  or  chain, respectively. Knockout efficiency was determined by staining with 
-CD3 antibody 3 days after introduction of the TALENs (Figure 4.6b). In both CEA-CAR_CD8- 
and CEA-CAR_CD4-transduced cells, the knockout of the TCR  or  chain could be achieved 
in up to 25% of the cells. The knockout efficiency of the TCR  chain was slightly lower, 
reflected by only 12 – 18% CD3-negative cells. However, for all approaches CD3-negative 
cells could be successfully enriched by negative isolation utilizing magnetic beads coated with 
-CD3 antibody 4 days after TALEN electroporation (Figure 4.6b). To evaluate the efficiency 
of the enrichment, the isolated cells were stained with -CD3 and -IgG antibody, which 
allowed the simultaneous verification of CAR expression in TCR- and CD3-negative cells. Flow 
cytometric analysis revealed a successful enrichment of CD3-negative cells with almost all 
TCR knockout cells expressing the transgenic CAR construct (Figure 4.6b). As observed 
before, CEA-CAR_CD8 expression levels were lower compared to CEA-CAR_CD4, which 
explained the slightly lower percentage of CD3-negative and CAR-positive cells in CEA-
CAR_CD8-transduced cells compared to CEA-CAR_CD4-expressing Clone 234 (CEA-
CAR_CD8: 86.2% and 91.7%; CEA-CAR_CD4: 97.7% and 95.7%). However, the negative 
isolation strategy enabled the enrichment of TCR knockout cells to a purity of up to 97% with 
only negligible numbers of CD3-positive cells still present in the cell preparation.  
Two days after enrichment, CAR-expressing TCR-negative cells were stimulated for expansion 
via CAR by incubation with CAR target cells at a ratio of 1:6. However, proliferation of the TCR 
knockout cells via CAR engagement was not observed (Figure 4.6c). Fourteen days after 
stimulation the cell numbers declined for 3 of the 4 approaches, indicating that the culture 
conditions could not promote survival of the cells. For CEA-CAR_CD4-transduced cells 
comprising TCR  chain knockout, the cell numbers increased slightly, but the proliferation rate 
was not comparable to previous activation of CAR-transduced Clone 234 via CAR 
engagement.  
 
4.3 Improved strategy for selection of CAR+ T cell clones 
To exclude the possibility that failed cell expansion via CAR in TCR knockout cells was an 
isolated effect based on the nature and proliferative capacity of the selected CD4+ T cell clone 
(Clone 234), the procedure was modified to allow the evaluation of various T cell clones (Figure 
4.7). For this, instead of transducing a single isolated T cell clone, a mixture of different T cell 
Results  
55 
clones with individual characteristics and proliferative capacities present in bulk PBL were 
transduced with the two CAR constructs introduced earlier. The CAR-expressing PBL were 
subsequently single cell cloned to enable the identification of T cell clones that show superior 
proliferation upon CAR engagement while retaining their physiological functionality. Once 
suitable candidates were identified the knockout of the TCR was performed using TALENs as 
described for Clone 234 above. The generated universal recipient cells should then be 
expanded via CAR engagement enabling the production of sufficient cell numbers for 
extensive evaluation of transgenic TCRs.   
 
Figure 4.7: Improved strategy for identification of CAR-positive T cell clones suitable for generating 
universal recipient cells. PBL isolated from healthy donors were transduced with CAR constructs. Single cell 
clones were generated from CAR-expressing T cells. After identification of suitable candidates exhibiting superior 
proliferative capacity upon CAR engagement while retaining functionality, the endogenous TCR was knocked out 
utilizing the TALEN technology. The generated TCR-negative universal recipient cells could then be expanded via 
CAR engagement.  
 
4.3.1 CAR transduction and expression 
For the generation of various T cell clones that express the desired CAR construct, PBL 
comprising T cell clones of different origin were transduced with either CEA-CAR_CD8 or CAE-
CAR_CD4, respectively. Following transduction, CD4+ or CD8+ single cell clones were 




Figure 4.8: Single cell sorting 
of CAR-transduced PBL by 
FACS. Prior to FACS CAR-
transduced PBL were stained 
with -CD4, -CD8 and -IgG 
antibodies. Untransduced PBL 
were used as negative control 
and to set the electronic sorting 
gates. CAR-expressing CD4+ or 
CD8+ T cells, were single-cell-
sorted into 96-well plates and 
subsequently activated utilizing 
irradiated feeder cells and LCL in 
combination with PHA and IL-2.  
 
 
The ratio of CD8+ to CD4+ T cells in PBL used for transduction of the CAR constructs was 
nearly 2:1 (Figure 4.8). Both cell populations were further screened for expression of CEA-
CAR_CD8 or CEA-CAR_CD4, respectively. CEA-CAR_CD8 transduction rate was slightly 
higher than for the CEA-CAR_CD4 construct in both CD4+ and CD8+ T cells. Even though 
CD4+ T cells represented the smaller fraction in PBL, the percentage of CAR-expressing cells 
was higher than for CD8+ T cells transduced with the same construct (CEA-CAR_CD8: 37.6% 
CD4+, 26.8% CD8+; CEA-CAR_CD4: 23.4% CD4+, 17.4% CD8+). Independent of transduction 
rate, sufficient numbers of CAR-expressing single cell clones could be generated from all 
approaches.  
 
4.3.2 Selection of well-proliferating CAR+ T cell clones  
Using the improved strategy for the generation of multiple CAR-expressing T cell clones, 
various CD4+ and CD8+ T cell clones could be isolated. To evaluate the suitability of the 
generated single cell clones as universal recipient cells that are able to proliferate independent 
of the endogenous TCR, they first had to be characterized for proliferative capacity upon CAR 
engagement. For this, 178 selected T cell clones were expanded from 96-well plates by 
repeated stimulation using phytohaemagglutinin (PHA) every two weeks for a period of 41 
days. While this expansion period allowed the accumulation of sufficient cell numbers for 
further evaluation of the selected T cell clones, it also enabled a pre-selection of clones that 
showed superior proliferative capacity. In a first experiment following the expansion period, 40 
well-expanding T cell clones were analyzed regarding CAR expression and functionality after 
the expansion period (Figure 4.9). This early evaluation of CAR reactivity allowed further 
discrimination of suitable T cell clones that expressed the respective CAR construct and 
showed the desired reactivity pattern, which included no recognition of CEA-negative cells. 
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CAR-specific activation of selected T cell clones was evaluated by specific IFN- release upon 
co-culture with irradiated target cells, either positive or negative for the CEA antigen.  
 
Figure 4.9: Evaluation of CAR expression and functionality of selected single cell clones. a) CAR (CEA-
CAR_CD8, CEA-CAR_CD4) expression of 40 individual CD4+ or CD8+ T cell clones analyzed by -IgG antibody 
staining and subsequent flow cytometric analysis. Level of CAR expression is shown as median FI (MFI). 
Untransduced T cell clones served as negative control. b) CAR functionality determined by IFN- ELISA 20 h after 
co-culturing selected T cell clones with irradiated target cells either positive (blue) or negative (pink) for the CEA 
antigen. LS174T served as CEA+ target cells and Jurkat-76 as CEA- target cells. 2 x 105 target cells were seeded 
per well and 50 µL of the respective T cell culture was added.  
As observed before, expression levels of CEA-CAR_CD8 were lower compared to CEA-
CAR_CD4 reflected by the detected median FI (MFI) values for -IgG antibody bound to CAR-
transduced single cell clones (Figure 4.9a). This was true for CD4+ as well as CD8+ T cell 
clones, demonstrating that CAR expression was not dependent on either co-receptor. 
However, MFI values of all 40 selected clones exceeded those of the negative control 
represented by untransduced T cell clones, showing that all clones expressed the transduced 
CAR construct. The qualitative assessment of CAR reactivity by ELISA showed that almost all 
T cell clones were able to produce IFN- when exposed to CEA antigen, while no or only little 
IFN- was released in the absence of antigen (Figure 4.9b). The CEA-CAR_CD8-expressing 
T cell clones 22 (CD8+) and 4 (CD4+) exhibited undesired reactivity in the absence of CEA 
antigen and were therefore not used in further experiments. As already reflected by the number 
of T cell clones isolated from each approach, CEA-CAR_CD4-expressing T cells seemed to 
expand better upon stimulation with PHA than cells transduced with CEA-CAR_CD8. However, 
whether these T cell clones would be able to proliferate upon CAR engagement independent 
of the endogenous TCR, had to be determined in subsequent experiments.  
To evaluate the proliferative capacity of selected T cell clones following stimulation via CAR 
engagement, the CAR-expressing T cell clones were exposed to CAR target cells (LS174T). 
To be able to quantify the observed expansion rates upon CAR stimulation, the same T cell 
clones were simultaneously activated by addition of phytohaemagglutinin (PHA) mimicking the 
engagement of the TCR. PHA is a plant-derived lectin that serves as a mitogen to trigger T 
cell division by binding carbohydrates on cell surface receptors, including the TCR, resulting 
Results  
58 
in TCR crosslinking (Chilson, Boylston and Crumpton, 1984). This mitogen-mediated activation 
of T cells was used since TCR specificities of the isolated T cell clones were unknown, 
rendering antigen-specific activation via the TCR impossible. For further evaluations, four 
representative T cell clones derived from each approach were selected. The proliferative 
capacity of the T cell clones when activated via CAR in comparison to TCR engagement was 
first assessed using CellTrace staining and subsequent flow cytometric analysis (Figure 4.10). 
For this, resting T cells were stained with Cell Trace Violet prior to co-culture with irradiated 
CAR target cells (CAR-specific activation) or PHA stimulation-mix (TCR-specific activation), 
respectively. The proliferation status of the individual T cell clones was determined on day 3 
and 7 after activation by analyzing CellTrace Violet median FI values using flow cytometry. 
 
Figure 4.10: Proliferation of CAR-transduced T cell clones induced either by TCR or CAR engagement. 
Expansion of T cell clones transduced with CEA-CAR_CD4 or CEA-CAR_CD8, respectively, was monitored 3 and 
7 days after activation by flow cytometric analysis of CellTrace Violet-stained T cells. CAR-specific stimulation (blue) 
was performed in 96-well utilizing 1 x 105 T cells and 4 x 105 irradiated CAR target cells (LS174T). TCR-specific 
activation (gray) of 1 x 105 T cells was mimicked using PHA stimulation-mix comprising 2 x 105 irradiated feeder 
cells and 2 x 104 irradiated LCL in the presence of PHA. Decreasing median FI values for CellTrace Violet indicated 
higher numbers of cell divisions reflecting proliferation. Unstimulated T cells served as a negative control (not 
shown).  
Proliferative capacity of each T cell clone could be estimated by decreasing CellTrace Violet 
median FI values following TCR- or CAR-specific activation (Figure 4.10). When comparing 
median FI values of T cells that were activated via TCR with those stimulated via CAR three 
days after initial co-culture, it became apparent that CAR-stimulated cells initially proliferated 
stronger. Higher proliferation rate was indicated by lower median FI values of approximately 
10 000 for T cell clones stimulated via CAR compared to median FI values ranging from 19 000 
to over 50 000 for TCR-stimulated T cells. However, seven days after activation median FI 
values as well as population shifts visible in the respective histograms were comparable both 
for cells stimulated via TCR or CAR, respectively. This demonstrated comparable proliferation 
rates seven days after stimulation for both approaches. Based on these results it could be 
Results  
59 
assumed that CAR-specific stimulation of the T cell clones would be sufficient to expand T cell 
clones once endogenous TCRs are absent after the knockout.  
To further quantify the proliferative capacity of T cells activated via CAR, the cell count was 
determined eleven days after CAR-specific activation of the same T cell clones using irradiated 
CAR target cells (LS174T) (Figure 4.11a). Expansion rates of the respective T cell clones 
following CAR engagement was compared to proliferation rates upon activation with PHA 
(TCR-specific stimulation). After the expansion period, the T cells clones that were either 
activated via CAR or TCR engagement, were subsequently analyzed for responsiveness to 
CAR target cells (Figure 4.11b). Since the selected T cell clones were previously able to 
specifically secrete IFN- upon encounter of CAR target cells, this method was used to ensure 
that only CAR-expressing T cells specifically recognizing the CEA antigen expanded after 
activation. 
 
Figure 4.11: Fold expansion and IFN- release of CAR-expressing T cell clones activated either via CAR or 
TCR, respectively. a) Fold expansion of 5 x 105 CAR-expressing T cells in 24-well plates was determined 11 days 
after co-culture with either 2 x 106 irradiated LS174T cells (CAR stimulation) or PHA stimulation mix (TCR 
stimulation). Representative expansion rates of CD8+ and CD4+ T cell clones either transduced with CEA-CAR_CD4 
or CEA-CAR_CD8, respectively, are depicted. b) After expansion period IFN- release of the same cells was 
determined in ELISA 20 h after co-cultivation with either CEA+ target cells (LS174T) or CEA- target cells 
(mLCL_ME). Co-culture was set up using 5 x 104 CAR-positive T cells at an E:T ratio of 1:4. 
For each CAR-expressing T cell clone, the expansion rates were comparable when stimulated 
either TCR- or CAR-specific (Figure 4.11a). These observations are in accordance with results 
obtained from CellTrace Violet staining upon activation of the same T cell clones (Figure 4.10). 
However, when comparing the fold expansion of the individual clones with each other, 
differences in proliferation rates could be observed (Figure 4.11a). T cell clones transduced 
with CEA-CAR_CD4 showed a higher proliferation rate compared to CEA-CAR_CD8-
expressing T cell clones. While CEA-CAR_CD8-transduced cells reached a maximal 
expansion rate of 10-fold, T cells expressing CEA-CAR_CD4 showed up to 20-fold expansion 
11 days after activation. Additionally, CD4+ T cell clones proliferated slightly stronger compared 
to CD8+ T cells transduced with the same CAR construct. Interestingly, this did not correlate 
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with IFN- release when exposed to the same CAR target cells (Figure 4.11b). T cell clones 
that were activated via TCR expressed much higher IFN- levels than CAR-stimulated T cells, 
even though proliferation rates were comparable. Additionally, CD4+ T cell clones initially 
activated via CAR secreted less INF- than the respective CD8+ T cell clones. However, none 
of the T cell clones reacted with CEA-negative control target cells, indicating that IFN- release 
observed with CEA-positive target cells represented specific recognition mediated through the 
transduced CAR. In summary, while all T cell clones could be expanded via CAR engagement, 
proliferation rates of CEA-CAR_CD4 transduced cells were slightly higher than for CEA-
CAR_CD8-expressing cells. At the same time, the amount of IFN- released in response to 
CAR target cells did not correlate with proliferative capacity. However, all T cell clones 
independent of activation approach specifically recognized the CAR target cells, which 
indicated specific expansion of CAR-expressing cells.  
 
4.3.3 Knockout of the endogenous TCR using TALENs 
Various CAR-expressing CD4+ and CD8+ T cell clones could be generated that could be 
successfully expanded via CAR engagement. The next step in the generation of universal 
recipient cells comprised the subsequent knockout of the endogenous TCR in these expanded 
T cell clones. For the specific knockout of either the TCR  or  chain, the TALEN technology 
introduced earlier was utilized. Knockout efficiency rate was determined by loss of CD3 on the 
cell surface 5 days after introduction of TALEN pairs (Figure 4.12a). While the knockout 
efficiency rate was comparable for targeting of TCR  and  chain, respectively, only TCR  
chain knockout is depicted in Figure 4.12a. TCR-negative T cell cells were subsequently 
isolated using magnetic beads coated with -CD3 antibody by extraction of TCR-positive cells 
that did not comprise a knockout of the endogenous TCR.  The isolated TCR-negative cells 
that expressed the introduced CAR construct were then stimulated via CAR engagement that 




Figure 4.12: Knockout of the endogenous TCR  chain in CAR-transduced T cell clones. a) Flow cytometric 
analysis of CAR-transduced CD8+ and CD4+ T cell clones (CEA-CAR_CD4 or CEA-CAR_CD8) using -CD3 
antibody for detection of successful TCR knockout 5 days after transfection with TALEN pairs targeting the TCR  
chain. Untransfected cells served as negative controls. b) Total cell count of CD3-negative cells after magnetic 
bead-based isolation and 14 days after subsequent stimulation of TCR-negative cells via CAR. TCR-negative T 
cells were isolated 7 days after incubation with 2.5 x 105 irradiated CAR target cells (LS174T) in the presence of 
IL-2 for 14 days. Cell count was determined after expansion period at day 14. Data are representative for two 
independent experiments.  
While in all four T cell clones the TCR  chain could be targeted using TALEN pairs, knockout 
efficiency was relatively low compared to previous experiments using Clone 234. Only 3 – 12% 
of the cells exhibited a knockout of the TCR  chain indicated by the loss of CD3 on the cell 
surface (Figure 4.12a). Consequently, the number of TCR-negative T cells that could be 
isolated utilizing -CD3 coated beads was also very low for all four approaches (CEA-
CAR_CD8: CD8+ = 115 x 103, CD4+ = 40 x 103; CEA-CAR_CD4: CD8+ = 75 x 103, CD4+ = 
80 x 103) (Figure 4.12b). Stimulation of these low numbers of cells via CAR engagement did 
not result in TCR-independent proliferation of T cells and the cells did not survive the 14-day 
expansion period.  
Independent of the nature or origin of the selected T cell clones, TCR-deficient T cells could 
not be stimulated to proliferate via the transduced CEA-CAR. While other mechanisms 
connected to regulation and signaling of the respective CAR construct could be responsible 
for the failed expansion, another possible explanation roots in the nature of the CAR target 
cells (LS174T). These fast-expanding, adherent tumor cell lines might not create an optimal 
environment for T cell expansion compared to a standard stimulation mix, which contains 
feeder cells and LCL providing co-stimulatory signals that promote T cell activation. Especially 
low numbers of T cells, as was the case after TCR knockout by TALENs, might be affected 
more drastically by this hostile environment. For this reason, one measure to improve the 
strategy for generating universal recipient cells for TCR-independent expansion comprised the 
expansion of the molecular toolbox (see 4.4).  
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4.4 Process improvements  
Because proliferation via CAR engagement could not be induced in TCR-deficient T cell 
clones, a re-evaluation of the process was performed. This comprised the expansion of the 
molecular toolbox by generating two new chimeric constructs that should improve T cell 
survival of TCR-knockout T cell clones. Additionally, different T cell subsets were investigated 
for their proliferative capacity and survival in vitro to determine whether CAR-T cell clones 
derived from a specific T cell compartment would be better suited as universal recipient cells. 
Based on results obtained with the two new chimeric constructs, a new strategy for the 
generation of universal recipient cells was developed that would allow a faster selection 
process of T cell clones comprising a TCR knockout that could be expanded simultaneously 
via CAR engagement.  
 
4.4.1 Expansion of molecular toolbox  
To improve the process of generating universal recipient cells, two new CAR constructs were 
generated and tested for their feasibility to promote T cell expansion. While the CEA-CARs 
mediated optimal proliferative capacity, the unsuccessful expansion of TCR knockout T cell 
clones from small cell numbers could possibly originate in the nature of the CEA positive target 
cells creating an unfavorable environment for T cell proliferation. To circumvent this, new CAR 
constructs were generated that could activate T cells in the presence of B cell-derived LCL 
providing various co-stimulatory signals to T cells during activation.  
 
4.4.1.1 CD19-CAR 
CD19 has proven to be a suitable target for CAR T cell therapy in patience with B cell 
malignancies. While CD19-CAR-transduced T cells effectively eradicate cancer cells, they 
have also been shown to persist in patience months after initial therapy (Porter et al., 2011). 
Since the CD19 antigen is highly expressed on malignant as well as healthy B cells, LCL 
included in the standard stimulation-mix of T cells could be utilized as target cells. Compared 
to tumor cells, these natural antigen-presenting cells would serve as ideal stimulation cells for 
T cell expansion since they express co-stimulatory molecules required for T cell activation and 
generally no inhibitory molecules, such as PD-L1 that would counteract T cell proliferation. 
While the ideal combination of co-stimulatory molecules in CAR constructs is still a subject of 
extensive debate, 4-1BB containing CD19-CARs showed more than 1000-fold expansion and 
long persistence in B cell chronic lymphocytic leukemia (CLL) patients (Kalos et al., 2011; 
Porter et al., 2011). Since the introduced CAR should be utilized for T cell expansion rather 
than tumor cell killing, survival of CAR-expressing T cells is the predominant focus for the 
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selection of a suitable construct. CD19-CARs comprising the 4-1BB signaling domain 
compared to CD28 mediated enhanced T cell survival in vivo, although the length and nature 
of the spacer region is decisive for CAR activity (Milone et al., 2009; Hudecek et al., 2015). 
Based on these data a CD19-CAR construct was generated that comprised the domain 
structure published by Hudecek et al., which included the -CD19 antibody FMC63 scFv 
coupled to a CD28 transmembrane domain and 4-1BB and CD3 signaling domains via an 
IgG4 hinge extracellular spacer  (Hudecek et al., 2015). Instead of using EGFRt as a 
transduction marker, eGFP was coupled to the CD19-CAR construct via a P2A element (Figure 
4.13). To ensure co-translational localization to the ER for correct folding and surface 
expression, the GM-CSF receptor  chain signal peptide was added 5’ of the CAR coding 
sequence (Wang et al., 2011). Molecular cloning of the CD19-CAR construct is described in 
3.1.14.  
 
Figure 4.13: Schematic representation of the CD19-CAR construct. -CD19 scFv is coupled to CD28 
transmembrane domain and intracellular signaling domains (4-1BB and CD3) via an IgG4 hinge region. GM-CSF 
signal peptide preceding the coding sequence for the CAR ensures translation on the ER membrane. CAR construct 
is coupled to eGFP via P2A element to allow tracking of transduction rate in T cells.   
In order to verify correct expression and functionality of the newly generated construct, PBL 
were transduced with the CD19-CAR construct. Transduction rate and expression of the 
CD19-CAR construct was evaluated by analyzing eGFP expression in the transduced T cells 
(Figure 4.14a). Specificity and functionality of the CD19-CAR was evaluated by IFN- ELISA 
after co-culture of transduced PBL with CD19+ (LCL_Eva1) and CD19- (Jurkat-76) target cell, 
respectively (Figure 4.14b). CD19-CAR-expressing single cell clones were generated, as 
described before for CEA-CAR constructs, by sorting transduced PBL into 96-well plates using 
FACS. However, due to the nature of the CAR target cells, the generated single cell clones 
could be directly activated via CAR by co-culturing them with irradiated CD19-positive LCL 
without addition of PHA or OKT-3 antibody that would deliver activation signals through the 
TCR. This allowed the pre-selection of clones that can be expanded via CAR engagement, 
since only those that could be activated sufficiently were able to survive the stimulation period 
for 14 days. After further expansion of the generated single cell clones, selected T cell clones 
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were analyzed for their proliferative capacity via CAR engagement and compared to 
physiological activation via the TCR utilizing a stimulation-mix comprising PHA (Figure 4.14c).  
 
Figure 4.14: CD19-CAR expression and functionality in PBL. a) Isolated PBL were transduced with the CD19-
CAR construct 4 days after activation. Successful transduction was confirmed 7 days after transduction utilizing 
eGFP expression as an indicator (blue). Untransduced cells served as negative controls (gray). b) Specificity and 
functionality of the CD19-CAR construct was evaluated by IFN- ELISA 20 h after co-culturing transduced PBL with 
target cells at an E:T ratio of 1:1. CD19-positive (LCL_Eva1) and CD19-negative (Jurkat-76) cells were used as 
target cells. c) Proliferative capacity of CD19-CAR-expressing single cell clones was evaluated by fold expansion 
over 14 days. Cell count was determined before and after the expansion period. 1 x 105 T cells per 96-well were 
either activated via CAR stimulation (4 x 105 irradiated CD19-positive LCL and 1 x 105 irradiated feeder cells) or 
TCR stimulation (stimulation-mix comprising 2 x 104 irradiated CD19-negative K562_A2_CD86, 2 x 105 irradiated 
feeder cells and PHA).  
The new CD19-CAR construct could be successfully expressed in PBL indicated by 30% eGFP 
positive cells (Figure 4.14a). Functionality and specificity of the transduced CAR construct was 
confirmed by IFN- ELISA (Figure 4.14b). Only CD19-CAR transduced cells showed significant 
IFN- release in the presence of CD19 antigen and did not react to antigen-negative cells. 
Untransduced cells served as control to estimate the amount of unspecific IFN- release of 
PBL in the presence of CD19-CAR target cells. This functional read-out showed that the CD19-
CAR construct was correctly assembled and expressed on the cell surface of transduced T 
cells. After single cell clones were generated from the transduced PBL, they could be 
individually analyzed for their expansion rate when activated via the CAR or TCR, respectively 
(Figure 4.14c). A selection of representative clones shows that CD4+ as well as CD8+ T cell 
clones could proliferate upon CAR engagement. While individual clones achieved a 6-fold 
expansion over 14 days, others could only increase their cell count about 2-fold. However, the 
generated CD19-CAR construct could support T cell proliferation in individual T cell clones 
comparable to proliferation rates observed for TCR-specific activation.  
 
4.4.1.2 CD3-Chimera 
To mimic physiological T cell activation via the TCR complex as closely as possible, an 
additional construct was designed that should promote T cell proliferation in the absence of 
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the endogenous TCR. For this, the modular domain structure of CAR constructs was combined 
with an extracellular domain of a CD3 dimer derived from the CD3 complex (Figure 4.16). In 
contrast to regular CAR constructs, this chimeric protein is not equipped with an antibody-
derived scFv that recognizes antigen. Instead, the single chain fragment (scF) is generated 
from the extracellular domains of the CD3 and  subunits, respectively, which naturally are 
expressed as two individual proteins. However, the Ig-fold ectodomains of CD3  and  form, 
via non-covalent interactions, one of the heterodimers of the CD3 complex, which supports 
signaling through the TCR (Arnett, Harrison and Wiley, 2004). It has been shown that T cell 
activation can be mediated by binding of antibodies, like OKT-3, to the  subunit of the CD3-
complex, thereby mimicking the physiological activation via TCR and MHC-peptide interaction 
(Van Wauwe, De Mey and Goossens, 1980). Therefore, binding of an -CD3 antibody to the 
CD3-Chimera should theoretically lead to an activation of the transduced T cell when 
intracellular signaling domains are present that can mediate signal transduction. In order to 
mimic the natural structure and signal transduction of the CD3-complex as closely as possible, 
only the intracellular domain of CD3 was chosen as a signaling domain, similar to first 
generation CARs. Complex interactions mediated by polar contacts in the transmembrane 
region and conserved motifs in the stalk domains of CD3 and TCR subunits are responsible 
for the correct assembly of the TCR-complex in the ER (Call et al., 2002). Therefore, none of 
the transmembrane domains derived from the multi-subunit TCR-complex seemed suitable for 
the expression of an unpaired monomeric protein like the CD3-Chimera. Instead, the single-
pass transmembrane domain of CD28 as well as the hinge domain of CD8 were chosen, both 
of which have been used and evaluated in various CAR constructs (Imai et al., 2004; Milone 
et al., 2009). Molecular cloning of the CD3-Chimera construct is described in 3.1.14. 
 
Figure 4.15: Domain structure of CD3-Chimera construct. The extracellular single chain fragment of CD3 
separated by a flexible (Gly4Ser)3 linker is coupled to the CD28 transmembrane domain and CD3 signaling domain 
via a CD8 hinge domain. The single chain CD3 dimer should retain the epitope for -CD3 antibody OKT-3 upon 
native folding. The coding sequence for the CD3-Chimera is preceded by a CD8 signal peptide to ensure co-
translational localization to the ER membrane. EGFP coupled via the P2A element can be used to monitor 
successful transduction in CD3-positive cells. Multiple cloning sites (MCS) allow easy cloning into different 
backbone vectors.  
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The extracellular domain of the CD3-Chimera construct was designed as a single-chain 
fragment consisting of the ectodomains of the CD3 and CD3 subunit. The native folding of 
soluble ectodomain CD3 dimers in combination with -CD3 antibody UCHT1 scFv has been 
demonstrated in a 1.9-Å crystal structure by Arnett et al. (Arnett, Harrison and Wiley, 2004). 
Simultaneously, the crystal structure of the CD3 dimer based on a soluble single chain 
fragment in complex with OKT-3 Fab’ fragment has been shown (Kjer-Nielsen et al., 2004). 
These findings proved that binding of the respective -CD3 antibodies was mediated via the 
CD3  subunit, which could be stably expressed together with the CD3  or  subunit, 
respectively, to achieve native folding of the soluble, isolated heterodimers. However, a study 
by Law et al. demonstrated a higher binding affinity of -CD3 antibodies to CD3 compared 
to CD3 fusion proteins (Law et al., 2002). While the soluble CD3 dimer could be stably 
expressed from a single polypeptide separated by a flexible (Gly4Ser)3 linker to comprise -
CD3 antibody epitopes, oligomerization probably due to unpaired cysteine residues in the 
CxxCxE motif comprising stalk domain could be observed (Law et al., 2002). This disulfide 
scrambling of the CD3 stalk domains was also observed by Kim et al. and led to the conclusion 
that the stalk domain was not necessary for native association of the respective CD3 subunits 
in a single chain fragment, but rather supported correct assembly of the TCR-complex in the 
ER (Kim et al., 2000; Sun et al., 2001). Based on these observations the extracellular domain 
of the CD3-Chimera was designed as a single chain CD3 dimer separated by a flexible 
(Gly4Ser)3 linker often used in scFv of CARs without the CxxCxE motif comprising stalk regions 
of the respective CD3 subunits. Utilizing this domain structure should ensure correct folding 
and binding of -CD3 crosslinking antibodies that mediate T cell activation. The proposed 
mode of action would then include the activation of TCR-complex-deficient cells via OKT-3 
binding to the CD3-Chimera in the presence of CD28 co-stimulation (Figure 4.16). This should 
resemble the natural activation via the TCR-complex and lead to cell proliferation in the 
absence of an endogenous TCR. Compared to regular CAR constructs comprising antibody-
derived scFv recognizing a target antigen, the CD3-Chimera construct does not bind any target 





Figure 4.16: Strategy for universal recipient cell utilizing CD3-Chimera. CD3-Chimera-transduced T cells can 
be activated by -CD3 and -CD28 antibodies to deliver signal 1 and 2 in the absence of the endogenous TCR 
after knockout. Antibodies binding CD3-Chimera can be soluble in the presence of feeder cells or bead-bound in 
combination with -CD28 antibody.  
In order to investigate correct expression and folding of the CD3-Chimera, TCR-deficient 
Jurkat-76 cells were used as a first test system. While this T cell lymphoma cell line serves as 
appropriate recipient cells to evaluate TCR or CAR expression, the cells have lost their ability 
to provide basic T cell effector functions, like cytokine secretion, rendering them unsuitable for 
functional read-outs (Heemskerk et al., 2003; Bürdek, 2009). However, due to lack of TCR 
expression, CD3 is also not present on the cell surface, which allows the detection of the CD3-
Chimera construct using -CD3 antibodies without interference from endogenous CD3. To 
evaluate expression, Jurkat-76 cells were transduced with the CD3-Chimera construct and 
expression of the CD3-Chimera was verified by staining with -CD3 antibody (Figure 4.17). To 
detect possible differences in CD3-Chimera surface expression in individual clones, single cell 
clones were generated by FACS and subsequently analyzed for expression of CD3-Chimera 
construct. Since the P2A element present in the vector construct allows bicistronic expression 
of CD3-Chimera and eGFP, which should ensure equimolar expression levels, eGFP 
expression was compared to staining with -CD3 antibody (Osborn et al., 2005).    
Figure 4.17: CD3-Chimera 
expression in TCR-deficient Jurkat-
76 cells. Transduced Jurkat-76 cells 
were analyzed for CD3-Chimera and 
eGFP expression 7 days after 
transduction by staining with -CD3 
antibody and subsequent flow 
cytometric analysis. Generated single 
cell clones were again evaluated for 
CD3-Chimera and eGFP expression 
by -CD3 antibody staining followed 
by flow cytometric analysis 2 weeks 
after FACS. Shown here are results of 
2 representative clones. Transduced 
cells are shown in blue. Untransduced 
Jurkat-76 cells served as negative 





CD3-Chimera expression indicated by -CD3 staining was present in 21% of Jurkat-76 cells 
7 days after transduction (Figure 4.17). In comparison, only 17% of the transduced cells 
showed eGFP expression exceeding the negative control. Neither -CD3 staining nor eGFP 
expression resulted in distinct positive populations in bulk-transduced Jurkat-76. Therefore, 
single cell clones were generated to allow visualization of differences in expression levels in 
individual clones. Two representative clones are shown in Figure 4.17 that expressed the CD3-
Chimera construct at different levels. While clone 1 exhibited low expression levels of the 
construct, Clone 2 expressed the CD3-Chimera at high levels, indicated by the shift of the 
positive population compared to the negative control. The same was true for eGFP expression, 
which was, however, lower compared to -CD3 staining for clone 2. Clone 1 did not show any 
positive population, while low CD3 expression could be observed. This demonstrated that 
expression of eGFP from the bicistronic construct did not yield equimolar expression levels 
compared to the CD3-Chimera construct. However, the marker could still be used to detect 
CD3-Chimera high-expressing cells. When comparing the single cell clones with the 
transduced population before sorting, it became apparent that expression levels varied greatly 
in individual clones, which explains the lack of a distinct positive population when a bulk mixture 
of transduced clones was present. Nevertheless, these results still demonstrated that the 
designed CD3-Chimera construct could be correctly folded and expressed on the cell surface, 
which was indicated by binding of the -CD3 antibody recognizing an epitope on natively 
folded CD3 subunits.  
 
4.4.2 Phenotypic evaluation of CAR-transduced T cells 
Besides generating new chimeric constructs to improve T cell expansion after the TCR 
knockout, another measure to prolong survival of T cell clones in vitro would comprise the 
selection of a defined T cell subset exhibiting superior proliferative capacity. Recent 
publications have shown the benefit of utilizing transgenic TCR- or CAR-transduced T cells 
derived from the central memory compartment to improve efficacy of adoptive T cell transfer 
in patients (Berger et al., 2008; Gattinoni et al., 2011; Graef et al., 2014; Sommermeyer et al., 
2015). These studies demonstrated better proliferative capacity, effector function and 
persistence of central-memory derived T cell populations compared to cells derived from the 
effector compartment in vivo. All these traits would be also favorable for universal recipient 
cells for in vitro testing of transgenic TCRs in order to generate an effective and stable test 
system. However, whether isolated T cell clones originating from the central-memory subset 




In order to evaluate whether a certain T cell subset exhibited a proliferative advantage, 
previously isolated CEA-CAR_CD4-expressing T cell clones were stained with common T cell 
markers to characterize their phenotype (Figure 4.18). To be able to identify differences in 
phenotype linked to proliferative capacity, four CEA-CAR_CD4-transduced T cell clones were 
chosen that showed either high or low proliferation rates and either expressed CD4+ or CD8+, 
respectively. Even though various markers were identified to distinguish different T cell 
subsets, the four most prominent T cell subsets can be identified utilizing two markers, CD62L 
and CD45RA (Seder and Ahmed, 2003; Golubovskaya and Wu, 2016). Utilizing these markers 
naive (CD45RA+ CD62L+), central memory (CD45RA- CD62L+), effector memory 
(CD45- CD62L-) and effector (CD45RA+ CD62L-) T cell subsets can be discriminated. By 
adding the memory marker CD95, naive T cells (CD45RA+ CD62L+ CD95-) can be 
distinguished from stem cell memory cells (CD45RA+ CD62L+ CD95+) (Lugli et al., 2012).   
 
Figure 4.18: Phenotypical characterization of high and low proliferating CAR-transduced T cell clones. 
CEA-CAR_CD4-transduced T cell clones showing differences in proliferation rates (high or low) and co-receptor 
expression (CD8+ or CD4+) were stained with -CD4, -CD8, -CD45RA, -CD62L, -CD95 and analyzed by flow 
cytometry. Unstained CEA-CAR_CD4-transduced cells served as a negative control. Median FI indicates population 
shift compared to unstained control (gray).  
 
All CAR-transduced T cell clones, independent of their proliferative capacity or co-receptor 
expression, exhibited the same phenotype (Figure 4.18). Based on the combination of cell 
surface markers, they could be characterized as effector memory T cells (TEM, 
CD4+/CD8+ CD45RA- CD62L- CD95+). This indicated that T cells all exhibit the same 
phenotype after several weeks in in vitro culture. Therefore, these cell surface markers could 
not be utilized to allow distinction between isolated T cell clones showing either high or low 
proliferation rates.  
Even though no correlation could be observed linking a distinct phenotype to proliferative 
capacity of T cell clones expanded in in vitro culture, differences could possibly still be rooted 
in the origin of the T cell clones. Therefore, it was investigated whether T cell clones derived 
from a specific T cell subset would show higher expansion rates. For this, freshly isolated PBL 
were transduced with the CD19-CAR construct and subsequently sorted into 96-well plates to 
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generate single cell clones. Prior to FACS the cells were stained for common T cell surface 
markers using -CD8, -CD45RA and -CD62L antibodies that would allow their classification 
into different T cell subsets. The sorting strategy comprised FACS of CAR-positive T cells, 
indicated by eGFP expression, that expressed either the CD4 or CD8 co-receptor. For sorting, 
the CD45RA and CD62L expression was neglected to allow the expansion of any CAR-
transduced T cell clone independent of subset origin. However, these markers could be later 
used to determine from which T cell subset the expanded T cell clones were derived. This 
could be achieved by analyzing index sort data of these markers that were collected during 
sorting using the BD FACSDivaTM Software (BD Bioscience) (Figure 4.19a). After single cell 
sorting, the cells were activated in the presence of OKT-3 antibody and expanded for 10 days 
before 142 growing T cell clones were identified and transferred into new 96-well plates using 
the automated workflow platform EVO200 (Tecan). Subsequently the picked T cell clones were 
activated using a modified rapid expansion protocol in 24-well plates (Riddell and Greenberg, 
1990; Hudecek et al., 2013). The proliferative capacity of 48 selected T cell clones was 
determined after the expansion period and could be subsequently connected to T cell subset 
descent (Figure 4.19b).  
 
Figure 4.19: Phenotypic characterization of CD19-CAR-transduced single cell clones. a) Analysis of index 
sort data using BD FACSDivaTM Software. Re-analysis of CD4+ or CD8+ single cell clones, respectively, for 
expression of CD45RA and CD62L at day of sort. Cells were derived either from naïve (Tn), central memory (Tcm), 
effector memory (Tem) or effector (Teff) compartment. b) Fold expansion of 48 selected single cell clones 28 days 
after sorting. After identification of single cell clones 10 days after sorting, the cells were stimulated via CAR 
engagement (without addition of OKT-3) using 2 x 106 irradiated feeder cells and 1 x 106 irradiated LCL_Eva1 that 
served as CAR target cells. Cell count was determined on day 14 after activation. Expansion rate was categorized 
as excellent (>10 x 106 cells), good (2-10 x 106 cells) or poor (<2 x 106 cells), respectively. Analysis of index sort 
data using BD FACSDivaTM Software allowed determination from which T cell subset single cell clones were 
derived. Data represent the mean of 2 donors.  
The CAR-transduced T cell clones that expanded after single cell sorting were derived from all 
four T cell subsets, however the majority of of the cells originated from the naïve (Tn) or central-
memory (Tcm) compartment (Figure 4.19a). While 67% of CD4+ T cells expressed marker that 
characterized them as Tcm cells at the time of sorting, only 41% of CD8+ T cells were derived 
from this compartment. However, 35% of the CD8+ T cells that expanded after sorting 
originated from native T cells. Whereas, a higher percentage of effector-memory (Teff) cells 
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compared to Tn cells proliferated in the CD4+ T cell compartment. When analyzing the 
proliferative capacity of 48 selected single cell clones 28 days after sorting, the majority of the 
cells were again derived either from Tcm or Tn cells, respectively, independent of expansion 
rate (Figure 4.19b). However, also T cell clones derived from Tem od Teff cells showed good 
or excellent expansion rate, respectively, at percentages comparable to poor proliferating 
clones. Therefore, the T cell compartment from which the T cell clones derived did not allow a 
prediction of their proliferative capacity in vitro. The distribution of certain T cell subset origins 
in the different expansion categories rather simply mirrored the percentages already observed 
at the time of sorting (Figure 4.19a). However, Figure 4.19b demonstrated that the majority of 
the isolated single cell clones exhibited a poor proliferation rate renderinging them unsuitable 
as an in vitro test system. Only 12% of the T cell clones could be expanded to more than 
1 x 107 cells four weeks after single cell sorting, which indicated that only a small fraction of 
isolated lymphocytes had the capacity to proliferate to sufficient cell numbers for use in in vitro 
experiments. However, based on the phenotype, this superior expanding cell population could 
not be identified. Therefore, to avoid exclusion of potentially suitable T cell clones for the 
generation of universal recipient cells, mixed PBL populations were used in subsequent 
experiments without restricting the starting material to a specific T cell subset.  
 
4.4.3 New strategy for generation of universal recipient cells 
The improved strategy introduced in 4.3 allowed the generation of various CAR-transduced 
T cell clones that exhibited a high proliferative capacity via CAR engagement. However, while 
the knockout of the endogenous TCR could be performed, the resulting TCR-deficient T cells 
failed to expand upon activation via the transduced CAR. One reason for this might have been 
the nature of the CEA-CAR target cells used, which might have constituted an unfavorable 
environment for T cell expansion from small cell numbers. This low expansion after TCR 
knockout should be circumvented when the newly generated constructs, CD19-CAR and CD3-
Chimera, are used for TCR-independent T cell activation. In contrast to CEA-CARs, the CD19-
CAR construct mediates T cell proliferation by binding the antigen on LCL, which constitute 
natural antigen presenting cells displaying various co-stimulatory molecules that should 
support proper T cell activation. The requirement of target cells for T cell stimulation has been 
bypassed when utilizing the CD3-Chimera construct by antibody-based activation via OKT-3, 
while LCL are only included in the stimulation-mix to provide co-stimulation to T cells. However, 
the poor expansion rate of the TCR-deficient cells revealed another complication that might 
occur even when the new constructs would be used. In order to generate a universal recipient 
cell after the knockout of the endogenous TCR, the cells need to be expanded again from 
single cell clones to allow the determination of the knockout status of the respective TCR 
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chains at the mRNA level. In a complex mixture of cells that all comprise different insertions or 
deletions in either one or both of the TCR chains, respectively, this would not be feasible. 
Therefore, the generated CAR-expressing TCR-deficient cells would have to go through an 
additional round of clonal expansion, which might drastically shorten their life span. To 
circumvent this, a new strategy was developed that allowed the simultaneous knockout of the 
endogenous TCR and the introduction of the CD19-CAR or CD3-Chimera construct, 
respectively, in a single step to promote T cell expansion in the absence of the TCR (Figure 
4.20). The resulting CAR-expressing TCR-deficient T cell clones would then only need to be 
expanded from a single T cell clone once, thereby shortening the in vitro expansion period 
considerably. Additionally, performing the TCR knockout and CAR transduction in one step 
before generating single cell clones would allow the immediate pre-selection of suitable T cell 
clones that are able to proliferate via engagement of the chimeric construct in the absence of 
the endogenous TCR. With the TCR no longer available to mediate T cell activation in these T 
cell clones, only T cell clones that can expand sufficiently via CD19-CAR or CD3-Chimera 
engagement would be detected after the expansion period, thereby accomplishing the 
prerequisite to generate desired universal recipient cells. Since any proliferating T cell clone 
would be derived from an individual single cell, the expanding cells would all comprise identical 
modifications in the TRAC and TRBC loci, allowing an easy determination of the knockout 
status of the respective TCR chains.  
 
Figure 4.20: Schematic representation of the new strategy for the generation of universal recipient cells. 
Simultaneous knockout of the endogenous TCR via TALEN technology and introduction of either the CD19-CAR 
or CD3-Chimera construct, respectively, generates TCR-deficient CAR-expressing T cells. Subsequent generation 
of single cell clones allows immediate pre-selection of T cell clones that are able to expand via the introduced 
constructs independent of the TCR.  
 
To perform and evaluate the new strategy for the generation and identification of suitable 
universal recipient cells, a high-throughput workflow was designed (Figure 4.21). While the 
example is shown for the CD19-CAR, it was also applied for the CD3-Chimera construct. After 
isolation of PBMC from donor blood,  T cells were enriched by FACS and subsequently 
activated. This enrichment step ensured that no other cell types, like  T cells, would be 
present in the starting material. On day 4 after activation, the cells were first electroporated 
with the respective TALEN pairs targeting the TCR  and  chain. After resting the cells for 
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approximately 4 h, the cells were transduced with the CD19-CAR construct. The successful 
transduction and simultaneous TCR knockout was determined 8 days later by flow cytometric 
analysis following a test staining for CAR and TCR expression. Two days later, the cells were 
sorted by FACS and the resulting single cell clones were subsequently activated via the 
transduced CAR. Following an expansion period of 11 days, emerging T cell clones were 
imaged and transferred into new 96-well plates for analysis and expansion using the 
automated workflow platform EVO200 (Tecan). One day later, the selected T cell clones were 
screened for lack of TCR expression and simultaneous presence of the transduced CAR 
construct utilizing the BDTM High Throughput Sampler (HTS) in combination with flow 
cytometric analysis on the BD LSRFortessaTM. This step enabled the selection of well-
expanding T cell clones that exhibited the desired phenotype and simultaneously identified T 
cell clones that were falsely sorted by FACS. T cell clones lacking TCR expression while 
showing successful transduction with CD19-CAR and promising expansion rates, were 
subsequently selected for NGS analysis to verify the knockout of the endogenous TCR at the 
mRNA level. The same clones were again activated and further expanded to investigate their 
proliferative capacity mediated via the CD19-CAR. At this point, data from NGS analysis was 
available, which allowed the merging of expansion rate with the corresponding TCR knockout 
status. Alternatively, T cells were frozen until NGS data could be analyzed. T cell clones that 
exhibited sufficient proliferative capacity and comprised frameshift mutations in TRAC and 
TRBC loci, respectively, could then be tested for their potential to serve as universal recipient 
cells for transgenic TCRs by evaluating their functional characteristics.  
 
 
Figure 4.21: Workflow for high-throughput approach for 
generation and identification of suitable universal 
recipient cells. PBMC are isolated from donor blood and 
enriched for  T cells by FACS before activation. 
Simultaneous TCR knockout via TALEN electroporation and 
transduction of the CAR construct is performed on day 4. After 
successful TCR knockout and CAR transduction is verified on 
day 12, the TCR-deficient cells are sorted by FACS and 
subsequ ently stimulated via CAR. Only the cells that can be activated via CAR engagement will proliferate and will 
be selected for further analysis after the expansion period. Cell imaging and transfer is performed by Clone Select 
Imager (Molecular Devices) in combination with the automated workflow platform EVO200 (Tecan). The transferred 
cells will then be screened for the desired phenotype utilizing HTS in combination with flow cytometry one day 
later. Well-expanding T cell clones lacking TCR expression while expressing the transduced CAR are selected for 
NGS analysis and further expansion. After another expansion period the proliferative capacity of individual T cell 
clones can be analyzed. These data can then be combined with the knockout status of the cell determined by NGS, 




4.4.3.1 Enrichment of  T cells by FACS 
To ensure that only  T cells would be used as starting material for the generation of universal 
recipient cells, freshly isolated PBMC were stained with -TCR and -CD3 antibody and 
subsequently sorted by FACS (Figure 4.22). This enrichment step allowed the exclusion of 
other cell populations present in isolated PBMC, like d T cells, that might interfere with 
subsequent sorting procedures. Instead of an TCR these T cells express TCRs that also 
form a TCR-complex together with the CD3 subunits. Therefore,  T cells would theoretically 
exhibit the same phenotype as TCR-deficient CD3-Chimera-expressing cells (TCR- CD3+) 
that would be generated subsequently by TCR knockout and transduction of the chimeric -
CD3 antibody-binding construct. To circumvent the unintended selection of these  T cells in 
successive FACS procedures,  T cells were enriched and subsequently evaluated for purity 
utilizing -TCR and -TCR antibody staining (Figure 4.22).  
 
Figure 4.22: Enrichment of  T cells from PBMC. Isolated PBMC from 2 donors were stained with -CD3 and 
-TCR antibodies for subsequent FACS. Only cells expressing both markers were sorted. After sorting the 
enriched  T cells were stained with -TCR and -TCR antibodies to evaluate purity of the sorted cells. 
Stained cells were analyzed by flow cytometry. A  T cell clone and TCR-deficient T cells were used as controls.  
Isolated PBMC from donor blood contained various cell populations (Figure 4.22). Besides 
TCR- and CD3-negative cells, that include B cells, NK cells and monocytes,  T cells were 
also present that express CD3 but not TCRs. These  T cells would also be activated by a 
standard stimulation mix comprising OKT-3 antibody that binds CD3. As demonstrated in 
Figure 4.22, the number of  T cells in the blood can vary greatly in different donors. While 
donor 6 cells comprised a quite dominant  T cell population, donor 5 cells only exhibited a 
small population of these cells. Accordingly, the number of  T cells can also vary between 
donors, with donor 6 sample comprising 50% and donor 5 sample comprising roughly 75% of 
this cell population. Analysis of the sorted cells clearly demonstrated a successful high-purity 
enrichment of  T cells. While no  T cells could be detected in the enriched cell population, 
the  T cell clone served as a positive control verifying successful staining with the -TCR 
antibody. TCR-deficient T cells were not bound by either -TCR or -TCR antibody, 




4.4.3.2 Refined sorting strategy 
The enriched  T cells served as starting material for the next step in the new workflow for 
generating universal recipient cells comprising the knockout of the endogenous TCR and 
simultaneous introduction of the chimeric constructs. For this, the enriched  T cells were first 
simultaneously electroporated with ivt-RNA coding for the TALEN pairs targeting the TCR  
and  chain 4 days after activation. After a short resting period, the electroporated cells were 
transduced with either the CD19-CAR or the CD3-Chimera construct. A new sorting strategy 
was developed to subsequently identify and sort T cell clones exhibiting the desired phenotype 
that was characterized by lack of TCR expression and presence of the transduced CD19-CAR 
or CD3-Chimera, respectively (Figure 4.23). For this, the cells were stained with -CD3, -
TCR and -CD8 antibody. While the lack of CD3 and TCR expression indicated a 
successful knockout of the TCR, the expression of eGFP proved the transduction of the CD19-
CAR or CD3-Chimera, respectively. The -CD8 antibody staining allowed the distinction 
between CD8+ and CD8- T cells. For CD19-CAR-transduced cells, CD3- and TCR-negative T 
cells were pre-gated and subsequently divided into CD8-positive or -negative cells that 
expressed eGFP (Figure 4.23a). In case of the CD3-Chimera-transduced cells, CD8- or CD8+ 
cells exhibiting eGFP expression were selected from TCR-negative cells that could still bind 
-CD3 antibody recognizing the CD3-Chimera construct (Figure 4.23b).  
 
Figure 4.23: New sorting strategy for isolation of TCR-deficient cells transduced with CD19-CAR or CD3-
Chimera, respectively. a) Sorting strategy for CD19-CAR-transduced cells for FACS. The cells were stained with 
-CD3 and -TCR antibodies to allow gating of CD3- and TCR-negative cells indicating successful knockout of 
the TCR. Staining with -CD8 antibody could distinguish CD4+ and CD8+ T cells expressing eGFP, which served 
as a marker for successful transduction. b) Sorting strategy for CD3-Chimera-transduced cells for FACS. The cells 
were stained with -CD3 and -TCR antibodies to allow gating of TCR-negative cells that are CD3-positive 
indicating successful knockout of the TCR and simultaneous expression of CD3-Chimera. By staining with -CD8 
antibody, CD8+ and CD4+ T cell could be distinguished that showed successful transduction indicated by eGFP. 
Untransduced  T cells served as controls (not shown). Results are representative for 3 donors.  
For CD19-CAR-transduced cells, 30% of the cells comprised a knockout of the endogenous 
TCR indicated by the lack of CD3 and TCR expression (Figure 4.23a). Gating of these cells 
allowed the further distinction of CD8+ and CD8- T cells that exhibited successful transduction 
with CD19-CAR, reflected by eGFP expression. Only 2 – 3% of the TCR-deficient cells were 
positive for eGFP revealing a relatively low transduction rate of the cells that were successfully 
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transfected with TALEN pairs. Cells that were transduced with the CD3-Chimera construct 
displayed the same TCR knockout rate as CD19-CAR-transduced cells since transduction was 
performed using cells derived from the same knockout experiment (Figure 4.23b). However, 
the number of cells that were successfully transduced with CD3-Chimera was relatively low, 
with only 1.38% of the cells able to bind -CD3 antibody. After gating on this low number of 
cells and dividing them into CD8- and CD8+ T cells, successful transduction could only be 
confirmed in 10% and 13% of the cells, respectively, which was indicated by eGFP expression. 
However, even if transduction rates of the TALEN-transfected cells were relatively low, single 
cell clones could still be generated from these few cells that exhibited the desired phenotype. 
The subsequent successful expansion of the sorted TCR-negative single cells clones mediated 
through the transduced chimeric construct, would then unambiguously demonstrate correct 
expression and functionality of the introduced CD19-CAR and CD3-Chimera constructs.  
 
4.4.3.3 Improved expansion strategy  
Expansion of TCR-deficient T cell clones via engagement of the respective transduced 
chimeric construct allowed the pre-selection of T cell clones with the ability to proliferate 
independent of TCR signaling. Due to the absence of the TCR on the cell surface of these T 
cell clones, activation could only be induced through the CD19-CAR or CD3-Chimera 
construct, respectively. For both approaches 5 x 103 irradiated LCL and 5 x 104 feeder cells 
were added per 96-well in the presence of IL-2. CD19-expressing LCL served simultaneously 
as target and co-stimulatory cells for activation of T cell clones expressing the CD19-CAR. For 
CD3-Chimera-transduced cells, LCL present in the stimulation-mix merely provided co-
stimulation and OKT-3 antibody was added additionally to achieve activation via engagement 
of the chimeric construct. After an expansion period of 11 days the 96-well plates were 
screened for expanded single cell clones by utilizing Clone Select Imager (Molecular Devices) 
in combination with an automated workflow platform EVO200 (Tecan). T cell clones that were 
able to proliferate upon engagement of the chimeric construct were selected and transferred 
into a new 96-well plate to allow further analysis and expansion. Picking of the T cell clones 
was performed with Hit Selector Software (Tecan) to guide the liquid handling arm LiHa 
(Tecan). In total 369 CD19-CAR- and only 8 CD3-Chimera-transduced single cell clones were 
picked, demonstrating that utilizing the new strategy resulted in the successful isolation of T 
cell clones that were able to proliferate in the absence of the endogenous TCR. The low 
number of CD3-Chimera-expressing T cell clones might be the result of the very low 
transduction rate observed in Figure 4.23b. Alternatively, the low number of expanded CD3-
Chimera-expressing T cell clones might indicate that the designed construct could not 
sufficiently support T cell expansion. Since the construct was previously only tested in 
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Jurkat-76 cells that proliferate independent of activation, the expression in TCR-deficient T cell 
clones represented the first functional evaluation of the CD3-Chimera construct.  
 
4.4.3.4 New screening process 
After the T cell clones exhibiting TCR-independent proliferation were identified, they were 
screened for the desired phenotype, which comprised the lack of TCR expression and 
detection of the transduced CD19-CAR or CD3-Chimera construct, respectively. This 
screening step allowed the identification of T cell clones that were falsely sorted by FACS and 
did not exhibit the desired phenotype as shown exemplarily for Clone 2 in Figure 4.24a.  The 
further analyses focused on CD19-CAR-transduced cells since cells transduced with CD3-
Chimera should exhibit a different phenotype, which will be discussed later in 4.5.2. All 369 
picked CD19-CAR-transdcued T cell clones were evaluated for their phenotype and 
summarized as percentage of TCR- and CD3-nagtive cells (%TCR/CD3 negative) and 
percentage of CAR-positive cells (%CAR-positive) reflected by eGFP expression (Figure 
4.24b). The detected phenotype allowed prediction of the TCR knockout status for each T cell 
clone. Dependent on TCR and CD3 expression levels the screened cells were categorized into 
3 groups: “TCR KO”, “TCR KO unconfirmed” and “No TCR KO” (Figure 4.24c). Subsequently, 
cells that were categorized as “TCR KO” were further analyzed for high, moderate and low 
CAR expression to determine whether TCR-negative cells expressed the transduced CAR 
sufficiently to allow activation.  
 
Figure 4.24: Screening for TCR-negative CAR-positive T cell clones by flow cytometric analysis. Cells were 
stained with -CD3 -TCR antibodies and subsequently analyzed utilizing BD® HTS in combination with flow 
cytometric analysis. a) Exemplary depiction of 2 T cell clones exhibiting different phenotypes. While Clone 1 exhibits 
unambiguously a knockout of the endogenous TCR, Clone 2 does not, depicted by low expression of CD3 and 
TCR. b) Phenotype of all 369 CD19-CAR-transduced clones summarized as %TCR/CD3-negative and %CAR-
positive cells. Gates for analysis were set as shown in a) based on negative and positive controls. c) Translation of 
phenotype determined by cytometric analysis to TCR knockout status. Categories comprised TCR KO (>80% TCR-
/CD3-), TCR KO unconfirmed (>30%; <80% TCR-/CD3-) and No TCR KO (<30% TCR-/CD3-). Cell categorized as 
TCR KO were further analyzed for high (>80%), moderate (>30%; <80%) and low (<30%) CAR expression reflected 
by eGFP detection. Cutoffs were set as described based on background detected in staining of positive and 
negative controls.  
Figure 4.24a shows examples of FACS blots of two representative T cell clones that were 
screened for CD3 and TCR expression. Clone 1 exhibited the desired phenotype with 99% 
CD3- and TCR-negative cells and was subsequently selected for NGS analysis and further 
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expansion. In contrast, Clone 2 still expressed low amounts of CD3 and TCR indicating 
incomplete TCR knockout as interpreted by flow cytometric analysis. The phenotypic analysis 
of all 369 CD19-CAR-transduced T cell clones presented as %TCR/CD3-negative and %CAR-
positive cells showed that the majority of the isolated clones highly expressed the transduced 
CAR while lacking the expression of CD3 and TCR (Figure 4.24b). While most of the cells 
exhibited the desired phenotype, clusters of cells could be detected that still did express the 
TCR-complex and showed either low or moderate CAR expression. Some T cell clones did not 
express the TCR-complex while CAR expression was nearly undetectable. The collected flow 
cytometry data served to predict the TCR knockout status of the individual T cell clones (Figure 
4.24c).  According to the defined categories, over 78% of the T cell clones exhibited a knockout 
of the endogenous TCR, whereas the TCR knockout could not be confirmed based on the 
phenotype for 15% of the T cell clones. No TCR knockout was detected in 7% of the T cell 
clones. This showed that by using the new sorting strategy described in Figure 4.23, the yield 
of T cell clones with the desired phenotype is very high with only a few outliers that represented 
technical contaminants. Accordingly, the majority of the cells that exhibited the TCR knockout 
also expressed the transduced CAR construct at high or moderate levels, with only 9% of the 
cells showing low CAR expression. T cell clones categorized as TCR KO with high CAR 
expression levels and promising expansion rates, that were determined by analyzing the data 
from Clone Select Imager (Molecular Devices), were selected for NGS analysis and further 
expansion (Figure 4.25). In order to validate the newly developed protocol for NGS sample 
preparation and analysis described in 4.4.3.5, clones that were categorized as not having a 
TCR knockout phenotype were also included. For these T cell clones, wildtype sequences in 
the TRAC and TRBC genes would be expected.   
 
Figure 4.25: Exemplary strategy for selection of T cell clones for NGS analysis. T cell clones showing a high 
percentage of TCR-/CD3-  and CAR+ cells while exhibiting high proliferation rates were selected for expansion and 
NGS analysis. Clones that did exhibit the same phenotype, but did not proliferate were not selected. Clones with 
high proliferative capacity and high percentages of TCR-/CD3- cells, but lower percentages of CAR+ cells were also 
selected for NGS and further expansion. Clones exhibiting low percentages of TCR-CD3- cells as well as CAR+ 






4.4.3.5 Development of a NGS protocol for identification of TCR knockout clones 
NGS analysis of the TCR repertoire usually focuses on the hypervariable complementary-
determining regions (CDRs) in the variable region of the TCR  and  chains, which mediate 
specific MHC- and peptide-binding (Bolotin et al., 2012). However, for determination of the 
knockout status of individual single cell clones, the TALEN target sites in the respective TCR 
 and  constant regions need to be analyzed (Figure 4.26a). Therefore, primers were 
designed that bind to a region 3’ of the respective TALEN target sites (Table 2.8). For 
amplification of all TCR  chain sequences a primer binding site was chosen that is 
homologous in the TRBC1 and TRBC2 genes. The preparation of DNA libraries for NGS 
analysis included two PCR reactions based on cDNA templates derived from mRNA isolated 
from each T cell clone. Since the recombined V(D)J segments defining the variable region of 
the respective TCR chains are joined to the constant regions by splicing to generate a mature 
transcript, mRNA rather than gDNA is used for sequence determination (Figure 4.26a). In the 
first PCR reaction (PCR I) Illumina universal oligos (IUO) were attached to the 5’ and 3’ ends 
of the cDNA templates. Reverse primers were designed, that would bind downstream of the 
TALEN target region in both TCR  and  chain cDNA, respectively (Figure 4.26b). The 3’ 
primers comprised the IUO to allow addition of Nextera® indices (Illumina) in the subsequent 
PCR II reaction, which in turn were required for cluster generation by bridge amplification in 
Illumina NGS analysis.  
 
Figure 4.26: NGS library preparation to include TALEN target sites. a) TALEN target sites schematically 
depicted in TCR  or  locus, respectively. Both target sites reside within exon 1 of the respective constant regions. 
3’ primers were designed to bind downstream of the TALEN target sites to allow detection of mutations introduced 
by TALEN-induced double strand breaks. Recombined V(D)J segments are joined to the constant regions by 
splicing after transcription. b) Universal 3’ primers for PCR I bind downstream of TALEN target sites in cDNA 
template and contain IUO sequences. cDNA contains spliced coding sequence of the respective TCR chain as well 
as barcoded (NNNNNN) switch oligo sequence that was ligated via (rG)5 added by SMARTScribeTM reverse 
transcriptase (Clonetech). An IUO sequence is required for addition of Nextera® (Illumina) indices in subsequent 
PCR II reaction.  
Once the DNA library was prepared using the new primer set, NGS utilizing MiSeq System 
(Illumina) was performed to identify T cell clones carrying a knockout of the endogenous TCR 
chains.  
After adapting sample preparation for NGS analysis, the next step included the modification of 
the analysis tool for generated NGS data. For this, bioinformatic analysis was perfomed by A. 
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Moesch that identified the TALEN target sites in sequences obtained from NGS and 
subsequently align the sequences in between two TALEN target sites with the wildtype 
sequences of the TRAC and TRBC genes (Figure 4.27). Raw FASTQ reads were searched 
for both flanking TALEN target sites and the target sequence in between was aligned to the 
wildtype sequence. Reads containing the same mismatches, deletions, insertions or the 
wildtype sequences were grouped, and average read quality was calculated. To 
unambiguously identify whether a T cell clone contained wildtype or mutated sequences, a 
high number of reads was required, comprising an average read quality of at least 30.  
 
Figure 4.27: Functional principle of the software for NGS data analysis. The software generated by A. Moesch 
identified TALEN target sites in sequences obtained from NGS and aligned the sequence in between two TALEN 
target sites with the wildtype sequence of the TRAC and TRBC genes, respectively. Clustering of reads comprising 
the same sequence allowed the hierarchical ordering of the resulting sequences to identify the sequence supported 
by the largest number of reads.  
 
 
Shown in Figure 4.28 is an exemplary output file summary for the different possible results for 
the knockout status of individual T cell clones. If no mutation could be detected in the TALEN 
target region, the results were homologous to the wildtype sequence indicated as “WT”. When 
mutations have been introduced, the modified sequence was displayed. This allowed the 
deeper analysis of the type of mutation that occurred as a consequence of base deletions or 
insertions, respectively, since only frame-shift mutations would most definitely result in non-
functional proteins. The translation of these frame-shift mutations generates aberrant amino 
acid sequences that frequently result in the introduction of premature stop codons preventing 
the expression of a functional protein, hence knocking out the respective gene. While T cell 
clones usually only express one rearranged TCR  chain, they can carry two TCR  chains 
due to simultaneous rearrangements of the TCR  locus on both alleles (Petrie et al., 1993). 
Allelic exclusion of a functional TCR  chain is thought to occur only after positive selection in 
the thymus (Borgulya et al., 1992; Malissen et al., 1992). This normally results in the 
expression of one functional TCR  chain that pairs with the corresponding TCR  chain. 
However, unproductive TCR  chains originating from the second silenced TCR  locus can 
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sometimes be detected at the mRNA level (Malissen et al., 1992). In rare cases even two 
productive TCR  chains can be found in one cell giving rise to two independent TCRs 
(Padovan et al., 1993). When two TCR  chains were detected in one sample, the variable 
region of the TCR sequence that was also amplified during the NGS sample preparation was 
analyzed utilizing the software MiTCR (Bolotin et al., 2013). The output sequence could then 
be evaluated for productive or unproductive TCR  chain rearrangements using the IMGT® 
tool IMGT/V-QUEST (Lefranc et al., 2015).  
Example output:  
  chain  chain 1  chain 2 Status 
Clone 1 WT unproductive TGCCGTGTAACCAGCTGAGAG  KO 
Clone 3 TGTG---GAGAGCCATCAG WT -  KO 
Clone 4 WT WT - no KO 
Clone 5 TGTGTTTG--CCATCAG TGCCGTGT-CCA-CTGAGAG unproductive KO
 
Figure 4.28: Exemplary output file for determination of TCR knockout status based on NGS data. Results of 
sequence alignments of the TALEN target sites with wildtype sequences of TRAC and TRBC genes for individual 
T cell clones. WT indicates no modification of the sequence. Dash (-) indicates base deletion and letters marked in 
red indicate base insertions. Knockout of either TCR chain only occurs when mutations in the TALEN target site 
result in frame-shift mutations. Unproductive TCR chains were identified by analysis of the NGS data utilizing MiTCR 
software and IMGT/V-Quest tool. Dependent on mutations in the TCR  or  constant regions, the cells exhibited 
either , ,  or no knockout (KO). 
 
A total of 161 T cell clones were selected for NGS and subsequently 
analyzed for TCR knockout status as described above. Three 
positive controls were included, that comprised T cell clones not 
exhibiting a TCR knockout based on the phenotype. Based on NGS 
data, nine T cell clones could be identified that unambiguously 
contained a knockout of both the TCR  and  chain (6%; Figure 
4.29). 38% of the analyzed T cell clones comprised cells with a 
knockout of either the TCR  or  chain, while 14% did only contain 
wildetype sequences of both TCR chains. A relatively large fraction 
of T cell clones (42%) could either not be analyzed due to low NGS 
data quality or comprised cells with two TCR  chains, with only 
one of the  chains containing mutations in the constant region. Since for universal recipient 
cells a knockout of both TCR chains would be preferable, further experiments focused on T 
cell clones comprising a knockout of both the TCR  and  chains. As controls, selected T cell 
clones comprising an unambiguous knockout of either the TCR  or  chain were also included 
in subsequent experiments.    
Figure 4.29: Summary 
TCR knockout status 
based on NGS analysis. 
158 T cell clones were 




4.5 Characterization of TCR-deficient T cell clones 
The new strategy for generation of universal recipient cells resulted in a large number of T cell 
clones that lost expression of the endogenous TCR while being successfully transduced with 
the CAR construct, according to flow cytometric data. Selected T cell clones that showed the 
desired phenotype, in combination with promising proliferative capacity, were evaluated for 
their TCR knockout status at the mRNA level by NGS analysis. T cell clones whose TCR 
knockout could be confirmed in NGS analysis were selected for further characterization to 
investigate their suitability as universal recipient cells. Certain criteria have to be met by a T 
cell clone in order to qualify as a suitable test system for the characterization of transgenic 
TCRs. First, the cells have to exhibit high proliferative capacity in order to allow the expansion 
of sufficient numbers of cells for in vitro experiments. Second, TCR knockout has to be 
achieved in the cells to enable expression of the transgenic TCR without dominant effects of 
the endogenous TCR, while the cells should otherwise retain their natural phenotype. And 
third, the TCR-deficient cells have to exhibit all effector functions required for a physiological 
read-out of transgenic TCR specificity, killing capacity and functional avidity. This extensive 
evaluation was performed with either CD19-CAR or CD3-Chimera-expressing T cell clones, 
respectively.  
 
4.5.1 CD19-CAR-transduced universal recipient cells 
4.5.1.1 Proliferative capacity 
For univeral recipient cells to be of value as an in vitro test system, they need to exhibit high 
proliferation rates over multiple in vitro restimulation cycles. Therefore, 21 selected TCR-
deficient T cell clones were expanded over a period of 56 days, while CAR-specific stimulation 
of the cells was performed every 14 days utilizing 1 – 2 x 106 irradiated LCL and 5 – 8 x 106 
feeder cells in the presence of IL-2 (Figure 4.30). All of the selected clones carried the knockout 
of the endogenous TCR as verified by NGS analysis. Clone CD4+_50, which still expressed 
the endogenous TCR, served as a positive control for proliferation in the presence of the TCR-
complex.    
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Figure 4.30: Fold expansion of 
selected TCR-deficient CD19-
CAR expressing T cell clones 
over a period of 56 days. 21 
selected T cell clones were 
expanded by repeated CAR-
specific stimulation every 14 days 
indicated by arrows. Cell count 
was determined after each 
expansion period and calculated to 
total fold expansion. Clone 
CD4+_50 that still expressed the 
endogenous TCR serves as 
control to evaluate proliferative 
capacity. Crosses indicate that T 
cell clones could not be expanded 
further and were categorized as 
dead. 21 T cell clones categorized 
as exhibiting high (dark blue), 
moderate (light blue) and low (red) 
proliferation rates.  
 
Of the 21 selected T cell clones that were initially activated on day 0, only seven could be 
expanded longer than 28 days (Figure 4.30). While 10 CD8+ T cell clones and 11 CD4+ T cell 
clones, including control Clone CD4+_50, were chosen based on NGS analysis and phenotype, 
only CD4+ T cell clones could be expanded over the entire 56-day period. All CD8+ T cell 
clones, except for Clone CD8+_62, went into apoptosis after the second expansion period. 
Clone CD8+_62 could be stimulated again on day 28, but failed to proliferate after the second 
stimulation. In contrast, the T cell clones exhibiting high proliferation rates, CD4+_74, CD4+_17, 
CD4+_50 and CD4+_17, continued to expand at comparable levels even after repeated 
stimulation. The moderately expanding T cell clones, CD4+_46 and CD4+_54, did not expand 
well after the first stimulation, but increased their proliferation rates upon repeated stimulation. 
In summary, only TCR-deficient CD4+ T cell clones could be expanded to sufficient cell 
numbers via engagement of the transduced CD19-CAR. The drop in the expansion rate after 
day 25 showed that cell numbers decline after day 11 following activation, which indicated that 
in order to achieve maximal proliferation rates, the cells would have to be activated every 11 
days instead of every 2 weeks. This 11-day stimulation cycle was used for further cultivation 
of the cells.  
 
4.5.1.2 NGS results and phenotype 
The NGS results and knockout (KO) status for the six TCR-deficient T cell clones that could 
be expanded longer than 28 days are summarized in Table 4.1. Based on NGS results the KO 
status of the individual T cell clones was categorized as comprising a knockout of both TCR 
chains ( + ) or only of the TCR  chain (). CD19-CAR-positive Clone CD4+_50 still 
expressing the endogenous TCR, served as a positive control to validate the integrity of the 
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performed data analysis. The NGS data were analyzed as described before and the results 
were additionally confirmed by RACE PCR.  
Table 4.1: NGS results for TCR-deficient CD19-CAR-transduced T cell clones. 
Clone  chain  chain 1  chain 2 
KO 
status 
74 TG---------CTTCAG* TG--------------AGAG TGCCGTG-ACCAGCTGAGAG (+ )  
24 TGTGTTTGA--CATCAG WT unproductive  





46 TGTG-TTGAGCCATCAG unproductive WT 
62 TGTGTTTGA-CCATCAG unproductive TGCCGTGTAACCAGCTGAGAG +  
50 WT WT unproductive No KO 
*in-frame mutation 
 
All mutations detected in NGS led to frame-shift mutations that resulted in a premature stop 
codon rendering the protein non-functional, except for Clone CD4+_74 in which an in-frame 
mutation was introduced by the TALEN pairs targeting the TCR  chain. Therefore, the KO 
status was indicated as “ (+ ) KO”, since the effect of this mutation on the functionality of the 
TCR  chain could not be predicted. For most of the T cell clones a second rearranged TCR  
chain was detected by NGS and the identification of the productive chain was performed by 
MiTCR analysis in combination with the IMGT/V-Quest tool as described before.  
After a 42-day expansion period, the phenotype of the TCR-deficient T cell clones was re-
examined by flow cytometry to ensure that the expanded cells still expressed the respective 
co-receptor while lacking TCR expression (Figure 4.31). Clone CD4+_50 served again as a 
positive control to ensure proper binding of the antibody. 
 
Figure 4.31: Combination of phenotype and knockout status of the CD19-CAR-transduced T cell clones. 
Phenotype of TCR-deficient T cell clones (blue) was determined after 42-day expansion period by staining with 
-CD3, -CD4 and -CD8 antibodies and subsequent flow cytometric analysis. TCR-positive Clone CD4+_50 
served as positive control (gray). Co-receptor expression was also determined by flow cytometry and results are 
indicated below the histograms. Knockout status was determined by NGS analysis and is shown below histograms 
for each T cell clone.   
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All of the selected T cell clones did not express the TCR complex on the cell surface indicating 
the knockout of the endogenous TCR, which was additionally verified by NGS analysis (Figure 
4.31). While some of the clones exhibited mutations in both TCR chains, some clones only 
contained mutations in the TRBC locus. However, independent of knockout status, the TCR 
could not be expressed on the cell surface when one or both TCR chains, respectively, 
exhibited frame-shift mutations. Additionally, even in the absence of the endogenous TCR, all 
T cell clones still expressed the CD4 or CD8 co-receptor, respectively. 
In order to verify that the knockout of the endogenous TCR complex did not have any impact 
on the phenotype of the expanded T cell clones, they were stained with antibodies for common 
T cell markers defining the T cell subset affiliation (Figure 4.32).  
 
The phenotype of the T cell clones 74, 24, 17 and 62 was comparable to the control and 
resembled a CCR7- CD45RA- CD62L- effector-memory phenotype as observed before for 
other T cell clones from in vitro cultures (Figure 4.32). Clones 54 and 46 exhibited expression 
of CD45RA, characterizing them as more terminally differentiated effector T cells. However, a 
large fraction of clone 54 cells additionally expressed CD62L, which is normally expressed on 
naïve or central-memory T cell subsets (Golubovskaya and Wu, 2016).  
 
4.5.1.3 Functional experiments 
To validate effector functions of the TCR-deficient T cell clones, a well-characterized TCR 
recognizing the NY-ESO-1 antigen was transduced into each T cell clone. This HLA-A2-
restricted TCR, termed NY-ESO TCR, recognizes the peptide SLLMWITQC corresponding to 
the residues 157 to 165 of NY-ESO-1 (NY-ESO-1157-165) (Longinotti, 2018). Successful 
transduction of the respective TCR-deficient T cell clones with the transgenic NY-ESO TCR 
could be easily monitored by re-expression of endogenous CD3 together with the introduced 
transgenic TCR on the cell surface. Expression of the transgenic TCR was verified by binding 
of -TCRV1 antibody recognizing the TCR  chain of the NY-ESO TCR. Using these cell 
surface markers, the NY-ESO TCR-transduced cells were enriched by FACS (Figure 4.33c). 
Figure 4.32: Phenotype of 
TCR-deficient T cell clones. 
The selected T cell clones 
exhibiting a knockout of the 
endogenous TCR (blue) were 
stained with -CD3, -CCR7, -
CD45RA and -CD62L 
antibodies and analyzed by flow 
cytometry. Endogenous TCR-
expressing T cell clone, Clone 
CD4+_50, served as control 
(gray). Noted median FI 
indicated levels of cell surface 




High purity of transduced cells could be achieved by FACS enrichment, which was indicated 
by over 95% double-positive cells. The lack of CD3 and TCR  chain expression in 
untransduced TCR-deficient cells demonstrated that endogenous CD3 will only be present on 
the cell surface when a functional TCR is translated, thereby proving the knockout of the 
endogenous TCR in the isolated T cell clones (Figure 4.33c). The enriched NY-ESO TCR-
positive T cell clones were expanded, using a rapid expansion protocol utilizing OKT-3 
antibody, before they were used in subsequent functional experiments. 
To investigate the killing capacity of the NY-ESO TCR-expressing T cell clones, tumor cell 
killing mediated by the enriched cells was monitored utilizing the IncuCyte® ZOOM System 
(Essen Bioscience). The cytotoxic capacity of T cell clones expressing the NY-ESO-1-specific 
TCR was visualized by the disappearance of IncuCyte® NucLight Red-labeled antigen-positive 
tumor cell line Mel624.38 (Figure 4.33a). To assess the specificity mediated by the introduced 
TCR the targeting of IncuCyte® NucLight Red-labeled NY-ESO-1-negative 647-V cells was 
monitored as a control. Specific activation of the TCR-transduced T cell clones was additionally 
assessed by IFN- release 20 hours after co-culture with the respective tumor cells (Figure 
4.33b). The supernatants utilized in IFN- ELISA were derived from the same co-culture used 
in the killing assay described above. Additional controls were used for ELISA co-culture that 
included CD19-positive LCL to determine activation of the respective T cell clones via the 
transduced CAR and the T cell clones alone to detect any background IFN- release when no 
target cells were present.   
Simultaneous expression of CD3 and the transgenic TCR in transduced cells allowed the 
assumption that a functional TCR-complex was present in these cells (Figure 4.33c). This 
could be proven by high levels of IFN- release of TCR-transduced cells after co-culture with 
NY-ESO-1-expressing Mel624.38 cells (Figure 4.33b). The transduced T cell clones did not 
produce any IFN- in the presence of NY-ESO-1-negative 647-V tumor cells, indicating that 
the activation of the cells was mediated specifically via the introduced NY-ESO TCR. IFN- 
release upon interaction with CD19-positive LCL served as a positive control that 
demonstrated the functionality of the expressed CD19-CAR and the general ability of the 
isolated T cell clones to produce this cytokine. This could be nicely observed for the T cell 
clones 74, 46 and 54. However, clone 17 failed to produce IFN- upon CAR engagement. No 
detection of IFN- in the absence of any target cells demonstrated that the isolated TCR-
deficient T cell clones did not spontaneously release IFN- and that the specificity was 
mediated through the transduced TCR or CAR, respectively. While IFN- release indicated 
specific recognition of the target antigen, it did not necessarily demonstrate specific killing. As 
shown in Figure 4.33a, specific lysis of the NY-ESO-1-expressing Mel624.38 tumor cells could 
only be achieved by the T cell clones 74 and 17, indicated by decreasing tumor cell numbers, 
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even though IFN- release was comparable for all T cell clones after co-culture with this target 
cell line (Figure 4.33b). While the specificity of all TCR-deficient T cell clones could be 
redirected via introduction of the transgenic TCR, not all of them exhibited the capacity to kill 
target cells. Proliferation of NY-ESO-1-negative 647-V cells was not influenced by the 
presence of the transduced T cell clones, which again demonstrated the specificity mediated 
by the introduced NY-ESO TCR (Figure 4.33a). 
 
Figure 4.33: Effector functions of isolated T cell clones after introduction of transgenic NY-ESO-1-specific 
TCR. a) Killing assay utilizing the IncuCyte® ZOOM System to monitor killing of NY-ESO-1-positive (Mel624.38) 
and -negative (647-V) tumor cells labeled with IncuCyte® NucLight Red dye over 42 hours with E:T ratio of 2:1. 
Respective tumor cells alone (grey) served as control for proliferation in the absence of effector cells. Cell count/well 
was determined by using IncuCyte® ZOOM Software 2016B to analyze quadruplicates of each approach. b) IFN- 
ELISA of supernatants derived from the same co-culture after 20 h of incubation. Co-culture with LCL (CD19-
positive, light blue) served as positive control for the transduced CD19-CAR. T cell clones without any target cells 
(w/o, gray) were used as negative control to assess background activation of the transduced T cells. c) Flow 
cytometric analysis of NY-ESO TCR-expressing T cell clones after enrichment by FACS. NY-ESO TCR-transduced 
T cell clones (blue) were stained with -CD3 and -TCR-V1 antibody specific for the TCR  chain of the NY-ESO 
TCR. The same antibodies were used for FACS enrichment of the cells 10 days after transduction. The respective 
untransduced T cell clones served as negative control (gray) to determine purity of the sorted cells expressing the 





4.5.2 CD3-Chimera-transduced universal recipient cells 
4.5.2.1 Proliferation 
In contrast to T cell clones transduced with the CD19-CAR, which mediates activation via CD19 
antigen recognition, cells expressing the CD3-Chimera construct have to be stimulated in an 
antigen-independent manner. As described in 4.4.1.2, the proposed mode of action includes 
the activation of the transduced TCR-deficient T cell clones via engagement of the CD3-
Chimera construct by binding of -CD3 OKT-3 antibody that exhibits mitogenic properties (Van 
Wauwe, De Mey and Goossens, 1980). To deliver the required co-stimulation for proper 
activation, -CD28 antibodies or CD28-interacting molecules, like CD80 or CD86 can be used. 
To assess the proliferative capacity, CD80- and CD86-expressing LCL were chosen to 
generate a more natural co-stimulatory signal in activated T cell clones. In contrast to the 
CD19-CAR approach, where 369 T cell clones could be isolated after the first stimulation 
period, only eight CD3-Chimera-transduced T cell clones could be detected. Four T cell clones 
exhibiting initial promising proliferative capacity, were further analyzed for their expansion over 
56 days (Figure 4.34a). For repeated stimulation via the transduced CD3-Chimera construct, 
the isolated T cell clones were co-cultured with 1 – 2 x 106 irradiated LCL and 5 – 8 x 106 
feeder cells in the presence of IL-2 and OKT-3 antibody. Clone CD4+_50, which expressed the 
CD19-CAR and did not comprise a TCR knockout, was used as a control to compare 
expansion via CD3-Chimera engagement to physiological activation via the TCR. To ensure 
that activation of the TCR-deficient T cell clones was mediated through the CD3-Chimera 
construct, two promising T cell clones, CD8+_001 and CD8+_002, were stimulated with and 
without OKT-3 antibody (Figure 4.34b).  
 
Figure 4.34: Fold expansion of TCR-deficient T cell clones transduced with CD3-Chimera construct. a) Fold 
expansion of 4 T cell clones, CD8+_001, CD8+_002, CD8+_003 and CD8+_004, over 56 days by repeated 
stimulation every 14 days. Cell count was determined at least after each expansion period. Clone CD4+_50 served 
as a control (red) to compare proliferative capacity. b) Fold expansion of 2 selected T cell clones over 1 stimulation 
cycle under different activation conditions. Cells were either stimulated with complete stimulations mix (dark blue) 
comprising LCL, feeder cells, IL-2 and OKT-3 antibody, or with stimulation mix lacking OKT-3 (light blue) or OKT-3 
and LCL (red), respectively. Cell count was determined on day 5 and 10.  
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While two of the TCR-deficient T cell clones died after two rounds of stimulation, Clone 
CD8+_001 und CD8+_002 showed exceptional proliferative capacity (Figure 4.34a). With more 
than 100-fold expansion after 56 days, Clone CD8+_001 exhibited comparable proliferation 
rates to the control. Clone CD8+_002 even reached 250-fold expansion after 56 days of in vitro 
culture. The observed high proliferation rates of the two TCR-deficient T cell clones were 
induced by binding of OKT-3 antibody, since cells that were activated in the absence of OKT-
3 failed to expand (Figure 4.34b). CD3-Chimera-expressing T cell clones that were activated 
without OKT-3 antibody or LCL went into apoptosis, while cells that still received co-stimulatory 
signals via LCL survived, but expanded only about 9-fold. In contrast, cells that were activated 
in the presence of OKT-3 antibody and co-stimulatory cells expanded 40 – 50-fold, indicating 
that OKT-3 antibody is required to achieve maximal stimulation.  
 
4.5.2.2 NGS results and phenotype 
Based on proliferative capacity, only the T cell clones CD8+_001 and CD8+_002 were further 
characterized for suitability as universal recipient cells. For this, the NGS data were analyzed 
to determine the TCR knockout status of these cells as described above. Table 4.2 
summarizes the results of the NGS analysis demonstrating that Clone CD8+_001 carried 
mutations in the TRAC gene, while CD8+_002 exhibited base deletions in the TRBC gene. 
Both resulted in frame-shift mutations that introduced a pre-mature stop codon in the amino 
acid sequence of the constant regions, thereby preventing cell surface expression of the TCR-
complex.  
Table 4.2: NGS results for TCR-deficient CD3-Chimera-transduced T cell clones. 
Clone  chain  chain 1  chain 2 
KO 
status 
001 WT unproductive TGCC-------AGCTGAGAG  
002 TGTG----AG—ATCAG WT -  
 
While the knockout of the endogenous TCR could also be visualized by flow cytometric 
analysis, the expression of the transduced CD3-Chimera construct could not be detected by 
-CD3 antibody staining (Figure 4.35a, b). Since most of the CD3 antibodies used were 
derived from the clone UCHT-1, the cells were additionally stained with -CD3 antibody OKT-3 
conjugated to eFluor 450 dye (Figure 4.35b). In this way the same antibody used for activation 
of the cells was also used for detection, even though both antibodies should be able to bind 
the CD3 subunit present in the CD3-Chimera construct (Arnett, Harrison and Wiley, 2004; 
Kjer-Nielsen et al., 2004). To exclude that the antibody concentrations used were not sufficient 
to detect the CD3-Chimera construct on the cell surface, 5-fold higher amounts of -CD3 
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antibody were used (Figure 4.35c). TCR complex-expressing T cell clone CD4+_50 was used 
as a positive control, while TCR-deficient T cell clone CD4+_74 transduced with CD19-CAR 
was utilized as a negative control for antibody staining.  
 
Figure 4.35: CD3 staining of CD3-Chimera-transduced TCR-deficient T cell clones. a) Staining of TCR-
deficient T cell clones CD8+_001 and CD8+_002 (blue) with -CD3 antibody and subsequent analysis by flow 
cytometry. Expression of eGFP indicated successful transduction with CD3-Chimera construct. b) Staining of Clone 
CD8+_002 with -CD3 antibody either derived from clone UCHT-1 (black) or OKT-3 (blue) and subsequent flow 
cytometric analysis. c) Staining of Clone CD8+_002 (blue) with -CD3 antibody using normal antibody concentration 
(1x antibody) or 5-times the usual concentration (5x antibody), respectively, followed by analysis by flow cytometry. 
TCR-deficient T cell clone CD4+_74 was used as a negative control (black). For all approaches (a-c) TCR-complex-
expressing T cell clone CD4+_50 was used as a positive control (gray).  
 
The two CD3-Chimera-transduced T cell clones that either comprised a knockout of the TCR 
 or  chain, respectively, exhibited the same phenotype as TCR-deficient T cell clones 
transduced with CD19-CAR (Figure 4.35a). The lack of CD3 or TCR expression indicated 
the successful knockout of the endogenous TCR, while expression of eGFP demonstrated a 
successful transduction with the CD3-Chimera construct. However, in contrast to the CD19-
CAR, the CD3-Chimera construct should have been detected by -CD3 antibody staining 
thereby resulting in a TCR- CD3+ phenotype. Even staining with high amounts of -CD3 OKT-3 
antibody, which was also used for activation of the cells, did not result in a positive staining of 
CD3-Chimera-transduced cells, while TCR-complex-positive cells could be nicely detected 
with both antibodies (Figure 4.35b). Direct comparison of CD3 staining of CD3-Chimera-
transduced T cell clone CD8+_002 with the negative control clone CD4+_74 (CD19-CAR-
positive, CD3-negative) revealed a slight positive shift of the clone CD8+_002 population 
compared to the negative control (Figure 4.35c). When the antibody concentration was 
increased 5-fold, the detected positive shift of -CD3-stained clone CD8+_002 could be slightly 
increased compared to the negative control. While the positive control was also stained at both 
antibody concentrations, the 5-fold higher antibody concentration also resulted in a 
comparable positive shift of the CD3-positive population. In summary, no distinct CD3-positive 
population could be detected for T cell clones transduced with CD3-Chimera, independent of 
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antibody clone or concentration. In contrast to the proliferation experiments, which 
demonstrated the mitotic properties and functionality of OKT-3 antibody (Figure 4.34b), OKT-3 
was not able to detect the chimeric construct in the flow cytometric analysis.  
To verify that the isolated TCR-deficient T cell clones, that exhibited high proliferation rates, 
still maintained the characteristic phenotype of in vitro cultured T cells, the cells were stained 
for common T cell markers (Figure 4.36). Clone CD4+_50 served as a control to compare the 
expression levels of selected cell surface markers.  
 
Figure 4.36: Phenotype of TCR-deficient T cell clones transduced with CD3-Chimera. The two CD8+ T cell 
clones 001 and 002 (blue) were stained with -CD3, -CCR7, -CD45RA and -CD62L antibodies and analyzed 
by flow cytometry. Endogenous TCR-expressing T cell clone, Clone CD4+_50, served as control (gray). Noted 
median FI indicated levels of cell surface expression of the respective phenotypic marker. 
The CD3-Chimera-transduced T cell clones exhibited a CCR7-CD45RA-CD62L- effector-
memory phenotype resembling the control (Figure 4.36). In contrast to Clone CD4+_50 they 
expressed the co-receptor CD8 and lacked CD3 expression, as observed before. Therefore, 
the isolated T cell clones showed a normal phenotype for in vitro cultured T cells. 
 
4.5.2.3 Functional experiments 
As mentioned before, high proliferative capacity and TCR knockout are two prerequisites for 
suitable universal recipient cells, which are met by the two isolated T cell clones. However, the 
third characteristic these cells need to display is retention of effector functions required for 
physiological read-outs after transgenic TCRs have been introduced. In order to evaluate the 
killing capacity, the two TCR-deficient T cell clones, CD8+_001 and CD8+_002, were 
transduced with two well-characterized TCRs recognizing the antigen tyrosinase. These TCRs, 
T58 and D115, bind the same tyrosinase369-377 peptide (YMDGTMSQV) presented by HLA-A2 
in a CD8-dependent manner. However, while T58 is characterized as a TCR conferring high 
functional avidity in a transgenic setting, T cells expressing transgenic D115 TCRs show lower 
functional avidity to the same target (Wilde et al., 2009). Utilizing these two TCRs allowed a 
detailed evaluation of the functionality as well as sensitivity of the CD3-Chimera-transduced T 
cell clones when transgenic TCRs were introduced. To use high-purity cell preparations in 
further experiments, the transduced cells were enriched by FACS after staining with -CD3 
and specific TCR-V antibodies (T58: -TCR-V23; D115: -TCR-V8) (Figure 4.38a). To 
allow a direct comparison with PBL, which have served as the standard test system for 
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transgenic TCRs up to date, freshly isolated PBL were also transduced with the two tyrosinase-
specific TCRs and prepared in the same manner as described for the isolated T cell clones.  
In order to assess the killing capacity of the enriched TCR-transduced T cell clones, clone 
CD8+_001 and CD8+_002 as well as transgenic TCR-expressing PBL were co-cultured with 
tyrosinase-positive Mel624.38 or tyrosinase-negative A375 cells, respectively (Figure 4.37). 
Outgrowth of the IncuCyte® NucLight Red-labeled tumor cells was monitored utilizing the 
IncuCyte® ZOOM System (Essen Bioscience) over a period of 72 hours. The tumor cell killing 
mediated by the T cell clones CD8+_001 and CD8+_002 expressing either TCR T58 or D115, 
was compared to tumor cell lysis induced by PBL transduced with the same TCRs. As an 
additional control, tumor cells were co-cultured under the same conditions with the respective 
untransduced T cell clones, which should not exhibit any activity due to lack of an endogenous 
TCR. Untransduced PBL served as a control to estimate the background killing mediated by 





Figure 4.37: Killing capacity of isolated CD3-Chimera-expressing T cell clones after introduction of 
transgenic tyrosinase-specific TCRs T58 and D115. Killing assay utilizing the IncuCyte® ZOOM System to 
monitor killing of tyrosinase-positive (Mel624.38) and -negative (A375) tumor cells labeled with IncuCyte® NucLight 
Red dye over 72 hours with E:T ratio of 2:1. Respective tumor cells alone (grey dots) served as control for 
proliferation in the absence of effector cells. Untransduced effector cells (gray squares) served as control to estimate 
background killing in the absence of transgenic TCRs. Cell count/well was determined by using the IncuCyte® 
ZOOM Software 2016B to analyze quadruplicates of each approach.  
The two T cell clones (CD8+_001 and CD8+_002) expressing either TCR T58 or D115, killed 
the tyrosinase-positive tumor cells, while tyrosinase-negative A375 cells were not targeted by 
the same effectors (Figure 4.37). Untransduced T cell clones CD8+_001 and CD8+_002 did 
not influence outgrowth of the respective target cells, indicating that the target specificity was 
mediated via the introduced transgenic TCR. PBL transduced with the transgenic TCRs could 
also eradicate tyrosinase-expressing Mel624.38 cells, while tyrosinase-negative cells were not 
affected by the same cells. However, PBL expressing the D115 transgenic TCR could not 
control tumor growth as efficiently as PBL transduced with T58, which exhibited higher 
Results  
94 
functional avidity. This difference in killing capacity was not observed in the isolated T cell 
clones CD8+_001 and CD8+_002 that lack an endogenous TCR. While transduced PBL did 
not kill A375 cells, untransduced control PBL seemed to target the tyrosinase-negative cells 
after 40 hours of co-culture. This indicated a background activity mediated by the mixture of 
different lymphocytes that was independent of the transgenic TCRs. In summary, the isolated 
TCR-deficient T cell clones exhibited the capacity to effectively kill tumor cells directed by the 
specificity of the introduced transgenic TCRs. However, different levels of killing capacity 
based on distinct functional avidities of the transgenic TCRs, T58 and D115, could only be 
observed in transduced PBL and were not detected in the TCR-deficient T cell clones 
CD8+_001 and CD8+_002.  
 
IFN- release upon specific recognition of target cells by TCR-transduced effector cells was 
determined in order to evaluate the capacity to produce cytokines (Figure 4.38b). For this, the 
supernatants of the same cells used in the killing assay were collected 20 hours after co-culture 
and analyzed by IFN- ELISA. Additional positive controls to determine maximal IFN- release 
included activation of the isolated T cell clones and PBL with the mitogens phorbol 12-myristate 
13-acetate (PMA) and ionomycin (Hashimoto et al., 1991). Successful enrichment of TCR-
transduced cells used in the co-culture experiments was determined by staining with -CD3 
and the respective -TCR-V-specific antibodies and subsequent flow cytometric analysis. 
Additionally, the cells were stained with -CD3 antibody and a tetramer comprising the 
tyrosinase-derived peptide YMDGTMSQV (YMD) bound to in vitro synthesized HLA-A2 
molecules coupled to a fluorescent dye (Figure 4.38a). These tetramers mimic the presentation 
of peptide via HLA-A2 molecules by antigen presenting cells and allows the estimation of 
expression of functional transgenic TCRs binding the peptide-MHC complexes by the 
transduced effector cells (Altman et al., 1996). Since the TCR T58 and D115 recognize the 
same tyrosinase peptide bound to HLA-A2, cells transduced with both TCRs can be stained 




Figure 4.38: Effector function of CD3-Chimera-transduced T cell clones after introduction of tyrosinase-
specific TCRs T58 and D115. a) Staining of isolated T cell clones (CD8+_001 and CD8+_002) and PBL transduced 
either with T58 (dark blue) or D115 (light blue), respectively, with -CD3 and -TCR-V antibodies specific for the 
respective transgenic TCR  chain and tretramer comprising the YMDGTMSQV (YMD) peptide. After enrichment 
by FACS, cells were subsequently analyzed by flow cytometric analysis. Untransduced CD8+_001 and CD8+_002 
T cell clones and untreated PBL were used as respective negative controls (gray). b) IFN- ELISA of supernatants 
derived from the same co-cultures used in the killing assay 20 hours after incubation of transduced T cells 
(CD8+_001, CD8+_002 or PBL) with target cells at an E:T ratio of 2:1. Positive control comprised effector cells 
activated with 750 ng/mL PMA and 5 ng/mL ionomycin (PMA/Iono). IFN- release of transduced PBL was 
determined in two independent experiments. Untransduced cells (w/o) served as negative control. Target cells 
comprised tyrosinase-positive (Mel624.38) and tyrosinase-negative tumor cells (A273). c) Functional avidity of 
TCR-transduced T cell clones (CD8+_001, CD8+_002) and PBL plotted as relative IFN- release to decreasing 
peptide concentrations. K562_A2_CD86 cells were loaded with decreasing amounts of peptide (10-4 to 10-12 M) and 
co-cultured with T58 or D115-expressing T cells, respectively, at fixed E:T ratio of 2:1. IFN- release was determined 
20 hours later by IFN- ELISA and relative IFN- release was calculated by setting maximal IFN- release to the 
reference value of 100%. Lower values were calculated according to this reference. Values were derived from 
biological duplicates. Dashed lines indicate calculated EC50 values. K652_A2_CD86 cells loaded with 10-4 M 
irrelevant SLLMWITQC peptide served as negative controls.   
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IFN- release, determined 20 h after co-culturing TCR-transduced cells with the respective 
target cells, mirrored the observations made in the killing assay (Figure 4.37). Isolated T cell 
clones transduced with either T58 or D115, specifically recognized tyrosinase-positive 
Mel634.38 cells while showing no recognition of tyrosinase-negative A375 cells (Figure 4.38b). 
The amount of IFN- secreted by the T cell clones CD8+_001 and CD8+_002 was comparable 
when target cells were recognized via TCR T58 and D115, respectively. The amount of IFN- 
released upon specific activation was comparable to stimulation via the mitogens PMA and 
Ionomycin that trigger maximal cell activation. Untransduced T cell clones secreted the same 
amounts of IFN- as transduced clone CD8+_001 and CD8+_002 upon activation with PMA 
and ionomycin. However, untransduced T cell clones did not release IFN- when co-cultured 
with tumor cells. PBL transduced with TCR D115 secreted approximately 3-times lower 
amounts of IFN- when co-cultured with tyrosinase-positive target cells than T58-transduced 
PBL. This is in accordance with observations made in the killing assay, where D115-
transduced PBL could not control tumor cell growth as efficiently as PBL expressing TCR T58, 
that confers higher functional avidity. However, the positive control comprising mitogen-based 
activation via PMA and ionomycin indicated that maximal IFN- release of D115-transduced 
cells was also lower compared to T58-transduced PBL. Unlike in the killing assay, no 
unspecific IFN- release of untransduced PBL upon incubation with tyrosinase-negative A375 
cells could be observed. Staining with -CD3 and -TCR-V antibodies indicated that 
enrichment of the transduced cells via FACS yielded TCR-V+CD3+ cell populations exhibiting 
a purity of up to 98% (Figure 4.38a). For both T cell clones, CD8+_001 and CD8+_002, 
expression of the respective transgenic TCR  chains correlated with binding to the YMD-
tetramer complex.  Specific binding of the YMD-tetramer indicated the presence of functional 
transgenic TCRs on the cell surface, which was confirmed by IFN- ELISA and specific tumor 
cell killing (Figure 4.37b, Figure 4.38). T cell clone CD8+_002 transduced with TCR T58 
exhibited two distinct CD3-positive cell populations that bound the YMD-tetramer as well as 
the specific TCR-V antibody to varying degrees. Nearly 97% of the TCR-transduced PBL 
showed expression of the respective transgenic TCR  chain. However, in contrast to isolated 
T cell clones, transgenic TCR  chain expression did not correlate with specific binding to the 
YMD-tetramer. Less than half of the enriched TCR-transduced PBL bound the YMD-tetramer, 
which indicated that PBL comprising various endogenous TCRs expressed lower amounts of 
functional transgenic TCR on the cell surface. This reduced transgenic TCR expression did 
not affect specific killing capacity or IFN- secretion of T58-transduced PBL exhibiting high 
functional avidity (Figure 4.37b, Figure 4.38). However, D115-expressing PBL, which exhibit a 
lower functional avidity, also showed reduced IFN- secretion and killing capacity when co-
cultured with tyrosinase-positive tumor cells compared to T58-transdcued PBL.  
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Functional avidity is a biological measure to determine the sensitivity of T cell clones to varying 
concentrations of antigen in vitro and can therefore be considered the activation threshold of 
a given T cell clone (Viganò et al., 2012). Therefore, T cell clones exhibiting high functional 
avidity require lower amounts of antigen to be activated compared to T cell clones of lower 
functional avidity. It has been shown that the sensitivity to antigen can be conferred to recipient 
cells via the introduced transgenic TCR (Wilde et al., 2009). To investigate the functional avidity 
of the isolated T cell clones expressing the transgenic TCRs T58 and D115, compared to 
transduced PBL, the cells were co-cultured with target cells loaded with titrated amounts of 
YMD peptide (Figure 4.38c). As target cells K562 transduced with HLA-A2 and CD86 were 
used (K562_A2_CD86). IFN- release indicated activation of these cells and served as a 
measure to determine the antigen concentration required for half-maximal response (EC50), 
corresponding to measured functional avidity of the transduced T cells.  
Peptide concentrations resulting in half-maximal IFN- release (EC50) were comparable in all 
three recipient cells (Figure 4.38c). All T58-transduced cells exhibited more than 10-fold higher 
functional avidity compared to the corresponding cells expressing TCR D115. EC50 for cells 
expressing T58 was calculated to be induced at peptide concentrations of nearly 10-8 M. In 
contrast, D115-transduced cells reached EC50 only at peptide concentrations ranging from 
6.5 - 6.8 x 10-6 M. This demonstrated that the generated TCR-deficient CD3-Chimera 
expressing T cell clones, CD8+_001 and CD8+_002, could exhibit peptide sensitivities 
comparable to PBL when expressing the same transgenic TCR. Therefore, the sensitive 
parameter “functional avidity” did not change, which demonstrated that these TCR-deficient T 
cell clones can serve as a valid test system to evaluate functional avidity conferred to T cells 











The aim of this thesis included the generation of universal recipient cells that could be used as 
a test system for the high-throughput functional characterization of transgenic TCRs. These 
universal recipient cells should carry certain characteristics in order to qualify as a suitable 
TCR test system. First, the cells should proliferate to high cell numbers independent of the 
endogenous TCR via engagement of an introduced chimeric construct, e.g. a CAR. Second, 
expression of the endogenous TCR should be prevented by gene knockout to enable 
expression and testing of transgenic TCRs in these cells without dominant negative effects of 
the endogenous TCR or possible TCR mispairing. Third, the generated TCR-deficient cells 
should exhibit all effector functions required for a physiological read-out of specificity, killing 
capacity and functional avidity mediated by the transgenic TCR. To date, bulk PBL, comprising 
a diverse mixture of different lymphocyte subsets, are commonly used as TCR recipient cells. 
To avoid the introduction of unknown variables into experiments based on heterogenous 
reactivity profiles of PBL, universal recipient cells were generated from individual T cell clones. 
Using selected T cell clones, it was first determined whether proliferation of T cell clones could 
be induced by engagement of an introduced CAR construct independent of the endogenous 
TCR. For these experiments well-characterized CAR constructs recognizing the CEA antigen 
were utilized and allowed the establishment of a stimulation procedure suitable for expansion 
of individual T cell clones independent of subset origin. Once proliferation could be induced 
sufficiently in individual T cell clones, the endogenous TCR was targeted for knockout using 
the TALEN technology. Initial poor survival of TCR-deficient T cell clones via CEA-CAR 
engagement led to the generation of new chimeric constructs that should better promote 
proliferation of T cell clones in the absence of the endogenous TCR. These included a CD19-
CAR construct published by Hudececk et al. and a CD3-Chimera construct that should mediate 
activation of T cells via binding of mitotic antibodies recognizing CD3. Using these chimeric 
constructs, a new high-throughput strategy could be developed that allowed the immediate 
identification of TCR-deficient T cell clones that could be expanded via engagement of CD19-
CAR or CD3-Chimera, respectively. The procedure included analysis of mutations introduced 
by TALEN-mediated targeting of the TCR  and  chains using NGS, which allowed the 
confirmation of the TCR knockout status on mRNA level for each individual T cell clone. This 
process contributed to the characterization of candidate universal recipient cells and enabled 
the preferential selection of TCR-deficient T cell clones exhibiting a knockout of both TCR 
chains. Based on this screening procedure, candidate universal recipient cells were selected 
and investigated for effector functions upon introduction of transgenic TCRs. The steps and 
experimental procedures contributing to the generation of universal recipient cells are 
discussed in detail below. 
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5.1 T cell stimulation via chimeric antigen receptors (CARs) 
The in vitro expansion of bulk PBL through CAR engagement has been investigated previously 
and resulted in cell numbers comparable to physiological TCR stimulation (Maher et al., 2002; 
Finney, Akbar and Alastair, 2004). However, whether proliferation of individual T cell clones 
could be induced through CAR engagement sufficiently to be of use as an in vitro test system 
has not been shown before. Additionally, since CAR constructs were generally designed to 
mediate tumor cell killing rather than T cell expansion, the CAR domain structure best suited 
for physiological expansion of T cell clones in vitro had to be determined. Several clinical 
studies also demonstrated the importance of CAR-induced T cell proliferation for clinical 
benefit and led to the generation of second and third generation CARs comprising additional 
co-stimulatory domains to promote activation and persistence of T cells in vivo (Sadelain, 
Brentjens and Rivière, 2013). To investigate proliferation of T cell clones upon CAR 
engagement in vitro, an established CD4+ T cell clone, Clone 234, was used as a first test 
system. Clone 234 was transduced with either CEA-CAR_CD4 or CEA-CAR_CD8, 
respectively, and could be successfully enriched via FACS (Figure 4.2a). Stable expression of 
the respective CAR construct was observed over a period of 42 days and was independent of 
TCR- or CAR-specific activation of the transduced T cells (Figure 4.2b). However, median FI 
values indicated that expression levels of CEA-CAR_CD4 were generally higher compared to 
CEA-CAR_CD8. No downregulation of either construct could be observed independent of the 
type of stimulation. When comparing X-fold expansion of the same cells over 42 days, it 
became apparent that proliferation rates of cells stimulated via CAR engagement were around 
3-fold lower than for cells that were activated via the endogenous TCR (Figure 4.3). In this 
initial expansion period, the same stimulation conditions were used for both types of activation, 
which included 1 x 106 T cells per 24-well in co-culture with 0.3 x 106 irradiated TCR or CAR 
target cells, respectively. The low expansion rates of cells stimulated via CAR could be 
overcome by increasing the amount of CEA antigen present during activation. When E:T ratios 
were greater than 1:5 for CAR-specific activation, proliferation rates comparable to native TCR 
engagement could be reached (Figure 4.4b). While direct comparison of CAR- and TCR-
mediated activation has been difficult due to their differences in antigen recognition and 
general structure, the TCR complex has been shown to be more sensitive compared to CARs 
that require higher amounts of antigen for activation of T cells (Harris and Kranz, 2016). 
Recently, a system has been developed by Stone et al. that allowed direct comparison by 
using the analog of a scFv, which comprised a single chain TCRV-TCRV fragment, 
combined with typical CAR signaling domains (Stone et al., 2014). However, also in this 
system, CAR constructs were 10 – 100-fold less sensitive than TCRs recognizing the same 
peptide-MHC complex, which indicated that signaling kinetics through the native TCR complex 
are more efficient (Harris et al., 2017). Therefore, increasing antigen density is a sensible 
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measure to achieve comparable activation rates for T cells stimulated via CAR or TCR, 
respectively. While this might reveal limitations for the use of CARs in cancer immunotherapy, 
increasing the numbers of CAR target cells is feasible for the use in an in vitro test system 
where the introduced CAR is supposed to mediate proliferation of T cells rather than killing of 
tumor cells. In this context, high antigen density in combination with the presence of co-
stimulatory molecules on B cells might contribute to the clinical efficacy of CD19-CARs 
observed in patients suffering from B cell malignancies (Kalos et al., 2011; Porter et al., 2011). 
Together, these results indicated that appropriate antigen density might have to be determined 
empirically for each CAR construct dependent on specificity and affinity of the scFv as well as 
intracellular signaling domains.  
While both CEA-CAR constructs mediated proliferation of Clone 234, CEA-CAR_CD8 
engagement did not result in IFN- release. In contrast, binding of CEA antigen by CEA-
CAR_CD4 led to IFN- release, which increased proportionally to the numbers of target cells 
and peaked at an E:T ratio of 1:4 (Figure 4.4a). This demonstrated that secretion of IFN- does 
not necessarily correlate with induction of proliferation in individual T cell clones. Both CAR 
constructs carry the same -CEA scFv, but differ in the composition of their signaling domains 
(Figure 4.1). While CEA-CAR_CD4 comprised a 4-1BB singling domain coupled to a CD4 
transmembrane domain, CEA-CAR_CD8 contained a CD28 transmembrane and signaling 
domain. This showed that in the established CD4+ T cell clone, which secrets IFN- in response 
to its native antigen recognized by the TCR, the CD28 co-stimulatory domain present in the 
CEA-CAR_CD8 could not mediate the same type of activation. These results are in contrast 
to previous observations, where engagement of CD28-containing CARs induced IFN- release 
in CD4+ as well as CD8+ T cells (Hombach and Abken, 2011). However, these experiments 
were performed in heterogenous bulk sorted CD4+ and CD8+ T cells, respectively, which 
showed that individual T cell clones may exhibit different effector functions in the presence of 
distinct signaling domains.   
 
5.2 Knockout of the endogenous TCR in CAR-transduced T cells  
Once proliferation of the T cell clone could be achieved by CAR engagement, the next step 
comprised the knockout of the endogenous TCR. For this, TALEN pairs as well as CRISPR 
gRNA have been designed to target the same region of exon 1 of the TRAC or TRBC locus, 
respectively (Figure 4.5). Unmodified Clone 234 served as a model system to assess knockout 
efficiency in isolated T cell clones utilizing either CRISPR/Cas9 or TALEN methods (Figure 
4.6a). Introduction of TALEN pairs targeting the respective TCR chains resulted in TCR 
knockout rates of 14.5% for TRAC and 20.3% for TRBC locus, as monitored by loss of CD3 
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expression 7 days after transfection. Comparable or higher knockout rates have been reported 
in primary human T cells utilizing overlapping target regions and introduction of TALEN pairs 
in the form of ivt-RNA (Berdien et al., 2014; Poirot et al., 2015). Recently, a study by Knipping 
et al. could demonstrate up to 81% TALEN-mediated TCR knockout rate, while CRISPR/Cas9 
introduction resulted only in up to 20% CD3-negative T cells (Knipping et al., 2017). Although 
higher knockout rates could be achieved by using nuclease-protected modified CRISPR 
gRNAs, poor gene-editing rates were observed when gRNA produced by in vitro transcription 
in the laboratory was introduced (Osborn et al., 2016). No detectable knockout of either TCR 
chain was observed when utilizing the CRISPR/Cas9 system in Clone 234. For these 
experiments CRISPR gRNA was also generated by in vitro transcription, which might explain 
the unsuccessful targeting of the endogenous TCR due to premature degradation of the gRNA. 
Since knockout of the TCR  and  chains could be achieved by TALEN pairs, ivt-RNA 
generated from these constructs was used for all subsequent knockout experiments. To our 
knowledge this represented the first TCR knockout performed in an individual T cell clone 
rather than in bulk populations of primary human T cells. Comparable knockout rates could 
also be detected in Clone 234 transduced with the respective CAR constructs (Figure 4.6b). 
Enrichment of TCR-deficient cells via bead-bound -CD3 antibody yielded 97% CD3-negative 
cells, which simultaneously expressed the introduced CEA-CAR. This represented an easy 
and fast method for isolation of TCR-knockout cells that left the cells of interest untouched by 
utilizing a negative isolation strategy. Using the established expansion protocol, the enriched 
CEA-CAR-positive cells were stimulated by co-culturing them at an E:T ratio of 1:6 with 
irradiated CAR target cells (Figure 4.6c). However, expansion of the TCR-deficient CAR-
expressing T cells could not be observed. To exclude the possibility that the failed expansion 
of TCR-negative cells via CAR engagement might be due the nature of the used model system, 
Clone 234, a new strategy was developed that would allow the testing of various individual T 
cell clones.  
 
5.3 Improved strategy for selection of CAR+ T cell clones 
The improved strategy comprised the transduction of bulk PBL followed by subsequent single 
cell cloning to enable the identification of T cell clones that showed superior proliferative 
capacity when activated via CAR engagement (Figure 4.7). Utilizing this strategy, 40 well-
expanding T cell clones could be isolated that were characterized for CAR expression and 
IFN- release upon co-culture with CAR target cells (Figure 4.9). As observed before, 
expression levels of CEA-CAR_CD4 were higher compared to CEA-CAR_CD8 as reflected by 
measured median FI values detected in flow cytometry. This was observed in CD4+ as well as 
CD8+ T cell clones, which demonstrated that CAR expression levels were independent of the 
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T cell subset. While almost all T cell clones transduced with CEA-CAR_CD4 were able to 
secret high amounts of IFN- upon encounter with LS174T tumor cells, half of the CEA-
CAR_CD8-expressing T cells clones showed very low IFN- release. As observed before for 
Clone 234, IFN- release did not always correlate with T cell expansion. This observation is 
relevant for the use of the CAR construct in immunotherapy, as autocrine IFN- release by T 
cells has been shown to enhance target cell killing (Bhat et al., 2017). Therefore, functionality 
of the CAR construct could not be unambiguously proven by IFN- secretion and would have 
to be evaluated based on proliferative capacity upon engagement of the CAR.  
Up to this point, expansion of T cells from a single T cell clone was performed utilizing the 
mitogen PHA in the stimulation mix, which triggers T cell division by crosslinking carbohydrates 
on cell surface receptors, including the TCR (Chilson, Boylston and Crumpton, 1984). Since 
the specificity of TCRs present on individual T cell clones derived from PBL was unknown, 
PHA served to mimic TCR-specific T cell activation. Utilizing this expansion method, the 
number of well-proliferating CEA-CAR_CD4-expressing T cell clones (n = 31) was much higher 
than T cell clones transduced with CEA-CAR_CD8 (n = 9). This was observed for PBL derived 
from two donors in two independent experiments (not shown). In particular, a large number of 
CD4+ T cell clones expressing CEA-CAR_CD4 exhibited fast expansion rates, while this was 
not necessarily the case for CEA-CAR_CD8-transduced CD4+ T cell clones. However, the 
number of well proliferating CD8+ T cell clones was comparable when transduced with either 
of the CAR constructs. These observations would suggest that T cells, in particular CD4+ T 
cells, expressing 4-1BB-comprising CAR constructs have a proliferative advantage even in the 
absence of CAR-specific activation. This antigen-independent increased proliferative capacity 
of T cells has also been observed for -CD19 CARs carrying the 4-1BB signaling domain and 
was contributed to tonic signaling due to the continuous presence of a 4-1BB domain on the 
cell surface (Milone et al., 2009).  
To examine proliferative capacity of the T cell clones upon CAR engagement, four 
representative T cell clones from each approach were selected for further evaluation. CAR-
driven proliferation was monitored after incubation with CEA-expressing CAR target cells and 
compared to expansion via a PHA-containing stimulation mix that was used for initial 
expansion of the individual T cell clones. CellTrace Violet staining allowed the monitoring of 
cell division 3 and 7 days after TCR or CAR-specific activation, respectively (Figure 4.10). 
While T cells stimulated via CAR engagement showed higher proliferation rates 3 days after 
co-culture with CAR target cells, expansion was comparable after 7 days independent of the 
type of stimulation. This was further confirmed by fold expansion 11 days after activation 
demonstrating that engagement of the introduced CAR construct could induce maximal 
proliferation rates comparable to standard activation via PHA, which was termed TCR 
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stimulation (Figure 4.11a). However, while all T cell clones could be expanded via CAR 
engagement, CEA-CAR_CD4 transduced cells showed up to 20-fold expansion compared to 
CEA-CAR_CD8-expressing cells, which exhibited a maximal 10-fold expansion rate. This 
supports the hypothesis that 4-1BB-containing CAR constructs promote T cell proliferation 
better than CARs carrying CD28 signaling domains. Additionally, expansion rates of CD4+ T 
cell clones was slightly higher compared to CD8+ T cell clones transduced with the same CAR 
construct. However, as observed before, T cell proliferation did not correlate with IFN- release 
observed upon CAR engagement (Figure 4.11b). All T cell clones showed antigen-specific 
secretion of IFN- to varying degrees, demonstrating that the transduced CAR constructs were 
present on the cell surface and specifically recognized the CEA antigen. While T cell clones 
stimulated via PHA exhibited much higher antigen-specific IFN- release compared to cells 
activated via CAR engagement, expansion rates were comparable. This suggests different 
activation states of the respective T cell clones dependent on TCR or CAR engagement 11 
days after stimulation. For stimulation via TCR, it has been shown that the activation threshold 
shifts to lower antigen concentrations with the duration of the last antigen encounter (Hesse et 
al., 2001). Similar effects might be seen for CAR engagement, where T cell clones stimulated 
via PHA were more responsive to CEA antigen, which they did not encounter in the previous 
stimulation cycle.  
These experiments clearly demonstrated that CD4+ as well as CD8+ T cell clones could be 
expanded via CAR engagement with proliferation rates comparable to standard T cell 
expansion protocols in vitro. However, after knockout of the endogenous TCR, the CAR-
expressing T cell clones could not be expanded via CAR engagement and did not survive the 
expansion period (Figure 4.12). This was observed in two independent experiments regardless 
of T cell subset affiliation and transduced CAR construct. Expansion of TCR-knockout T cells 
via CAR engagement has not been shown on a single cell level yet, therefore it can not be 
excluded that intrinsic mechanisms connected to signaling and regulation of the CAR 
constructs were responsible for the failed expansion. Additionally, most of the studies 
regarding CAR functionality in T cells were performed utilizing cells that still did express the 
endogenous TCR (Milone et al., 2009; Hombach and Abken, 2011; Hudecek et al., 2015; 
Sommermeyer et al., 2015). However, recent publications could show that CD19-CAR 
integration into the TRAC locus of PBL is feasible to generate CAR-expressing T cells that lack 
the endogenous TCR and do not exhibit impairment of proliferation or functionality (Eyquem 
et al., 2017; MacLeod et al., 2017). Both approaches utilized CAR constructs recognizing 
CD19, which is highly expressed on B cells that naturally interact with T cells. Based on these 
observations, the failed expansion of TCR-deficient T cell clones via CEA-CARs might be 
attributed to CEA-positive target cells (LS174T) used in the experiments. CEA is a glycoprotein 
associated with cell adhesion, which is normally only expressed during fetal development and 
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serves as a marker for colorectal cancer in adults (Duffy, 2001). While the restricted expression 
of CEA on tumors makes it a suitable target for cancer immunotherapy, available CEA-
expressing cell lines are consequently adherent tumor cell lines, like LS174T. Due to their 
growth behavior and potential expression of inhibitory molecules characteristic for tumor cells, 
these adherent tumor cells might not be favorable for the purpose of T cell expansion from low 
cell numbers. Nevertheless, proliferation could be induced in isolated CEA-CAR-expressing T 
cell clones in the presence of LS174T tumor cells from cell numbers as low as 1 x 105 (Figure 
4.10). However, the low number of TALEN-modified T cells that were isolated after 
electroporation might be affected more drastically by the unfavorable culture conditions 
produced by LS174T cells. In order to test this hypothesis, new chimeric constructs were 
generated that would allow the activation of modified T cell clones in the presence of LCL, 
which are rich in co-stimulatory molecules and should therefore create a more favorable 
environment for T cell expansion.  
 
5.4 Process improvements 
To improve the survival of TCR-deficient T cell clones after the TCR knockout has been 
performed utilizing the TALEN technology, two new constructs were generated that were used 
for T cell expansion in the absence of the endogenous TCR. These included a previously 
published CD19-CAR as well as a newly developed chimeric construct, termed CD3-Chimera. 
Additionally, the phenotype of T cell clones expanded via CAR engagement was evaluated to 
determine if a given T cell subset would exhibit superior proliferative capacity when stimulated 
independent of the endogenous TCR. These cells could serve as a basis for universal recipient 
cells and would allow a pre-selection for T cell clones exhibiting desired characteristics for 
prolonged in vitro expansion. Based on results obtained with the newly generated CD19-CAR 
and CD3-Chimera construct, a new high-throughput strategy for the generation of universal 
recipient cells was established that allowed immediate identification of suitable TCR-deficient 
T cell clones and shortened the in vitro expansion period.  
 
5.4.1 Expansion of molecular toolbox 
The CD19-CAR was generated based on the structure published by Hudecek et al. and 
comprised a CD28 transmembrane domain followed by a 4-1BB signaling domain, which 
should support T cell survival and expansion as demonstrated in clinical studies and in vitro 
analyses (Milone et al., 2009; Porter et al., 2011; Hudecek et al., 2015). Successful 
transduction could be monitored by eGFP expression and the functionality of the CAR 
construct was confirmed by IFN- release upon co-culture with CD19-expressing LCL (Figure 
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4.14a, b). Initial expansion of CD19-CAR-expressing single cell clones demonstrated that 
proliferation rates comparable to activation via the TCR complex could be achieved in CD4+ 
as well as CD8+ T cell clones when exposed to CD19-positive B cell lines (Figure 4.14c). This 
demonstrated that the CD19-CAR construct was able to support expansion of individual T cell 
clones like the CEA-CAR constructs used previously.  
The CD3-Chimera construct was designed based on crystal structures that demonstrated 
native folding of CD3 and CD3 dimeric ectodomains in complex with bound -CD3 
antibodies recognizing the CD3 subunit (Arnett, Harrison and Wiley, 2004; Kjer-Nielsen et al., 
2004). Another study by Law et al. additionally showed that CD3  and  subunits could be 
expressed as a soluble scF to generate epitopes recognizable by mitotic -CD3 antibodies 
(Law et al., 2002). Based on these data, a scFv fragment was designed that linked the CD3 
to the CD3 ectodomain via a flexible (Gly4Ser)3 linker. To avoid oligomerization and disulfide 
scrambling, the conserved stalk domains were not included in the construct (Kim et al., 2000; 
Sun et al., 2001; Law et al., 2002). Instead, the CD8 hinge region was fused to a CD28 
transmembrane region to enable expression of a monomeric unpaired protein on the plasma 
membrane. To provide signaling that would mimic the physiological activation through the TCR 
complex, the CD3 domain was added to the intracellular part of the chimeric protein (Figure 
4.15). In contrast to conventional CAR constructs that were designed for tumor cell killing 
through recognition of a specific antigen, the CD3-Chimera does not bind any target and should 
therefore abolish the risk of off-target recognition. The proposed mode of action includes the 
activation of TCR-deficient T cells via binding of mitotic -CD3 antibodies to the CD3-Chimera 
construct analogous to standard unspecific in vitro expansion of T cells. To enable 
physiological T cell proliferation, co-stimulation by engagement of CD28 has to be provided in 
the form of -CD28 antibodies or by natural binding of CD80 and CD86 molecules present on 
antigen presenting cells. Since T cells endogenously express CD3 on the cell surface, the 
functionality of this chimeric construct could only be evaluated in TCR-deficient T cells after 
the knockout of the endogenous TCR. However, expression and native folding could be tested 
in the TCR-deficient T cell lymphoma cell line Jurakt-76 (Figure 4.17). These cells have lost 
their ability to provide basic T cell effector functions and do not express endogenous CD3 
(Heemskerk et al., 2007; Bürdek, 2009). After transduction of Jurkat-76 cells with the chimeric 
construct, CD3-Chimera expressing cells could be detected by -CD3 antibody staining, which 
demonstrated native folding based on recognition of the -CD3 epitope usually present in 
endogenously expressed CD3. Isolated single cell clones transduced with CD3-Chimera 
showed that expression levels could vary between individual clones. While some clones 
exhibited high expression levels reflected by distinct CD3-positive populations, others showed 
just small shifts compared to the negative control, which suggested low expression levels. 
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Differences in the levels of the CD3-Chimera construct expression might result from different 
copy numbers present in the individual host genomes or respective integration sites of these 
randomly integrating retroviral vectors. Dependent on target loci, the integrated provirus can 
be subject to transcriptional silencing, which has been associated with mechanisms like DNA 
methylation or histone modification (Swindle and Klug, 2002; Ellis, 2005). Compared to -CD3 
staining, eGFP expression levels also varied in individual clones, but were much lower as 
reflected by low median FI values. Even though the P2A element coupling CD3-Chimera and 
eGFP should ensure equimolar expression levels, it has been shown that protein expression 
can be decreased at the second gene position compared to the first gene position in bicistronic 
constructs, probably due to discontinued translation (Osborn et al., 2005; Liu et al., 2017). 
Nevertheless, eGFP could be still used as a marker to identify high-expressing CD3-Chimera 
cells. In summary, the results demonstrated that the designed CD3-Chimera construct was 
folded correctly and expressed on the cell surface of TCR-deficient Jurkat-76 cells, even 
though expression levels could vary between individual clones.  
 
5.4.2 Phenotypic evaluation of CAR-transduced T cells 
To evaluate whether certain T cell subsets exhibit proliferative advantages in vitro, CAR-
expressing CD4+ and CD8+ T cell clones showing either low or high proliferation rates, 
respectively, were analyzed for their phenotypes (Figure 4.18). According to common T cell 
markers, all T cell clones were characterized as effector memory T cells exhibiting a 
CD4+/CD8+ CD45RA- CD62L- CD95+ phenotype. All isolated T cell clones showed the same 
phenotype after several weeks of in vitro culture. This is consistent with observations of in vitro 
cultured PBL derived from different T cell subsets and probably reflects the principle of T cell 
differentiation upon repeated activation in the presence of IL-2 (Foster et al., 2008; Gattinoni, 
Klebanoff and Restifo, 2012; Schmueck-Henneresse et al., 2017).  
It has been shown that transgenic TCR- or CAR-transduced T cells derived from the central 
memory compartment exhibited better proliferative capacity, effector function and persistence 
in vivo compared to cells derived from the effector compartment (Berger et al., 2008; Gattinoni 
et al., 2011; Graef et al., 2014; Sommermeyer et al., 2015). However, whether this superior 
expansion and prolonged survival would also be observed for T cell clones originating from the 
central-memory subset after prolonged culture in vitro has not been investigated yet. Since 
these properties would be essential when generating universal recipient T cells, the 
proliferative capacity of CD19-CAR-expanded T cell clones derived from distinct T cell subsets 
was evaluated. Based on previous observations, the phenotype of T cells after several weeks 
in culture allowed no conclusion concerning the T cell subset from which they originated. 
Therefore, the CD19-CAR transduced PBL were labeled with -CD45RA and -CD62L 
Discussion  
107 
antibodies at the time of sorting, which enabled their classification into distinct T cell subsets 
retrospectively by analyzing index sort data acquired by the BD FACSDivaTM Software (BD 
Bioscience). The majority of CD4+ and CD8+ CAR-transduced T cell clones that expanded 14 
days after FACS were derived from the naïve or central-memory compartment, which simply 
reflected the mean T cell subset distribution in two donors (Figure 4.19a). To further evaluate 
the impact of T cell compartment origin on proliferation, 48 selected single cell clones were 
expanded via CAR engagement and classified as excellent, good or poor expanding T cell 
clones, respectively, 28 days after sorting (Figure 4.19b). In all three groups, the majority of 
the cells were derived either from the naïve or central-memory subset independent of their 
proliferation rate. Additionally, T cell clones originating from the effector-memory or effector 
compartments also exhibited good or excellent expansion rates, respectively, while 
frequencies were comparable to poorly proliferating cells. If T cell clones derived from the 
central-memory subset would show superior proliferation rates in vitro, as observed for in vivo 
experiments, it would have been expected to find fewer cells derived from the effector-memory 
or effector compartments exhibiting good or excellent expansion rates. Therefore, no 
correlation could be observed between T cell subset origin and proliferative capacity in vitro. 
The distribution of T cell compartment descent in the three expansion categories simply 
mirrored the percentages already observed at the time of sorting. The experimental procedure 
additionally revealed that only 12% and 21% of the selected T cell clones exhibited excellent 
or good expansion rates, respectively. However, the majority of the cells could not be 
expanded to sufficent numbers, rendering them unsuitable for use in an in vitro test system. 
This demonstrated that the fraction of cells exhibiting superior proliferative capacity is rather 
low and could not be identified based on T cell subset origin. Whether other factors, like telomer 
length, metabolism or alternative signal transduction due to the presence of the CAR, might 
contribute to better survival in vitro needs to be evaluated. To avoid exclusion of potentially 
suitable T cell clones for generation of universal recipient cells, bulk PBL were used for further 
experiments without focusing on a certain T cell subset as starting material.  
 
5.4.3 New strategy for the generation of universal recipient cells 
The collective results obtained from experiments performed with CAR-transduced T cell clones 
enabled the setup of expansion procedures for stimulation via CAR engagement independent 
of the endogenous TCR and served as a preliminary proof of principle. However, they also 
revealed shortcomings of the procedure that needed to be resolved to successfully generate 
universal recipient T cells. This included the failed expansion of CEA-CAR-transduced T cells 
from small cell numbers after electroporation with TALEN pairs. Based on the assumption that 
the nature of the CEA-CAR target cells might create an unfavorable environment for T cell 
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expansion, this should be circumvented by utilizing the newly generated CAR constructs, 
CD19-CAR and CD3-Chimera, which mediate activation of T cells in the presence of LCL 
equipped with co-stimulatory molecules. Another factor that could impact T cell clone survival 
is repeated clonal expansion required to (I) identify T cell clones exhibiting superior proliferative 
capacity upon CAR-specific stimulation and to (II) subsequently determine the TCR knockout 
status of CAR-expressing T cell clones. The requirement of expanding selected recipient cells 
from a single T cell clone twice could substantially prolong the in vitro culture period and 
probably considerably shortens the life span of the isolated T cells. However, determining the 
TCR knockout status is imperative in order to create a fully characterized and reproducible test 
system for the direct comparison of transgenic TCRs. Recent studies published by various 
groups predominately focused on disruption of the TRAC locus in bulk PBL to avoid expression 
of the endogenous TCR in CAR-engineered T cells for cancer therapy (Poirot et al., 2015; 
Eyquem et al., 2017; MacLeod et al., 2017; Ren et al., 2017). In these studies, CARs rather 
than a transgenic TCR were introduced in the generated TCR-deficient cells to redirect T cell 
specificity. Therefore, the risk of TCR mispairing could be neglected and targeting only one 
TCR chain was sufficient to prevent expression of the endogenous TCR.  However, when 
introducing a transgenic TCR in universal recipient cells for functional characterization, a 
knockout of both TCR chains is needed in order to avoid the risk of TCR chain mispairing. This 
entails that two separate gene segments (TRAC and TRBC) had to be targeted in a single cell 
simultaneously rather than sequentially to circumvent an additional round of clonal expansion.  
In order to shorten the in vitro culture period and avoid repeated clonal expansion, a new 
strategy was developed, which would generate T cell clones that could be directly selected for 
essential criteria characterizing desired universal recipient cells. These criteria included: (I) 
knockout of the endogenous TCR, which could be monitored by loss of CD3 expression and 
(II) high expansion rates via CAR engagement in the absence of the endogenous TCR. To 
achieve an early selection of T cells clones exhibiting these criteria, the strategy was modified 
to allow simultaneous TCR targeting and CAR introduction in one stimulation cycle (Figure 
4.20). The generated T cell clones could immediately be screened for TCR knockout and CAR 
expression by antibody staining and subsequent expansion of the sorted cells enabled the 
direct identification of T cell clones exhibiting the ability to proliferate solely via CAR 
engagement. The process was integrated into the automated workflow platform EVO200 to 
allow the high-throughput screening of various candidate T cell clones displaying the required 
criteria to become universal recipient cells (Figure 4.21). In order to genetically modify 
candidate T cell clones only once at the beginning of the procedure, the constant regions of 
both TCR chains (TRAC and TRBC) were targeted simultaneously by introducing both TALEN 
pairs targeting the TCR  and  chain, respectively. Utilizing this strategy, the generated T cell 
clones would only need to be expanded once from a clonal level, which simultaneously ensures 
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that the expanded T cells derived from a single T cell clone all have the same modifications in 
TRAC and TRBC gene segments.  However, while ensuring that all descendants of selected 
T cell clones exhibit the same genotype, targeting both TCR chains at the same time also 
implies that the TCR knockout status of individual T cell clones had to be determined at a later 
time point. Depending on TALEN activity, the resulting T cell clones could comprise one of 
three possible knockout states: (I) knockout of both TCR chains ( +  KO), (II) knockout of 
only the TCR  chain ( KO) or (III) knockout of only the TCR  chain ( KO). Because cells 
comprising any possible knockout status would exhibit the same CD3-negative phenotype, the 
successful targeting of either TCR chain could only be determined by DNA sequencing. 
Therefore, a high-throughput NGS procedure was developed for the determination of the TCR 
knockout status that allowed the identification of unique mutations in TRAC and TRBC loci of 
each individual T cell clone (Figure 4.26). This enabled a detailed analysis of the modifications 
introduced by targeting the respective TCR chains utilizing TALEN pairs. In contrast, the 
analysis of TCR knockout in bulk T cell populations can not be performed on a single cell level 
and rather represent a quantification of the general knockout efficiency. Generally, the T7 
endonuclease assay is used to detect mutations in the TRAC and TRBC loci of mixed PBL, 
which is based on the preference of T7 endonuclease to cleave heteroduplex DNA (Osborn et 
al., 2016; Knipping et al., 2017). Subsequent topo cloning of PCR fragments followed by 
sequencing can only give a general overview over mutations that occurred. Additionally, when 
targeting both loci simultaneously, identification of T cells comprising a knockout of both TCR 
chains is not feasible with this method. For this reason, Berdien et al. developed a strategy 
that would allow the sequential targeting of respective loci, while a successful knockout is 
monitored via CD3-staining. In this protocol TCR -deficient T cells are transduced with 
transgenic TCR  chain, which enables enrichment due to re-expression of CD3 on the cell 
surface, followed by subsequent TCR  knockout and introduction of the transgenic TCR  
chain (Berdien et al., 2014). While this ensures the generation of T cells expressing the 
transgenic TCR that carries a knockout of both TCR chains, the procedure has to be repeated 
for each transgenic TCR. This should be circumvented by generating universal recipient cells 
that proliferate independently of TCR expression and that are ready-to-use for the introduction 
of various transgenic TCRs.    
 
5.5 Characterization of TCR-deficient T cell clones 
In order to serve as a suitable test system for transgenic TCRs, TCR-deficient universal 
recipient cells that proliferate to high cell numbers upon CAR engagement have to exhibit all 
effector functions required for a physiological read-out. This implies that antigen specificity, 
killing capacity and functional avidity of universal recipient cells has to be redirected by the 
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introduced transgenic TCR. Several candidate universal recipient cells either expressing the 
CD19-CAR or CD3-Chimera construct, respectively, were evaluated for their capacity to 
display effector functions conferred to the cells by transgenic TCRs.  
 
5.5.1 CD19-CAR 
Utilizing the CD19-CAR construct, the new high-throughput approach for the generation and 
identification of suitable universal recipient cells could be successfully implemented (Figure 
4.21). The enrichment of  T cells prior to introduction of TALENs and transduction of the 
CD19-CAR ensured that no other cell types, like  T cells, present in bulk PBL would be 
included in the procedure (Figure 4.22). The simultaneous TCR knockout and CD19-CAR 
introduction could be monitored in subsequent flow cytometric analysis. Utilizing the sorting 
strategy described in Figure 4.23a, T cell clones exhibiting the desired phenotype could be 
single-cell sorted to allow clonal expansion of T cell clones that can proliferate upon interaction 
with CAR target cells, independent of the endogenous TCR. Screening of the expanded single 
cell clones, utilizing flow cytometry in combination with HTS, demonstrated that the new high-
throughput strategy resulted in the isolation of high numbers of T cell clones that comprised 
TCR knockout cells while expressing the introduced CAR (Figure 4.24). 7% of the T cell clones 
did exhibited no, 15% only incomplete TCR knockout and were mistakenly sorted utilizing the 
described strategy. These cells were transduced with the CD19-CAR and could therefore 
proliferate in the presence of CAR target cells. While the presence of the CD19-CAR could 
only be monitored via eGFP expression from a bicistronic construct that sometimes results in 
lower expression of the second gene, it is assumed that actual CD19-CAR expression was 
higher than reflected by detection of eGFP (Osborn et al., 2005; Liu et al., 2017). Numerous T 
cell clones (n = 158), exhibiting the desired phenotype while showing good proliferative 
capacity, were selected for NGS analysis. After excluding some datasets due to low read 
count, the majority of the cells exhibited a knockout of the TCR  or  chain, respectively. 
While single-chain knockouts were prominent, only nine T cell clones could be identified that 
showed successful targeting of both TCR chains. This indicated that the efficiency for targeting 
both TCR chains simultaneously is much lower compared to targeting each TCR chain 
separately, where knockout rates of up to 20% could be achieved (Figure 4.6). This might be 
due to the fact that for a double knockout to occur, four relatively large ivt-RNAs (ca. 2.8 kb), 
coding for the two TALEN pairs, have to enter the cell simultaneously. While all TALEN ivt-
RNAs have been mixed prior to electroporation, allowing a homogenous distribution, four 
TALEN ivt-RNAs might border on nucleotide levels toxic for the electroporated cells, thereby 
reducing the number of cells that survive the procedure. In total, 20 T cell clones were selected 
for further analysis, which included the nine T cell clones exhibiting the knockout of both TCR 
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chains and 11 T cell cones that comprised either the knockout of the TCR  or  chain, 
respectively. One CD4+ T cell clone transduced with the CD19-CAR, that lacked any 
modification of the TRAC or TRBC locus, was also included as a control to identify possible 
effects on proliferation when the endogenous TCR is absent in CAR-transduced cells. While 
ten CD4+ and ten CD8+ T cell clones were selected to monitor expansion over a 56-day period, 
only six CD4+ T cell clones proliferated sufficiently to be of use for an in vitro test system (Figure 
4.30). The other 12 T cell clones, which included all the isolated CD8+ T cell clones, did not 
survive the expansion period. This poor survival of CD8+ T cell clones in vitro is also a concern 
when isolating tumor-specific cytotoxic T cells for use in immunotherapy and the reason why 
strategies for fast identification of suitable CD8+ T cell clones and the rapid isolation of the 
corresponding TCR sequences have been developed (Wilde, Sommermeyer, et al., 2012; 
Dössinger et al., 2013; Simon et al., 2014). Additionally, better expansion of CD4+ bulk PBL, 
transduced with an CD19-CAR, compared to CD8+ PBL has also been observed by 
Sommermeyer et al. (Sommermeyer et al., 2015). This effect might be pronounced on a clonal 
level and might explain why isolated CD4+ T cell clones show better survival compared to CD8+ 
T cell clones in vitro.  
A summary of the knockout status for the seven T cell clones exhibiting the highest proliferation 
rates is shown in Table 4.1. Clone CD4+_50 served as a control to validate the NGS results 
and carried no modification of either TCR chain. The other clones contained either mutations 
in both TCR chains or only in the TRBC locus, respectively. The two T cell clones CD4+_74 
and CD4+_17 exhibited the best expansion rates via CAR engagement, comparable to the 
control CD4+_50, while carrying mutations in both TCR chains. This indicated that the lack of 
the endogenous TCR did not have a negative impact on proliferation, although proliferation 
rates of individual T cell clones could vary (Figure 4.30).  
All T cell clones, except for the control CD4+_50, exhibited the desired CD3-negative 
phenotype, demonstrating the absence of the endogenous TCR from the cell surface, while 
still expressing the co-receptor CD4 or CD8, respectively (Figure 4.31). Knockout of the 
endogenous TCR did not have any effect on other cell surface markers characterizing the T 
cell clones CD4+_74, CD4+_24, CD4+_17 and CD8+_62 as effector-memory T cells, as 
observed before for in vitro cultured T cells (Figure 4.32). However, the T cell clones CD4+_54 
and CD4+_46 expressed CD45RA, categorizing them as terminally differentiated effector T 
cells. Interestingly, clone CD4+_54 additionally expressed CD62L at low levels, which is 
normally expressed on naive or central-memory T cells (Golubovskaya and Wu, 2016). 
However, there is evidence for heterogeneity of CD62L expression among the effector-
memory CD4+ T cell compartment (Sallusto et al., 1999; Ahmadzadeh, Hussain and Farber, 
2001). While low CD62L expression has been shown to indicate high proliferative capacity, 
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resembling effector cells; high CD62L expression was indicative for resting memory T cells 
exhibiting lower proliferative capacity (Sallusto et al., 1999; Ahmadzadeh, Hussain and Farber, 
2001). Since the described cells have been cultured in vitro over multiple simulation cycles, it 
is not clear to which extent T cell compartment affiliation is accurate and representative for T 
cell effector function.  
In order to evaluate the effector functions of these TCR-deficient T cell clones, a well-
characterized TCR recognizing the NY-ESO-1157-165 peptide (SLLMWITQC; HLA-A2-restricted) 
was introduced into four selected T cell clones. Staining of the specific TCR-V chain in 
combination with CD3 demonstrated simultaneous expression of the transgenic TCR and re-
expression of endogenous CD3 on the cell surface of the transduced T cell clones (Figure 
4.33c). The specificity of all four T cell clones could be redirected by the transgenic TCR, which 
was reflected by specific IFN- release upon co-culture with NY-ESO-1-expressing Mel624.38 
tumor cells (Figure 4.33b). Co-culture with CD19-expressing LCL served as a positive control 
to measure IFN- secretion induced by CAR-specific activation. All T cell clones, except for 
clone CD4+_17, showed recognition of CD19-CAR target cells reflected by release of high 
amounts of IFN-. Clone CD4+_17 did not secret IFN- upon co-culture with CD19-positive 
LCL, even though the T cell clone could be successfully expanded utilizing the same target 
cells. This phenomenon has already been observed in the established CD4+ T cell clone, 
Clone 234, transduced with CEA-CAR_CD8, which did not release IFN- upon encounter of 
CAR target cells while the same cells induced proliferation via the transduced CAR (Figure 
4.4). In both cases, recognition of antigen presented by MHC molecules via the TCR resulted 
in high amounts of IFN- secretion. While these CD4+ T cell clones are generally able to 
produce IFN-, activation via the CAR construct might not result in IFN- transcription due to 
altered signal transduction. IFN- secretion is normally induced by binding of the master 
regulator for Th1 differentiation, T-bet, to the IFN- promoter site. T-bet, in turn, is induced by 
TCR engagement or cytokine-mediated signaling (Placek et al., 2009; Lai et al., 2011; Zhu et 
al., 2012). Even though the absence of IFN- secretion upon CAR engagement has not been 
reported before, this phenomenon might not be detectable in bulk PBL. However, the results 
obtained here for individual T cell clones suggest that signal transduction via CAR 
engagement, independent of the intrinsic CAR-signaling domains, might be altered for distinct 
CD4+ T cells without affecting proliferative capacity of these cells. Since CARs are artificially 
assembled receptors that mediate T cell activation via mechanisms yet to be determined, 
alterations of the signaling pathways associated with proliferation and effector function might 
occur (Harris and Kranz, 2016).  
It has been demonstrated that the effector functions, including tumor cell killing and cytokine 
secretion, can be transferred to recipient cells by an introduced transgenic TCR (Wilde et al., 
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2009; Wilde, Sommermeyer, et al., 2012). While this was reflected by specific IFN- release of 
all four NY-ESO TCR-expressing T cell clones, only two of the T cell clones could be redirected 
by the NY-ESO TCR to target NY-ESO-1-positive tumor cells. T cell clone CD4+_17, 
specifically killed NY-ESO-1-expressing tumor cells, while not inhibiting the outgrowth of NY-
ESO-1-negative 647-V cells (Figure 4.33a). This was also observed for T cell clone CD4+_74, 
whose killing capacity was even higher, reflected by faster decay in Mel624.38 cell count. 
However, T cell clones CD4+_54 and CD4+_46, which specifically produced IFN- in response 
to NY-ESO-1-expressing tumor cells and CAR target cells, were not able to inhibit outgrowth 
of NY-ESO-1-positive tumor cells. These T cell clones differed from cytolytic CD4+ T cell clones 
regarding their phenotype, which was characterized by expression of CD45RA in both T cell 
clones and additional CD62L expression in clone CD4+_54 (Figure 4.32). However, whether 
expression of these cell surface markers might indicate reduced killing capacity is not clear. 
The different killing capacities observed for CD4+ T cell clones transduced with the same NY-
ESO TCR indicated that the introduced transgenic TCR could not redirect the effector functions 
of all T cell clones sufficiently. However, in contrast to previous studies, effector functions 
mediated by a MHC class I-restricted TCR were tested not in CD8+ T cells, but in CD4+ T cell 
clones. CD4+ T cells are generally known to help mediate adaptive immune responses rather 
than exhibiting specific killing capacity. However, a CD4+ T cell subset with   cytotoxic activity 
has been observed, that targets tumor cells in an MHC class II-restricted manner. While this 
subset has been thought to be an artifact of long-term in vitro culture, increasing evidence 
demonstrated their importance in antiviral and anti-tumor immunity in vivo (Takeuchi and Saito, 
2017). Whether MHC class II-restricted TCRs derived from these cytotoxic CD4+ T cells can 
transfer killing capacity to all CD4+ T cells when transgenically expressed is not clear. However, 
the fact that the transgenic NY-ESO TCR could confer killing capacity only to some CD4+ T 
cell clones might suggest intrinsic lineage-dependent transcriptional programs that can not be 
changed by introduction of transgenic TCRs. Therefore, NY-ESO TCR-transduced T cell 
clones exhibiting cytolytic activity might derive from CD4+ T cell clones that already possessed 
cytolytic capacities prior to introduction of the transgenic TCR.   
Since no CD8 co-receptor is present in these CD4+ T cells, the transgenic NY-ESO-1-specific 
TCR has to mediate antigen recognition in a co-receptor independent manner. The co-
receptors CD4 and CD8 augment the sensitivity and reactivity of T cells to cognate peptide-
MHC complexes by stabilizing the interaction and recruitment of Lck to the TCR complex 
(Veillette et al., 1989). However, it has been shown that the extent of co-receptor dependency 
is inversely correlated to affinity of TCR s to peptide-MHC complexes (Holler and Kranz, 2003; 
Laugel et al., 2007; Artyomov et al., 2010). TCRs exhibiting high affinity to peptide-MHC 
complexes, are less or non-dependent on the presence of CD8 co-receptor, while TCRs 
exhibiting affinities typical for syngeneic interactions require CD8 co-stimulation (Munz et al., 
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1999; Wilde et al., 2009). This demonstrated that the generated recipient cells can be used to 
test co-receptor dependency of transgenic TCRs. For clinical application, transgenic TCRs 
showing no dependency on the CD8 co-receptor could broaden the spectrum of reactive T 
cells in a non-enriched clinical PBL product because the transgenic TCR would be functional 
in CD4+ as well as CD8+ T cells.  
The results demonstrated that two of the CD19-CAR-expressing CD4+ T cell clones, CD4+_74 
and CD4+_17, can be used as suitable test system for MHC class-I transgenic TCRs that do 
not show co-receptor dependency. The two T cell clones carry mutations in both TCR chains 
preventing the expression of an endogenous TCR. Therefore, transgenic TCR expression can 
be tested in these recipient cells without the risk of TCR mispairing or negative influences 
originating from dominant endogenous TCR expression. This enables the validation of correct 
assembly and expression of transgenic TCR constructs that have been reconstructed from 
isolated TCR sequences in silico. Additionally, isolated transgenic candidate TCRs, derived 
from cytotoxic CD8+ T cells, can be evaluated for co-receptor dependency in these CD4+ T cell 
clones. Transgenic TCRs that can transfer effector functions without requirement for the CD8 
co-receptor, can be characterized for specificity and killing capacity in the generated TCR-
deficient CD4+ T cell clones.  
 
5.5.2 CD3-Chimera 
Activation of T cells transduced with the CD3-Chimera construct was mediated by binding of 
the -CD3 antibody to the chimeric construct in presence of co-stimulation provided by LCL 
and feeder cells. Utilizing the new strategy comprising simultaneous knockout and transduction 
of the construct, only a small number of T cell clones could be isolated compared to the CD19-
CAR approach. While this low recovery could be due to ineffective activation mediated via the 
CD3-Chimera, another likely explanation is based on the low transduction rate observed in 
Figure 4.23. In contrast to the CD19-CAR construct, the sorting strategy comprised the gating 
on T cells exhibiting lack of TCR expression while -CD3 antibody should bind to the CD3-
Chimera construct. However, less than 1% of the T cells showed the desired phenotype and 
expressed eGFP, that indicated a successful transduction with the CD3-Chimera construct. 
While the TCR knockout efficiency mediated by TALEN pairs was sufficient to generate nearly 
30% TCR-negative T cells, the transduction procedure needs optimization to obtain higher 
transduction rates and increase the yield of TCR-deficient CD3-Chimera-expressing T cell 
clones.    
The two T cell clones, CD8+_001 and CD8+_002, that could be expanded over the 56-day 
expansion period exhibited high proliferation rates, which were comparable or even higher 
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than the positive control CD4+_50 (Figure 4.34a). In contrast to the CD19-CAR approach, 
where only CD4+ T cell clones could be expanded, the two CD3-Chimera-transduced T cell 
clones were both derived from the CD8 compartment. The high 40 – 50-fold expansion could 
only be observed when OKT-3 was present in the stimulation-mix (Figure 4.34b). This 
demonstrated that proliferation in these TCR-deficient T cell clones had to be induced by 
binding of OKT-3 antibody to the introduced CD3-Chimera construct. Cells that were 
stimulated without the addition of OKT-3 antibody exhibited highly reduced proliferation rates 
with only 9-fold expansion 10 days after activation. This moderate proliferation of T cells 
mediated only via CD28 engagement in the presence of IL-2 has been observed previously 
and was attributed to a possible mechanism for memory T cell homeostasis in the absence of 
antigen (Flynn and Müllbacher, 1997; Siefken et al., 1998). In another study, activation of TCR-
negative PBL utilizing CD3/CD28 beads resulted in only 5-fold expansion due to lack of TCR 
expression, whereas the low proliferation rates observed were also attributed to CD28 co-
stimulation (Berdien et al., 2014; Osborn et al., 2016). Taken together, these results allowed 
the conclusion that the observed high expansion rates of CD3-Chimera-transduced T cell 
clones, lacking endogenous TCR expression, was mediated by binding of OKT-3 antibody to 
the CD3-Chimera construct.  
According to results obtained from NGS analysis, clone CD8+_001 displayed mutations in the 
TCR  chain, while CD8+_002 contained modifications in the TCR  chain (Table 4.2). In both 
cases, base deletions in the TCR constant region resulted in a frame-shift mutation that 
introduced a pre-mature stop codon in the amino acid sequence, thereby preventing cell 
surface expression. This was consistent with the observed TCR-negative phenotype (Figure 
4.35a). However, while both T cell clones expressed eGFP, indicating successful transduction 
of CD3-Chimera construct, the construct could not be detected using -CD3 antibody. The 
utilized -CD3 antibody was derived from clone UCHT-1, which is described to bind the CD3 
subunit present in the CD3-Chimera construct (Arnett, Harrison and Wiley, 2004). To exclude 
that this -CD3 antibody used for detection might be responsible for the unsuccessful staining 
of the CD3-Chimera construct, the staining was repeated using an antibody derived from clone 
OKT-3 (Figure 4.35b). As demonstrated in Figure 4.34b, this mitotic -CD3 antibody was 
successfully used for expansion of TCR-deficient T cell clones and should therefore bind the 
CD3-Chimera construct. However, the CD3-Chimera construct could not be detected with 
either -CD3 antibody, independent of the hybridoma from which they were derived. This was 
a surprising observation, since the CD3-Chimera construct could be successfully detected in 
transduced Jurkat-76 utilizing the same antibodies, even though expression levels varied in 
different clones (Figure 4.17). In transduced Jurkat-76, low CD3-Chimera expression was 
connected to equally low eGFP expression. However, this could not be observed in the two 
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TCR-deficient T cell clones, that exhibited a distinct eGFP-positive population while the CD3-
Chimera could not be detected using the same -CD3 antibody concentrations. Increasing the 
-CD3 antibody concentration 5-fold resulted in a small positive shift of the CD8+_002 
population compared to the negative control (Figure 4.35c). This positive shift was also 
observed in CD3-expressing T cells used as positive control, which could be expected when 
exposing cells positive for the CD3 antigen to higher antibody concentrations. While this might 
indicate the presence of low of CD3-Chimera expression on the cell surface of transduced T 
cell clones, no distinct CD3-positive cell population could be observed. Whether CD3-Chimera 
expression was too low for detection or the construct assumed a conformation on the cell 
surface that did not allow binding of -CD3 antibody conjugated to fluorophores will need to 
be investigated in further experiments. However, more CD3-Chimera-expressing T cell clones 
need to be isolated in order to detect possible differences in cell surface expression levels 
already observed in Jurkat-76 clones. Additionally, the domain structure of the CD3-Chimera 
construct could be re-evaluated to determine whether the use of different hinge or 
transmembrane domains, like a IgG4-hinge or CD8 transmembrane domain, might improve 
expression levels. Unfortunately, Western blot analysis to determine expression of the 
construct on a protein level could not be performed due to the presence of the endogenous 
CD3 complex in T cells. Nevertheless, functionality and therefore binding of the structural 
epitope of mitotic OKT-3 antibody could be demonstrated by high expansion rates of the CD3-
Chimera-transduced T cell clones activated in the presence of OKT-3 antibody (Figure 4.34). 
Phenotypically, the two T cell clones resembled T cells of the effector-memory compartment, 
as previously observed for in vitro cultured T cell clones (Figure 4.36).  
While these CD3-Chimera-transduced T cell clones exhibited high proliferation rates in the 
absence of the endogenous TCR, their suitability as an in vitro test system had to be evaluated 
based on effector functions mediated by introduced transgenic TCRs. For this, two well 
characterized TCRs, T58 and D115, recognizing the same tyrosinase369-377 peptide 
(YMDGTMSQV; YMD) presented by HLA-A2 were transduced into the T cell clones CD8+_001 
and CD8+_002. While T58 is characterized as a TCR conferring high functional avidity in a 
transgenic setting, PBL expressing transgenic D115 showed lower functional avidity to the 
same target (Wilde et al., 2009). This difference in functional avidity allowed to estimate the 
sensitivity of the generated in vitro test system. By comparing killing capacity, IFN- secretion 
and functional avidity of the transduced T cell clones to bulk PBL expressing the transgenic 
TCRs, representing the standard test system, it could be evaluated whether effector functions 
conferred by the transgenic TCRs are adequately reflected in the generated universal recipient 
cells.    
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Both T cell clones, CD8+_001 and CD8+_002, transduced either with T58 or D115, specifically 
recognized and killed the tumor cells, while untransduced control cells did not inhibit outgrowth 
of Mel624.38 cells (Figure 4.37). Additionally, T58- and D115-transduced cells did not target 
tyrosinase-negative A375 tumor cells, indicating high specificity mediated by the transgenic 
TCRs. This demonstrated that both T cell clones could be successfully redirected by the 
introduced TCRs and displayed effector functions required to mediate target cell killing. While 
in CD3-Chimera-transduced T cell clones both TCRs eradicated tumor cells to a comparable 
level, D115-transduced PBL exhibited lower killing capacity compared to T58-expressing PBL. 
These observations were also reflected by specific IFN- release of transduced T cell clones 
and PBL when co-cultured with tyrosinase-positive tumor cells (Figure 4.38b). The T cell 
clones, CD8+_001 and CD8+_002, transduced with either TCR and T58-expressing PBL, that 
showed high tumor cell killing, secreted IFN- at the same level as the PMA/ionomycin control, 
that served as a measure for maximal T cell activation. In contrast, D115-transduced PBL 
released reduced amounts of IFN- when co-cultured with Mel624.38 tumor cells compared to 
the PMA/ionomycin positive control. This reduced IFN- secretion and killing capacity of PBL 
transduced with D115 TCR might be attributed to lower functional avidity compared to T58-
transduced PBL. In turn, this would also suggest that the generated CD3-Chimera-expressing 
T cell clones lacked sensitivity to reflect different functional avidities conferred by the two 
TCRs. However, when functional avidity was determined by exposure to graded amounts of 
peptides, universal recipient cells expressing either T58 or D115 exhibited different functional 
avidities dependent on the transgenic TCR present in the cells (Figure 4.38c). While T cells 
transduced with T58 were more sensitive and released half-maximal amount of IFN- at a 
peptide concentration of 10-8 M, D115-expressing cells required higher amounts of antigen to 
reach EC50. These results were comparable to the functional avidity measured in PBL 
transduced with the same TCRs and in accordance with previous observations by Wilde et al. 
when autologous PBL were used for peptide presentation (Wilde et al., 2009). Therefore, even 
though tumor cell recognition of CD3-Chimera-expressing T cell clones was comparable when 
mediated by T58 and D115 TCR, sensitivity for tyrosinase369-377 peptide reflected functional 
avidity of PBL transduced with the same TCRs.  
Unlike PBL transduced with the transgenic TCRs, D115-transduced T cell clones eradicated 
tyrosinase-positive tumor cells as efficiently as T58-expressing T cell clones. However, the 
generated universal recipient cells expressing the transgenic TCRs, T58 and D115, exhibited 
the expected sensitivity to tyrosinase369-377 peptide. Therefore, the differences in tumor cell 
killing could not be attributed to altered functional avidity mediated by transgenic TCR-
expressing universal recipient cells. However, the observed increased killing capacity of D115-
transdcued T cell clones might correlate with transgenic TCR expression levels in the 
respective recipient cells (Figure 4.38a). In both TCR-deficient T cell clones, CD8+_001 and 
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CD8+_002, expression of the specific TCR-V chain and binding of YMD-tetramer correlated 
with re-expression of endogenous CD3, which could not be detected in untransduced cells. 
Introduction of TCR D115 resulted in both T cell clones in distinct CD3+YMD-tertramer+ cell 
populations, which indicated the expression of only one functional TCR on the cell surface. In 
contrast, PBL transduced with D115 showed nearly 97% TCR-V-positive cells, while less than 
40% of the cells specifically bound the YMD-tetramer. This indicated that expression of a 
functional transgenic D115 TCR was reduced in PBL compared to the generated universal 
recipient cells. The reduced expression of functional transgenic D115 TCR can be attributed 
to the presence of various endogenous TCRs in bulk PBL, which increase the risk of TCR 
mispairing and might compete with the transgenic TCR for CD3 molecules required for cell 
surface expression (Ahmadi et al., 2013). In contrast, the generated universal recipient cells 
lack a functional endogenous TCR that could sequester the CD3 complex. This indicated that 
the increased cell surface expression of functional transgenic D115 TCR was responsible for 
the increased killing capacity of D115-transduced universal recipient cells.  
For T58-transduced PBL, the killing capacity was comparable to universal recipient cells 
expressing the transgenic T58 TCR (Figure 4.37). This efficient control of tumor cell growth by 
T58-transduced PBL was observed despite low specific YMD-tetramer binding, which 
suggested that less than 50% of the PBL expressed of functional transgenic T58 TCRs (Figure 
4.38a). This allows the assumption that TCRs conferring high functional avidity, can counteract 
lower cell surface expression by exhibiting higher sensitivity for the specific peptide. Therefore, 
T58-transduced PBL showing high functional avidity could mediate adequate tumor cell killing 
despite lower cell surface expression of functional T58 transgenic TCRs.  
The generated universal recipient cells exhibited high expression levels of the introduced 
transgenic TCRs and showed the expected functionality (Figure 4.37, Figure 4.38). Unlike in 
transduced PBL, high expression levels of functional transgenic TCRs could be demonstrated 
by specific binding to the YMD-tetramer complex. However, in T cell clone CD8+_002 
transduced with T58 two distinct CD3+TCR-V+ and CD3+YMD-tetramer+ cell populations 
could be detected by flow cytometric analysis (Figure 4.38a). The two cell populations might 
indicate high and low expression levels of the introduced transgenic TCR or potential 
mispairing of transgenic TCR  chain and endogenous TCR  chain. While both CD3-Chimera-
expressing T cell clones carry a knockout of one of the endogenous TCR chains (CD8+_001: 
TCR  knockout; CD8+_002: TCR  knockout) resulting in the TCR-negative phenotype, the 
respective second TCR chain was not targeted by the TALEN pairs (Table 4.2). Therefore, the 
respective endogenous TCR chain comprising the wildtype sequence could potentially pair 
with introduced transgenic TCR chains. This emphasizes that in order to abolish the risk of 
TCR mispairing completely, both TCR chains need to be targeted in recipient cells. To achieve 
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this, additional universal recipient cells have to be generated that carry a knockout of both the 
endogenous TCR  and  chain. Alternatively, the respective second wildtype TCR chain could 
be targeted for knockout in the generated T cell clones CD8+_001 and CD8+_002 to 
accomplish a complete knockout of the endogenous TCR. However, clonal expansion from a 
single cell level would be required to detect a successful targeting of the second TCR chain, 
which would considerably shorten the life span of the isolated T cells. Even though the 
generated universal recipient cells carry only a knockout of one TCR chain, no functional 
endogenous TCR is present in these cells that could influence experimental read-out through 
dominant negative effects. Additionally, based on the absence of a functional endogenous 
TCR, competition for CD3 molecules should be reduced, therefore supporting cell surface 
expression of transgenic TCRs (Ahmadi et al., 2013).  
The functional experiments demonstrated that the generated universal recipient cells served 
as a sensitive and reliable test system to evaluate functional avidity conferred to T cells by 
transgenic TCRs. While the universal recipient cells displayed different sensitivities to antigen 
dependent on the transgenic TCR, high expression of functional TCRs on the cell surface could 
overcome the higher activation threshold of D115-transduced cells and allowed effective tumor 
cell killing comparable to T58-expressing T cells. Modification of the TCR constant regions to 
achieve preferential pairing has so far been a promising measure to improve transgenic TCR 
expression and prevent TCR mispairing (Sommermeyer and Uckert, 2010). However, 
complete knockout of the endogenous TCR would entirely abolish the risk of off-target toxicity 
mediated by mispairing and allow effective redirection of T cell specificity by solitary expression 
of the introduced transgenic TCR. Berdien et al. proposed a process that would allow the 
successive knockout of TCR chains while gradually introducing respective transgenic chains 
by lentiviral transduction (Berdien et al., 2014). However, recent studies demonstrated the 
benefits of integrating CARs into the TRAC locus, thereby placing them under the 
transcriptional control of endogenous regulatory elements (Eyquem et al., 2017; MacLeod et 
al., 2017). Therefore, in order to achieve effective physiological reprogramming of T cells, the 
ideal solution would entail the replacement of endogenous TCR chains by targeting the 
respective transgenic TCR chains to the native TCR locus. Results obtained with TCR T58 
and D115 in this thesis suggest that knockout of endogenous TCRs in clinical products T cell 
products might open the door for clinical use of TCRs conferring lower functional avidity, that 
exhibit optimal safety profiles.   
The generated universal recipient cells represent the first reproducible test system that allows 
the direct comparison of transgenic TCRs in a T cell without potential negative interfering 
factors often observed when PBL are used as recipient cells. The absence of an endogenous 
functional TCR in universal recipient cells reduces the risk of introducing unspecific 
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background into complex cellular assays. This unspecific background predominately originates 
from dominant negative effects of endogenously expressed TCRs of unknown specificity. 
Without an endogenous functional TCR present, competition of transgenic and endogenous 
TCR is reduced and high transgenic TCR expression levels can be reached. As observed for 
the transgenic D115 TCR that confers lower functional avidity to recipient cells, knockout of at 
least one TCR chain resulted in control of tumor cell growth comparable to high avidity TCR 
T58 (Figure 4.37), which could not be observed in bulk PBL. Due to the negative effects of 
endogenous TCRs, the TCR D115 would have been excluded as a potential candidate for 
clinical application. However, by using universal recipient cells, also transgenic TCRs with high 
antigen specificity that exhibit impaired killing capacity only in the presence of endogenous 
TCRs can be identified. With the new gene editing techniques available, also these transgenic 
TCR could be of potential clinical benefit, when endogenous TCR expression is abolished. 
Therefore, utilizing universal recipient cells that lack a functional endogenous TCR opens the 
possibility to evaluate actual effector functions transferred to recipient cells solely by the 
transgenic TCR independent of interfering factors that are introduced by donor PBL. This is 
particularly important for safety-relevant assays, since decreasing unknown variables in the 
test system helps to unambiguously determine off-target or on-target/off-tumor recognition 
mediated by the candidate transgenic TCR. 
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6 Conclusions & Outlook 
Based on results obtained from experiments with isolated T cell clones expressing CEA-CARs, 
a new strategy could be developed that allowed the identification and isolation of TCR-deficient 
T cell clones that can be expanded solely via engagement of the introduced chimeric construct. 
Simultaneous knockout of the endogenous TCR and introduction of the chimeric construct 
provided a fast selection method for T cell clones that could proliferate in the absence of the 
endogenous TCR and reduced the in vitro expansion period considerably. High-throughput 
screening of T cell clones in combination with modified NGS protocols enabled an early 
determination of the knockout status for individual T cell clones, which could be selected for 
further evaluation of effector functions required for physiological read-out after introduction of 
candidate transgenic TCRs. Utilizing a CD19-CAR, high expansion rates for CD4+ T cell clones 
could be achieved that exhibited knockout of either one or both TCR chains. Introduction of a 
NY-ESO-1-specific TCR in these cells resulted in high expression levels of the transgenic TCR 
without impairment mediated by endogenous TCR chains. While IFN- release could be used 
as a measure to determine transgenic TCR specificity in all selected T cell clones, only two 
CD4+ T cells exhibited cytolytic activity and could serve as a test system for killing capacity. 
Due to the absence of CD8 in these T cells, only MHC class I restricted TCRs showing co-
receptor independent activation can be evaluated. However, this opens the possibility to use 
these universal recipient cells to test for co-receptor dependency of transgenic TCRs. Since 
antigen-recognition of CD8-dependent TCRs would not result in activation of the recipient cells, 
effector functions should be restored when CD8 is provided simultaneously. Additionally, the 
generated universal recipient cells provide an ideal environment for evaluating correct 
expression and multimer-binding of in silico reconstructed transgenic TCRs in absence of 
endogenous TCR chains. This can be helpful when identified tumor-specific cytotoxic T cell 
clones express two productive alpha chains of which only one mediates the desired specificity; 
this has been estimated to occur at a frequency as high as 20% (Malissen et al., 1992; Piper, 
Litwin and Mehr, 1999). In contrast to the CD19-CAR approach, only a small number of T cell 
clones could be isolated that could be expanded utilizing OKT-3 antibody for the engagement 
of the designed CD3-Chimera construct in TCR-deficient T cell clones. However, two well-
proliferating T cell clones could be identified that were derived from the CD8+ T cell 
compartment carrying either a knockout of the TCR  or  chain, respectively. Both T cell 
clones exhibited high proliferation rates in the absence of the endogenous TCR, which was 
mediated by binding of mitogenic OKT-3 antibody to its structural epitope. While correct folding 
and surface expression of CD3-Chimera could be demonstrated in Jurkat-76 cells, expression 
of the construct by binding of fluorophore-labeled antibodies has yet to be unambiguously 
determined in TCR-deficient T cell clones. The generated universal recipient cells exhibited all 
effector functions required to mediate tumor cell killing directed by the introduced transgenic 
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tyrosinase-specific TCRs, T58 and D115. While both TCRs recognize the same tyrosinase369-
377 peptide in the context of HLA-A2, PBL transduced with T58 show higher functional avidity 
than D115-transduced PBL (Wilde et al., 2009). This difference in peptide sensitivity could be 
successfully reproduced in the isolated T cell clones, demonstrating that the generated 
recipient cells allow the direct comparison and evaluation of different TCRs recognizing the 
same target. In contrast to PBL expressing various endogenous TCRs of unknown 
specificities, universal recipient cells enabled the testing and characterization of transgenic 
TCRs without the risk of introducing unspecific background into complex cellular assays. In 
case of the transgenic D115 TCR, that exhibits lower sensitivity to the target peptide, the 
absence of a functional endogenous TCR allowed expression of transgenic TCR that resulted 
in improved tumor cell recognition and killing. This indicated that the generated universal 
recipient cells represent a sensitive test system that allows the identification of effector 
functions that are transferred to recipient cells solely by the transgenic TCR when potential 
influencing factors are diminished.  
Therefore, the generated universal recipient cells lacking the endogenous TCR represent the 
first stable and physiological test system for in vitro efficacy and safety testing of transgenic 
TCRs. TCR-independent proliferation via engagement of the introduced chimeric construct 
allows expansion of the TCR-deficient T cells to sufficient numbers to serve as ready-to-use 
recipients for the introduction of various transgenic TCRs. Testing of different transgenic TCRs 
in the same defined universal recipient cells enables the reproducible and direct comparison 
regarding transgenic expression, specificity and functionality. This reproducibility is especially 
important when comparing different TCRs recognizing the same target to identify the most 
potent candidate. In contrast, unknown specificities of endogenously expressed TCRs and 
diverse effector functions of bulk PBL can vary in each donor and interfere with functional read-
outs and make interpretation of experimental results difficult.  
By utilizing universal recipient cells as a standardized test system, these unknown influences 
could be circumvented to allow the unbiased identification of transgenic TCRs. Based on the 
developed high-throughput strategy, additional CD4+ and CD8+ universal recipient cells could 
be generated that would carrying a knockout of both TCR chains and proliferate upon 
engagement of the same chimeric construct. In contrast to the CD19-CAR, the CD3-Chimera 
construct does not show any target recognition and therefore reduces the risk of background 
reactivity mediated mediated by the recipient cells in cellular assays. Characterization of this 
chimeric protein has to be improved to enable the isolation of larger numbers of T cell clones. 
However, the principle of activating TCR-deficient T cells solely via OKT-3 binding and CD28 
engagement, e.g. by using CD3/CD28 beads, opens new possibilities for the generation of 
universal recipient cells for clinical use. Since generating individual clinical products from cells 
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derived from critically ill cancer patients, usually pre-treated with chemotherapy can be 
challenging regarding both the production process and logistics, establishing “off-the-shelf” 
biobanks with genetically modified T cells from healthy third-party donors represents a 
promising alternative for the future of adoptive T cell therapy (Poirot et al., 2015; Torikai and 
Cooper, 2016). Even though CRISPR/Cas9 mediated knockout of endogenous HLA class I 
molecules by targeting -microglobulin could abolish the requirement for HLA-matched donors, 
an area of possible concern is the in vivo targeting of HLA-deficient cells by the patients’ NK 
cells specialized in detecting HLA-downregulation (Ren et al., 2017). The described “off-the-
shelf” approaches are designed for TCR-knockout T cells expressing predominantly a CD19-
CAR for the treatment of B cell malignancies. Since TCR mispairing is not a concern in CAR-
T cell therapy, the knockout of one TCR chain is sufficient to abolish TCR expression and avoid 
off-target toxicities mediated through the endogenous TCR. It has been demonstrated that 
introducing the CD19-CAR into the TRAC locus achieves both TCR knockout and CD19-CAR 
expression in a single step and can thereby reduce production steps for genetically modified 
T cells (Eyquem et al., 2017; MacLeod et al., 2017). However, to avoid mispairing and 
dominant negative effects of endogenous TCRs in adoptive T cell therapy utilizing transgenic 
TCRs both endogenous TCR chains would have to be targeted in donor T cells. This could be 
achieved either by sequential knockout of the respective TCR chains as described by Berdien 
et al. or by directed knockin of transgenic TCR chains in the respective native TCR loci 
mediated by TALEN pairs or CRISPR/Cas9 introduction together with template DNA coding 
for transgenic TCR chains. Although both TCR chains could be targeted with these methods, 
just as for proposed “off-the-shelf” CAR-based approaches, the clinical cell products would 
require the repeated individual preparation for each transgenic TCR that would be used in 
clinical application. To avoid this, a biobank from various allogenic donors could be generated 
that comprises T cells exhibiting a complete knockout of the endogenous TCR. These 
prepared TCR-deficient T cells could then be selected based on HLA-match with the patient 
and modified to express the required transgenic TCR designed for the respective indication. 
This would enable a fast generation of clinical products for each patient based on allogenic T 
cells from healthy donors that could be validated in advance for safety. By TALEN- or 
CRISPR/Cas9-mediated knockin of reporter proteins, like the fluorescence proteins GFP or 
mCherry, into the TRAC and TRBC locus, respectively, T cells comprising a knockout of both 
TCR chains could be easily enriched by FACS. The critical point would be to enable T cell 
activation and proliferation in the absence of the endogenous TCR to allow subsequent 
introduction of transgenic TCRs. For this, much like for universal recipient cells for in vitro 
testing, the cells could be equipped with a construct similar to the CD3-Chimera. While the 
construct could be used for ex vivo expansion, it would not be required once the transgenic 
TCR is introduced. However, since the construct does not recognize any target and therefore 
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does not show off-target recognition, it should not negatively influence effector function of 
genetically modified T cells. Additionally, in vivo activation via the CD3-Chimera should not 
occur due to the lack of mitotic -CD3 antibodies. TCR-deficient CD3-Chimera-expressing 
universal recipient cells activated via e.g. CD3/CD28 beads could then again be modified to 
express the desired transgenic TCR by utilizing TALEN- or CRISPR/Cas9-mediated knockin 
of transgenic TCR chains. While this method would abolish the requirement for retroviral 
transduction, it would also allow the introduction of the transgenic TCRs into their respective 
natural loci under the control of endogenous regulatory elements. Additionally, successful 
introduction of transgenic TCRs could be easily monitored by expression of the transgenic 
TCR and simultaneous loss of the respective fluorescence proteins. Therefore, the designed 
CD3-Chimera construct could serve as a basis for generating biobanks of universal recipient 
cells for clinical applications that lack the endogenous TCR and can be activated via 
engagement of the chimeric construct and CD28 by -CD3 and -CD28 antibodies, 
respectively. These ready-to-use recipient cells could then be utilized for the fast and virus-







%   Percent  
°C   Degree Celsius  
A   Adenine  
aa   Amino acid  
AmpR  Ampicillin resistance gene 
APC  Antigen presenting cell 
ATP   Adenosine triphosphate  
bp   Base pair  
BSA   Bovine serum albumin  
C   Cytosine  
CAR  Chimerica antigen receptor 
CD  Cluster of differentiation 
cDNA   Complementary DNA 
CMV  Cytomegalovirus  
CMV  Human cytomegalovirus  
CO2   Carbondioxide 
CRISPR Clustered regularly-interspaced short palindromic repeats 
CTL  Cytotoxic T lymphocites   
d   Day  
DMEM  Dulbecco´s Modified Eagle Medium  
DMSO  Dimethylsulfoxide  
DNA   Desoxyribonucleic acid  
dNTPs  deoxy nuleoside triphosphates 
EBV  Epstein-Barr virus 
EDTA   Ethylenediaminetetraacetic acid 
EF1A  Elongation factor 1A 
eGFP  enhanced green fluorescence protein  
EP  Electroporation  
EtBr   Ethidium bromide 
FACS  Fluorescence activated cell sorter  
FCS  Fetal calf serum  
FCS  Furin cleavage site 
FCS   Fetal calf serum  
FITC  Fluorescein isothiocyanate 
g   Gramme  
g   Gravitational acceleration  
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G   Guanine  
GTP   Guanosine triphosphate 
Gy  Gray  
h   Hour  
H2O   Water  
HEK   Human embryonic kidney 
HLA  Human leukocyte antigen  
HR   Homologous recombination 
HS  Human Serum 
IFN  Interferon  
IL  Interleukin 
ivt-RNA in vitro transcribed RNA   
kb   Kilobase  
L   Liter  
LB   Lysogenic broth  
LTR  Long terminal repeats 
M   Molar  
MCS  Multiple cloning site 
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MHC  Major histocompatibility complex   
min   Minute  
MIT  Medigene immunotherapies 
mL   Milliliter  
MoMuLV Moloney murine leukemia virus 
MPSV  Myeloproliferative sarcoma virus 
mRNA  messenger RNA   
ms   Millisecond 
NaCl   Sodium chloride  
NaOH   Sodium hydroxide  
ng   Nanogramme 
NHEJ  Non-homologous end joining   
nm   Nanometer  
O2   Oxygen 
P2A  porcine teschovirus-1 2A "self-cleaving" protein 
PB  Pacific Blue 
PBL  Peripheral blood lymphocytes   
PBMC  Peripheral blood mononuclear cells 
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PBS   Phosphate buffered saline  
PCR   Polymerase chain reaction 
PE  Phycoerythrin 
PerCP  Peridinin chlorophyll protein 
PFA  Paraformaldehyde    
pH   potentia hydrogenii  
RNA   Ribonucleic acid  
rpm   Rounds per minute 
RT   Room temperature  
RVD   Repeat-variable di-residue  
s   Second  
scFv  Single chain variable fragment  
SDS   Sodiumdodecylsulfate 
SIN  self-inactivating 
SSA  Single strand annealing   
T   Thymine 
TAA  Tumor associated antigen 
TAE  Tris-acetate-EDTA  
TALEN  Transcription activator-like effector nuclease 
TCR  T cell receptor 
Th  T helper cells   
TM  Transmembrane domain 
TNF  Tumor necrosis factor 
TRA locus TCR  locus  
TRB locus TCR  locus   
U   Unit  
UTR  Untranslated region 
UV  Ultraviolett  
V   Volt  
WPRE Woodchuck hepatitis virus posttranscriptional regulatory element short version 
(overlap between the WPRE elements used in MMLV and HIV based vectors) 
ZNF   Zinc finger nuclease  
μg   Microgramme  
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